Compositions and methods for treating or preventing preterm labor
Patent Information
- Application Number
- JP2023552388
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-16
- Filing Date
- 2021-11-16
- Publication Date
- 2024-11-27
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There is a need for drug combinations and dosing regimens to treat or prevent preterm birth in pregnant subjects, particularly to prolong gestation and improve fetal development, while minimizing risks to the mother and fetus.
Administering Prostaglandin F2α receptor antagonists, such as (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidin-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valinate, in combination with oxytocin receptor antagonists like atosiban, to delay preterm labor and promote fetal organ maturation.
The combination therapy prolongs gestation, allowing critical fetal organ development, particularly of the respiratory and nervous systems, thereby increasing newborn survival chances.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of therapeutic treatment of pregnant subjects such as human subjects during pregnancy who have experienced preterm birth in the early stages of pregnancy or are at risk of experiencing it.
Background Art
[0002] Preterm birth is a common cause of perinatal mortality in developed countries and occurs in approximately 7% - 10% of all births (Berkowitz et al. Epidemiol. Rev. 15:414 - 443 (1993)). Severe morbidity, particularly respiratory distress syndrome, intraventricular hemorrhage, bronchopulmonary dysplasia, and necrotizing enterocolitis, is much more common in preterm infants than in term infants. Long - term disabilities such as cerebral palsy, visual impairment, and hearing loss are also more frequently seen in preterm infants. Currently in the United States, preterm birth remains a major cause of infant mortality and morbidity, and despite significant improvements in obstetric care, infant mortality is higher than in many other developed countries, and neonatal intensive care for low - birth - weight infants incurs costs exceeding $5 billion annually. The actual costs associated with this care are even higher when considering the medical provision for diseases related to preterm birth such as respiratory distress syndrome, heart disease, cerebral palsy, epilepsy, and severe learning disabilities.
[0003] Basically, term and preterm births are similar processes in that they share a common physiological endpoint characterized by uterine contractions, cervical dilation, and activation of the fetal membranes. The differences lie in the gestational period during which these processes occur and the mechanisms by which they are activated. Term birth is thought to result from the physiological activation of the terminal pathway, while preterm birth is a pathological condition characterized by multiple etiologies in which one or more components of this pathway are abnormally activated.
[0004] There is still a need for combinations of agents that can be used to treat or prevent preterm birth, as well as dosing regimens for using such agents at therapeutically effective and physiologically safe levels.
Summary of the Invention
[0005] The present disclosure relates to compositions and methods for treating or preventing preterm labor in patients, particularly mammalian patients, such as human female patients. Using the compositions and methods described herein, a prostaglandin F2α (PGF2α) receptor antagonist and an oxytocin receptor antagonist, such as atosiban, can be administered in combination to a patient experiencing preterm labor or at risk of experiencing preterm labor, e.g., a subject preparing for cesarean section, to delay the onset of labor for, e.g., hours, days or weeks. The compositions and methods described herein can further be used to relieve one or more symptoms of preterm labor, e.g., to reduce the frequency of uterine contractions, delay or stop vaginal bleeding, and / or suppress rupture of the fetal membranes. The PGF2α receptor antagonist can be, for example, a 1,3-thiazolidine-2-carboxamide compound described herein, e.g., (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidin-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valinate or a pharmaceutically acceptable salt thereof, e.g., (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidin-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valinate, or in vivo, another 1,3-thiazolidine-2-carboxamide that gives rise to 3-([1,1'-biphenyl]-4-ylsulfonyl)-N-[1-(4-fluorophenyl)-3-hydroxypropyl]-1,3-thiazolidine-2-carboxamide.
[0006] The compositions and methods disclosed herein offer a variety of important therapeutic benefits. Using the compositions and methods described herein, PGF2α receptor antagonists, such as the 1,3-thiazolidine-2-carboxamide compounds described herein, can be administered in combination with atosiban to patients such as pregnant human female patients who are experiencing or at risk of experiencing premature birth. Administration of these agents to patients can prolong the patient's gestation period and provide the fetus with additional time for the development of vital organs and tissue systems. This activity is for the period of pregnancy from approximately 24 weeks to approximately 34 weeks (for example, the period of pregnancy from approximately 28 and 0 / 7 weeks to approximately 33 and 6 / 7 weeks, for example, approximately 28 and 0 / 7 weeks, 28 and 1 / 7 weeks, 28 and 2 / 7 weeks, 28 and 3 / 7 weeks, 28 and 4 / 7 weeks, 28 and 5 / 7 weeks, 28 and 6 / 7 weeks, 29 and 0 / 7 weeks, 29 and 1 / 7 weeks, 29 and 2 / 7 weeks, 29 and 3 / 7 weeks, 29 and 4 / 7 weeks, 29 and 5 / 7 weeks, 29 and 6 / 7 weeks, 30 and 0 / 7 weeks, 30 and 1 / 7 weeks, 30 and 2 / 7 weeks, 30 and 3 / 7 weeks, 30 and 4 / 7 weeks, 30 and 5 / 7 weeks, 3 This is particularly valuable for patients characterized by early gestational ages (0 and 6 / 7 weeks, 31 and 0 / 7 weeks, 31 and 1 / 7 weeks, 31 and 2 / 7 weeks, 31 and 3 / 7 weeks, 31 and 4 / 7 weeks, 31 and 5 / 7 weeks, 31 and 6 / 7 weeks, 32 and 0 / 7 weeks, 32 and 1 / 7 weeks, 32 and 2 / 7 weeks, 32 and 3 / 7 weeks, 32 and 4 / 7 weeks, 32 and 5 / 7 weeks, 32 and 6 / 7 weeks, 33 and 0 / 7 weeks, 33 and 1 / 7 weeks, 33 and 2 / 7 weeks, 33 and 3 / 7 weeks, 33 and 4 / 7 weeks, 33 and 5 / 7 weeks, or 33 and 6 / 7 weeks). During such early gestational ages, the fetus may not be fully mature, particularly in its vital organ networks, especially the respiratory and nervous systems.Without being limited by mechanism, in patients who have experienced or are at risk of experiencing delivery before full term, PGF2α receptor antagonists (e.g., (3S)-3-({[(2S)-3-(biphenyl)-4-ylsulfonyl)-1,3-thiazolidinedione-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valineate or a pharmaceutically acceptable salt thereof, e.g., (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidinedione-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valine, or in By combining another 1,3-thiazolidine-2-carboxamide, which in vivo produces 3-([1,1'-biphenyl]-4-ylsulfonyl)-N-[1-(4-fluorophenyl)-3-hydroxypropyl]-1,3-thiazolidine-2-carboxamide, with atosiban and providing it according to the administration schedule described herein, the gestation period can be extended for a sufficient period for the fetus to achieve important developments in the growth of lung and nerve cells. This maturation, in turn, can significantly increase the chances of neonatal survival.
[0007] To obtain these favorable treatment outcomes, patients may be administered therapeutically effective doses of a PGF2α receptor antagonist and atosiban, for example, simultaneously or at different times. Patients may receive multiple consecutive doses of the PGF2α receptor antagonist and / or atosiban. Patients may be administered the PGF2α receptor antagonist and atosiban on the same or different dosing schedules. For example, each time a patient receives one dose of these drugs, they may or may not receive a dose of the second drug. Patients may be administered the PGF2α receptor antagonist once or twice daily, for example, once or twice daily, and atosiban may be administered to the target, for example, once or every 24 hours, 36 hours, 48 hours, 60 hours, 72 hours, 84 hours, 96 hours, or more, for example, in the form of a single individual bolus or in the form of a series of doses such as a series of intravenous infusions. The combination therapy of atosiban and a PGF2α receptor antagonist may be administered once or more times a day, week, or month, as described herein, and may be continued, for example, until the patient experiences childbirth or reaches the full term of pregnancy.
[0008] In a first aspect, the disclosure provides a therapeutically effective amount of atosiban and a PGF2α receptor antagonist, for example, a compound represented by formula (I), [ka] (wherein the formula, the Ar ring is an optionally condensed and optionally substituted aryl group, or an optionally condensed and optionally substituted heteroaryl group; The Cy ring is optionally condensed and optionally substituted aryl group, optionally condensed and optionally substituted heteroaryl group, optionally condensed and optionally substituted cycloalkyl group, or optionally condensed and optionally substituted heterocycloalkyl group; R 1H, carboxy, acyl, alkoxycarbonyl, C1~C5-alkylcarboxy, C1~C5-alkylacyl, C1~C5-alkylalkoxycarbonyl, C1~C5-alkylacyloxy, C1~C5-alkylsulfanyl, C1~C5-alkylsulfinyl, C1~C5-alkylsulfonyl, C1~C5-alkylsulfonyloxy, C1~C6-alkyl, C2~C6-alkenyl, C2~C6-alkynyl, aryl, heteroaryl, C3~C8-cycloalkyl, C1~C6-alkylaryl, C1~C6-alkylheteroaryl, C1~C6-alkylcycloalkyl, C2~C6-alkenylaryl, C2~C6-alkenylheteroaryl, C2~C6-alkynylaryl, C2~C6-alkynylheteroaryl, substituted carboxy, substituted acyl, substituted alkoxycarbonyl These are substituted C1-C5-alkylcarboxy, substituted C1-C5-alkylacyl, substituted C1-C5-alkylalkoxycarbonyl, substituted C1-C5-alkylacyloxy, substituted C1-C5-alkylsulfanyl, substituted C1-C5-alkylsulfinyl, substituted C1-C5-alkylsulfonyl, substituted C1-C5-alkylsulfonyloxy, substituted C1-C6-alkyl, substituted C2-C6-alkenyl, substituted C2-C6-alkynyl, substituted aryl, substituted heteroaryl, substituted C3-C8-cycloalkyl, substituted C1-C6-alkylaryl, substituted C1-C6-alkylheteroaryl, substituted C1-C6-alkylcycloalkyl, substituted C2-C6-alkenylaryl, substituted C2-C6-alkenylheteroaryl, substituted C2-C6-alkynylaryl, or substituted C2-C6-alkynylheteroaryl; Each R 2 These are independently C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, substituted C1-C6-alkyl, substituted C2-C6-alkenyl, or substituted C2-C6-alkynyl; n is an integer between 0 and 2. The method is characterized by delaying the onset of labor in pregnant subjects, such as pregnant human subjects, by administering a pharmaceutically acceptable salt thereof to the subject.
[0009] According to this embodiment, the compound can be administered to the subject in an amount of approximately 250 mg to approximately 2,500 mg per dose.
[0010] For example, the compound is present in amounts of approximately 250 mg to 750 mg per dose, for example, approximately 255 mg to 745 mg, approximately 260 mg to 740 mg, approximately 265 mg to 735 mg, approximately 270 mg to 730 mg, approximately 275 mg to 725 mg, approximately 280 mg to 720 mg, approximately 285 mg to 715 mg, approximately 290 mg to 710 mg, approximately 295 mg to 705 mg, approximately 300 mg to 700 mg, and approximately 305 mg per dose. mg ~ about 695mg, about 310mg - about 690mg, about 315mg - about 685mg, about 320mg - about 680mg, about 325mg - about 675mg, about 330mg - about 670mg, about 335mg - about 665mg , about 340 mg to about 660 mg, about 345 mg to about 655 mg, about 350 mg to about 650 mg, about 355 mg to about 645 mg, about 360 mg to about 640 mg, about 365 mg to about 635 mg, about 370 mg to about 630mg, about 375mg to about 625mg, about 380mg to about 620mg, about 385mg to about 615mg, about 390mg to about 610mg, about 395mg to about 605mg, about 400mg to about 600mg, about 4 05mg to about 595mg, about 410mg to about 590mg, about 415mg to about 585mg, about 420mg to about 580mg, about 425mg to about 575mg, about 430mg to about 570mg, about 435mg to about 565 The compound may be administered to the subject in amounts of mg, approximately 440 mg to 560 mg, approximately 445 mg to 555 mg, approximately 450 mg to 550 mg, approximately 455 mg to 545 mg, approximately 460 mg to 540 mg, approximately 465 mg to 535 mg, approximately 470 mg to 530 mg, approximately 475 mg to 525 mg, approximately 480 mg to 520 mg, approximately 485 mg to 515 mg, approximately 490 mg to 510 mg, or approximately 495 mg to 505 mg. In some embodiments, the compound is administered to the subject in amounts of approximately 500 mg per dose.
[0011] In some embodiments, the compound is present in amounts ranging from approximately 250 mg to approximately 2,000 mg per dose, for example, approximately 255 mg to approximately 1,990 mg, approximately 260 mg to approximately 1,980 mg, approximately 265 mg to approximately 1,970 mg, approximately 270 mg to approximately 1,960 mg, approximately 275 mg to approximately 1,950 mg, approximately 280 mg to approximately 1,940 mg, approximately 285 mg to approximately 1,930 mg, approximately 290 mg to approximately 1,920 mg, approximately 295 mg to approximately 1,910 mg, approximately 300 mg to approximately 1,900 mg, approximately 305 mg to approximately 1,890 mg, approximately 310 mg to approximately 1,880 mg, and approximately 315 mg per dose. mg ~ about 1,870 mg, about 320 mg - about 1,860 mg, about 325 mg - about 1,850 mg, about 330 mg - about 1,840 mg, about 335 mg - about 1,830 mg, about 340 mg - about 1,820 mg, about 345 mg - about 1,810 mg, about 350 mg - about 1,800 mg , about 355 mg to about 1,790 mg, about 360 mg to about 1,780 mg, about 365 mg to about 1,770 mg, about 370 mg to about 1,760 mg, about 375 mg to about 1,750 mg, about 380 mg to about 1,740 mg, about 385 mg to about 1,730 mg, about 390 mg to about 1,7 20mg, approximately 395mg to 1,710mg, approximately 400mg to 1,700mg, approximately 405mg to 1,690mg, approximately 410mg to 1,680mg, approximately 415mg to 1,670mg, approximately 420mg to 1,660mg, approximately 425mg to 1,650mg, approximately 430mg to 1,640mg, approximately 435mg to 1,630mg, approximately 440mg to 1,620mg, approximately 445mg to 1,610mg, approximately 450mg to 1,600mg, approximately 455mg to 1,590mg, approximately 460mg to 1,580mg, approximately 465mg to 1,570mg, approximately 4 70mg to about 1,560mg, about 475mg to about 1,550mg, about 480mg to about 1,540mg, about 485mg to about 1,530mg, about 490mg to about 1,520mg, about 495mg to about 1,510mg, about 500mg to about 1,500mg, about 505mg to about 1,495m g, approx. 510 mg ~ approx. 1,490 mg, approx. 515 mg ~ approx. 1,485 mg, approx. 520 mg ~ approx. 1,480 mg, approx. 525 mg ~ approx. 1,475 mg, approx.455mg, approximately 550mg to approximately 1,450mg, approximately 555mg to approximately 1,445mg, approximately 560mg to approximately 1,440mg, approximately 565mg to approximately 1,435mg, approximately 570mg to approximately 1,430mg, approximately 575mg to approximately 1,425mg, approximately 580mg to approximately 1,420mg, approximately 585mg to approximately 1,415mg, approximately 590mg to approximately 1,410mg, approximately 595mg to approximately 1,405mg, approximately 600mg to approximately 1,400mg, approximately 605mg to approximately 1,395mg, approximately 610mg to approximately 1,390mg, approximately 615mg to approximately 1,385mg, approximately 620mg to approximately 1,380mg, approximately 6 25mg~approx. 1,375mg, approx. 630mg~approx. 1,370mg, approx. 635mg~approx. 1,365mg, approx. 640mg~approx. 1,360mg, approx. 645mg~approx. 1,355mg, approx. 650mg~approx. 1,350mg, approx. 655mg~approx. 1,345mg, approx. 660mg~approx. 1,340mg, approx. 665mg~approx. 1,335mg, approx. 670mg~approx. 1,330mg, approx. 675mg~approx. 1,325mg, approx. 680mg~approx. 1,320mg, approx. 685mg~approx. 1,315mg, approx. 690mg~approx. 1,310mg, approx. 695mg~approx. 1,305mg, approx. 700mg~approx. 1, 300mg, approximately 705mg~approx. 1,295mg, approximately 710mg~approx. 1,290mg, approximately 715mg~approx. 1,285mg, approximately 720mg~approx. 1,280mg, approximately 725mg~approx. 1,275mg, approximately 730mg~approx. 1,270mg, approximately 735mg~approx. 1,265mg, approximately 740mg~approx. 1,260mg, approximately 745mg~approx. 1,255mg, approximately 750mg~approx. 1,250mg, approximately 755mg~approx. 1,245mg, approximately 760mg~approx. 1,240mg, approximately 765mg~approx. 1,235mg, approximately 770mg~approx. 1,230mg, approximately 775mg~approx. 1,225mg, approximately 7 80mg~approx. 1,220mg, approx. 785mg~approx. 1,215mg, approx. 790mg~approx. 1,210mg, approx. 795mg~approx. 1,205mg, approx. 800mg~approx. 1,200mg, approx. 805mg~approx. 1,195mg, approx. 810mg~approx. 1,190mg, approx. 815mg~approx. 1,185mg, approx. 820mg~approx. 1,180mg, approx. 825mg~approx. 1,175mg, approx. 830mg~approx. 1,170mg, approx. 835mg~approx. 1,165mg, approx. 840mg~approx. 1,160mg, approx. 845mg~approx. 1,155mg, approx. 850mg~approx. 1,150mg, approx. 855mg~approx. 1,145mg, about 860mg to about 1,140mg, about 865mg to about 1,135mg, about 870mg to about 1,130mg, about 875mg to about 1,125mg, about 880mg to about 1,120mg, about 885mg to about 1,115mg, about 890mg to about 1,110mg , about 895 mg to about 1,105 mg, about 900 mg to about 1,000 mg, about 905 mg to about 1,095 mg, about 910 mg to about 1,090 mg, about 915 mg to about 1,085 mg, about 920 mg to about 1,080 mg, about 925 mg to about 1,075 mg, about 930 The compound is administered to the subject in amounts ranging from approximately 1,070 mg to 9,070 mg, 935 mg to 1,065 mg, 940 mg to 1,060 mg, 945 mg to 1,055 mg, 950 mg to 1,050 mg, 955 mg to 1,045 mg, 960 mg to 1,040 mg, 965 mg to 1,035 mg, 970 mg to 1,030 mg, 975 mg to 1,025 mg, 980 mg to 1,020 mg, 985 mg to 1,015 mg, 990 mg to 1,010 mg, or 995 mg to 1,005 mg. In some embodiments, the compound is administered to the subject in amounts ranging from approximately 1,000 mg per dose.
[0012] In some embodiments, the compound is present in amounts of approximately 1,500 mg to approximately 2,500 mg per dose, for example, approximately 1,505 mg to approximately 2,495 mg, approximately 1,510 mg to approximately 2,490 mg, approximately 1,515 mg to approximately 2,485 mg, approximately 1,520 mg to approximately 2,480 mg, approximately 1,525 mg to approximately 2,475 mg, approximately 1,530 mg to approximately 2,470 mg, approximately 1,535 mg to approximately 2,465 mg, approximately 1,540 mg to approximately 2,460 mg, approximately 1,545 mg to approximately 2,455 mg, approximately 1,550 mg to approximately 2,450 mg, and approximately 1,555 mg to approximately 2,445 mg per dose. , about 1,560mg to about 2,440mg, about 1,565mg to about 2,435mg, about 1,570mg to about 2,430mg, about 1,575mg to about 2,425mg, about 1,580mg to about 2,420mg, about 1,585mg to about 2,415mg, about 1,590mg to about 2,410m g, approx. 1,595 mg ~ approx. 2,405 mg, approx. 1,600 mg ~ approx. 2,400 mg, approx. 1,605 mg ~ approx. 2,395 mg, approx. 1,610 mg ~ approx. 2,390 mg, approx. mg, approx. 1,630 mg ~ approx. 2,370 mg, approx. 1,635 mg ~ approx. 2,365 mg, approx. 1,640 mg ~ approx. 2,360 mg, approx. 1,645 mg ~ approx. 2,355 mg, approx. 0mg, about 1,665mg to about 2,335mg, about 1,670mg to about 2,330mg, about 1,675mg to about 2,325mg, about 1,680mg to about 2,320mg, about 1,685mg to about 2,315mg, about 1,690mg to about 2,310mg, about 1,695mg to about 2,3 05mg, about 1,700mg to about 2,300mg, about 1,705mg to about 2,295mg, about 1,710mg to about 2,290mg, about 1,715mg to about 2,285mg, about 1,720mg to about 2,280mg, about 1,725mg to about 2,275mg, about 1,730mg to about 2, 270mg, about 1,735mg to about 2,265mg, about 1,740mg to about 2,260mg, about 1,745mg to about 2,255mg, about 1,750mg to about 2,250mg, about 1,755mg to about 2,245mg, about 1,760mg to about 2,240mg, about 1,765mg to about 2,235mg, approximately 1,770mg to approximately 2,230mg, approximately 1,775mg to approximately 2,225mg, approximately 1,780mg to approximately 2,220mg, approximately 1,785mg to approximately 2,215mg, approximately 1,790mg to approximately 2,210mg, approximately 1,795mg to approximately 2,205mg, about 1,800mg to about 2,200mg, about 1,805mg to about 2,195mg, about 1,810mg to about 2,190mg, about 1,815mg to about 2,185mg, about 1,820mg to about 2,180mg, about 1,825mg ~2,175mg, 1,830mg~2,170mg, 1,835mg~2,165mg, 1,840mg~2,160mg, 1,845mg~2,155mg, 1,850mg~2,150mg, 1,855 mg ~ approx. 2,145 mg, approx. 1,860 mg ~ approx. 2,140 mg, approx. 1,865 mg ~ approx. 2,135 mg, approx. 1,870 mg ~ approx. 2,130 mg, approx. 85mg to about 2,115mg, about 1,890mg to about 2,110mg, about 1,895mg to about 2,105mg, about 1,900mg to about 2,100mg, about 1,905mg to about 2,095mg, about 1,910mg to about 2,090mg, about 1 , 915mg to about 2,085mg, about 1,920mg to about 2,080mg, about 1,925mg to about 2,075mg, about 1,930mg to about 2,070mg, about 1,935mg to about 2,065mg, about 1,940mg to about 2,060mg, The compound is administered to the subject in amounts of approximately 1,945 mg to 2,055 mg, 1,950 mg to 2,050 mg, 1,955 mg to 2,045 mg, 1,960 mg to 2,040 mg, 1,965 mg to 2,035 mg, 1,970 mg to 2,030 mg, 1,975 mg to 2,025 mg, 1,980 mg to 2,020 mg, 1,985 mg to 2,015 mg, 1,990 mg to 2,010 mg, or 1,995 mg to 2,005 mg. In some embodiments, the compound is administered to the subject in amounts of approximately 2,000 mg per dose.
[0013] For example, in some embodiments, the compound is used in doses of approximately 250 mg, 255 mg, 260 mg, 265 mg, 270 mg, 275 mg, 280 mg, 285 mg, 290 mg, 295 mg, 300 mg, 305 mg, 310 mg, 315 mg, 320 mg, 325 mg, 330 mg, 335 mg, 340 mg, 345 mg, 350 mg, 355 mg, 360 mg, 365 mg, 370 mg, 375 mg, 380 mg, 385 mg, 390 mg, 395 mg, 400 mg, 405 mg, 410 mg, 415 mg, 420 mg, 425 mg, and 430 mg per dose. g, 435mg, 440mg, 445mg, 450mg, 455mg, 460mg, 465mg, 470mg, 475mg, 480mg, 485mg, 490mg, 495mg, 500mg, 505mg, 510mg, 515mg, 520mg, 525mg, 530mg, 53 5mg, 540mg, 545mg, 550mg, 555mg, 560mg, 565mg, 570mg, 575mg, 580mg, 585mg, 590mg, 595mg, 600mg, 605mg, 610mg, 615mg, 620mg, 625mg, 630mg, 635mg, 6 40mg, 645mg, 650mg, 655mg, 660mg, 665mg, 670mg, 675mg, 680mg, 685mg, 690mg, 695mg, 700mg, 705mg, 710mg, 715mg, 720mg, 725mg, 730mg, 735mg, 740mg , 745mg, 750mg, 755mg, 760mg, 765mg, 770mg, 775mg, 780mg, 785mg, 790mg, 795mg, 800mg, 805mg, 810mg, 815mg, 820mg, 825mg, 830mg, 835mg, 840mg, 845 mg, 850mg, 855mg, 860mg, 865mg, 870mg, 875mg, 880mg, 885mg, 890mg, 895mg, 900mg, 905mg, 910mg, 915mg, 920mg, 925mg, 930mg, 935mg, 940mg, 945mg, 9 50mg, 955mg, 960mg, 965mg, 970mg, 975mg, 980mg, 985mg, 990mg, 995mg, 1,000mg, 1,005mg, 1,010mg, 1,015mg, 1,020mg, 1,025mg, 1,030mg, 1,035mg, 1,040mg、1,045mg、1,050mg、1,055mg、1,060mg、1,065mg、1,070mg、1,075mg、1,080mg、1,085mg、1,090mg、1,095mg、1,100mg、1,105mg、1,110mg、1,115mg、1,120mg、1,125mg、1,130mg、1,135mg、1,140mg、1,145mg、1,150mg、1,155mg、1,160mg、1,165mg、1,170mg、1,175mg、1,180mg、1,185mg、1,190mg、1,195mg、1,200mg、1,205mg、1,210mg、1,215mg、1,220mg、1,225mg、1,230mg、1,235mg、1,240mg、1,245mg、1,250mg、1,255mg、1,260mg、1,265mg、1,270mg、1,275mg、1,280mg、1,285mg、1,290mg、1,295mg、1,300mg、1,305mg、1,310mg、1,315mg、1,320mg、1,325mg、1,330mg、1,335mg、1,340mg、1,345mg、1,350mg、1,355mg、1,360mg、1,365mg、1,370mg、1,375mg、1,380mg、1,385mg、1,390mg、1,395mg、1,400mg、1,405mg、1,410mg、1,415mg、1,420mg、1,425mg、1,430mg、1,435mg、1,440mg、1,445mg、1,450mg、1,455mg、1,460mg、1,465mg、1,470mg、1,475mg、1,480mg、1,485mg、1,490mg、1,495mg、1,500mg、1,505mg、1,510mg、1,515mg、1,520mg、1,525mg、1,530mg、1,535mg、1,540mg、1,545mg、1,550mg、1,555mg、1,560mg、1,565mg、1,570mg、1,575mg、1,580mg、1,585mg、1,590mg、1,595mg、1,600mg、1,605mg、1,610mg、1,615mg、1,620mg、1,625mg、1,630mg、1,635mg、1,640mg、1,645mg、1,650mg、1,655mg、1,660mg、1,665mg、1,670mg、1,675mg、1,680mg、1,685mg、1,690mg、1,695mg、1,700mg、1,705mg、1,710mg、1,715mg、1,720mg、1,725mg、1,730mg、1,735mg、1,740mg、1,745mg、1,750mg、1,755mg、1,760mg、1,765mg、1,770mg、1,775mg、1,780mg、1,785mg、1,790mg、1,795mg、1,800mg、1,805mg、1,810mg、1,815mg、1,820mg、1,825mg、1,830mg、1,835mg、1,840mg、1,845mg、1,850mg、1,855mg、1,860mg、1,865mg、1,870mg、1,875mg、1,880mg、1,885mg、1,890mg、1,895mg、1,900mg、1,905mg、1,910mg、1,915mg、1,920mg、1,925mg、1,930mg、1,935mg、1,940mg、1,945mg、1,950mg、1,955mg、1,960mg、1,965mg、1,970mg、1,975mg、1,980mg、1,985mg、1,990mg、1,995mg、2,000mg、2,005mg、2,010mg、2,015mg、2,020mg、2,025mg、2,030mg、2,035mg、2,040mg、2,045mg、2,050mg、2,055mg、2,060mg、2,065mg、2,070mg、2,075mg、2,080mg、2,085mg、2,090mg、2,095mg、2,100mg、2,105mg、2,110mg、2,115mg、2,120mg、2,125mg、2,130mg、2,135mg、2,140mg、2,145mg、2,150mg、2,155mg、2,160mg、2,165mg、2,170mg、2,175mg、2,180mg、2,185mg、2,190mg、2,195mg、2,200mg、2,205mg、2,210mg、2,215mg、2,220mg、2,225mg、2,230mg、2,235mg、2,240mg、2,245mg、2,250mg、2,255mg、2,260mg、2,265mg、2,270mg、2,275mg、2,280mg、2,285mg、2,290mg, 2,295mg, 2,300mg, 2,305mg, 2,310mg, 2,315mg, 2,320mg, 2,325mg, 2,330mg, 2,335mg, 2,340mg, 2,3 45mg, 2,350mg, 2,355mg, 2,360mg, 2,365mg, 2,370mg, 2,375mg, 2,380mg, 2,385mg, 2,390mg, 2,395mg, 2,40 The drug is administered to the target individual in doses of 0 mg, 2,405 mg, 2,410 mg, 2,415 mg, 2,420 mg, 2,425 mg, 2,430 mg, 2,435 mg, 2,440 mg, 2,445 mg, 2,450 mg, 2,455 mg, 2,460 mg, 2,465 mg, 2,470 mg, 2,475 mg, 2,480 mg, 2,485 mg, 2,490 mg, 2,495 mg, or 2,500 mg.
[0014] In another embodiment, the present disclosure relates to a therapeutically effective dose of atosiban and a PGF2α receptor antagonist, for example, a compound represented by formula (I), [ka] (wherein the formula, the Ar ring is an optionally condensed and optionally substituted aryl group, or an optionally condensed and optionally substituted heteroaryl group; The Cy ring is optionally condensed and optionally substituted aryl group, optionally condensed and optionally substituted heteroaryl group, optionally condensed and optionally substituted cycloalkyl group, or optionally condensed and optionally substituted heterocycloalkyl group; R 1H, carboxy, acyl, alkoxycarbonyl, C1~C5-alkylcarboxy, C1~C5-alkylacyl, C1~C5-alkylalkoxycarbonyl, C1~C5-alkylacyloxy, C1~C5-alkylsulfanyl, C1~C5-alkylsulfinyl, C1~C5-alkylsulfonyl, C1~C5-alkylsulfonyloxy, C1~C6-alkyl, C2~C6-alkenyl, C2~C6-alkynyl, aryl, heteroaryl, C3~C8-cycloalkyl, C1~C6-alkylaryl, C1~C6-alkylheteroaryl, C1~C6-alkylcycloalkyl, C2~C6-alkenylaryl, C2~C6-alkenylheteroaryl, C2~C6-alkynylaryl, C2~C6-alkynylheteroaryl, substituted carboxy, substituted acyl, substituted alkoxycarbonyl These are substituted C1-C5-alkylcarboxy, substituted C1-C5-alkylacyl, substituted C1-C5-alkylalkoxycarbonyl, substituted C1-C5-alkylacyloxy, substituted C1-C5-alkylsulfanyl, substituted C1-C5-alkylsulfinyl, substituted C1-C5-alkylsulfonyl, substituted C1-C5-alkylsulfonyloxy, substituted C1-C6-alkyl, substituted C2-C6-alkenyl, substituted C2-C6-alkynyl, substituted aryl, substituted heteroaryl, substituted C3-C8-cycloalkyl, substituted C1-C6-alkylaryl, substituted C1-C6-alkylheteroaryl, substituted C1-C6-alkylcycloalkyl, substituted C2-C6-alkenylaryl, substituted C2-C6-alkenylheteroaryl, substituted C2-C6-alkynylaryl, or substituted C2-C6-alkynylheteroaryl; Each R 2 These are independently C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, substituted C1-C6-alkyl, substituted C2-C6-alkenyl, or substituted C2-C6-alkynyl; n is an integer between 0 and 2. The present invention relates to a method of treating or preventing premature delivery in pregnant subjects, such as pregnant human subjects, by administering a pharmaceutically acceptable salt thereof to a subject.
[0015] According to the above-described embodiment, the compound can be administered to the subject in an amount of approximately 250 mg to approximately 2,500 mg per dose.
[0016] For example, the compound is present in amounts of approximately 250 mg to 750 mg per dose, for example, approximately 255 mg to 745 mg, approximately 260 mg to 740 mg, approximately 265 mg to 735 mg, approximately 270 mg to 730 mg, approximately 275 mg to 725 mg, approximately 280 mg to 720 mg, approximately 285 mg to 715 mg, approximately 290 mg to 710 mg, approximately 295 mg to 705 mg, approximately 300 mg to 700 mg, and approximately 305 mg per dose. mg ~ about 695mg, about 310mg - about 690mg, about 315mg - about 685mg, about 320mg - about 680mg, about 325mg - about 675mg, about 330mg - about 670mg, about 335mg - about 665mg , about 340 mg to about 660 mg, about 345 mg to about 655 mg, about 350 mg to about 650 mg, about 355 mg to about 645 mg, about 360 mg to about 640 mg, about 365 mg to about 635 mg, about 370 mg to about 630mg, about 375mg to about 625mg, about 380mg to about 620mg, about 385mg to about 615mg, about 390mg to about 610mg, about 395mg to about 605mg, about 400mg to about 600mg, about 4 05mg to about 595mg, about 410mg to about 590mg, about 415mg to about 585mg, about 420mg to about 580mg, about 425mg to about 575mg, about 430mg to about 570mg, about 435mg to about 565 The compound may be administered to the subject in amounts of mg, approximately 440 mg to 560 mg, approximately 445 mg to 555 mg, approximately 450 mg to 550 mg, approximately 455 mg to 545 mg, approximately 460 mg to 540 mg, approximately 465 mg to 535 mg, approximately 470 mg to 530 mg, approximately 475 mg to 525 mg, approximately 480 mg to 520 mg, approximately 485 mg to 515 mg, approximately 490 mg to 510 mg, or approximately 495 mg to 505 mg. In some embodiments, the compound is administered to the subject in amounts of approximately 500 mg per dose.
[0017] In some embodiments, the compound is present in amounts ranging from approximately 250 mg to approximately 2,000 mg per dose, for example, approximately 255 mg to approximately 1,990 mg, approximately 260 mg to approximately 1,980 mg, approximately 265 mg to approximately 1,970 mg, approximately 270 mg to approximately 1,960 mg, approximately 275 mg to approximately 1,950 mg, approximately 280 mg to approximately 1,940 mg, approximately 285 mg to approximately 1,930 mg, approximately 290 mg to approximately 1,920 mg, approximately 295 mg to approximately 1,910 mg, approximately 300 mg to approximately 1,900 mg, approximately 305 mg to approximately 1,890 mg, approximately 310 mg to approximately 1,880 mg, and approximately 315 mg per dose. mg ~ about 1,870 mg, about 320 mg - about 1,860 mg, about 325 mg - about 1,850 mg, about 330 mg - about 1,840 mg, about 335 mg - about 1,830 mg, about 340 mg - about 1,820 mg, about 345 mg - about 1,810 mg, about 350 mg - about 1,800 mg , about 355 mg to about 1,790 mg, about 360 mg to about 1,780 mg, about 365 mg to about 1,770 mg, about 370 mg to about 1,760 mg, about 375 mg to about 1,750 mg, about 380 mg to about 1,740 mg, about 385 mg to about 1,730 mg, about 390 mg to about 1,7 20mg, approximately 395mg to 1,710mg, approximately 400mg to 1,700mg, approximately 405mg to 1,690mg, approximately 410mg to 1,680mg, approximately 415mg to 1,670mg, approximately 420mg to 1,660mg, approximately 425mg to 1,650mg, approximately 430mg to 1,640mg, approximately 435mg to 1,630mg, approximately 440mg to 1,620mg, approximately 445mg to 1,610mg, approximately 450mg to 1,600mg, approximately 455mg to 1,590mg, approximately 460mg to 1,580mg, approximately 465mg to 1,570mg, approximately 4 70mg to about 1,560mg, about 475mg to about 1,550mg, about 480mg to about 1,540mg, about 485mg to about 1,530mg, about 490mg to about 1,520mg, about 495mg to about 1,510mg, about 500mg to about 1,500mg, about 505mg to about 1,495m g, approx. 510 mg ~ approx. 1,490 mg, approx. 515 mg ~ approx. 1,485 mg, approx. 520 mg ~ approx. 1,480 mg, approx. 525 mg ~ approx. 1,475 mg, approx.455mg, approximately 550mg to approximately 1,450mg, approximately 555mg to approximately 1,445mg, approximately 560mg to approximately 1,440mg, approximately 565mg to approximately 1,435mg, approximately 570mg to approximately 1,430mg, approximately 575mg to approximately 1,425mg, approximately 580mg to approximately 1,420mg, approximately 585mg to approximately 1,415mg, approximately 590mg to approximately 1,410mg, approximately 595mg to approximately 1,405mg, approximately 600mg to approximately 1,400mg, approximately 605mg to approximately 1,395mg, approximately 610mg to approximately 1,390mg, approximately 615mg to approximately 1,385mg, approximately 620mg to approximately 1,380mg, approximately 6 25mg~approx. 1,375mg, approx. 630mg~approx. 1,370mg, approx. 635mg~approx. 1,365mg, approx. 640mg~approx. 1,360mg, approx. 645mg~approx. 1,355mg, approx. 650mg~approx. 1,350mg, approx. 655mg~approx. 1,345mg, approx. 660mg~approx. 1,340mg, approx. 665mg~approx. 1,335mg, approx. 670mg~approx. 1,330mg, approx. 675mg~approx. 1,325mg, approx. 680mg~approx. 1,320mg, approx. 685mg~approx. 1,315mg, approx. 690mg~approx. 1,310mg, approx. 695mg~approx. 1,305mg, approx. 700mg~approx. 1, 300mg, approximately 705mg~approx. 1,295mg, approximately 710mg~approx. 1,290mg, approximately 715mg~approx. 1,285mg, approximately 720mg~approx. 1,280mg, approximately 725mg~approx. 1,275mg, approximately 730mg~approx. 1,270mg, approximately 735mg~approx. 1,265mg, approximately 740mg~approx. 1,260mg, approximately 745mg~approx. 1,255mg, approximately 750mg~approx. 1,250mg, approximately 755mg~approx. 1,245mg, approximately 760mg~approx. 1,240mg, approximately 765mg~approx. 1,235mg, approximately 770mg~approx. 1,230mg, approximately 775mg~approx. 1,225mg, approximately 7 80mg~approx. 1,220mg, approx. 785mg~approx. 1,215mg, approx. 790mg~approx. 1,210mg, approx. 795mg~approx. 1,205mg, approx. 800mg~approx. 1,200mg, approx. 805mg~approx. 1,195mg, approx. 810mg~approx. 1,190mg, approx. 815mg~approx. 1,185mg, approx. 820mg~approx. 1,180mg, approx. 825mg~approx. 1,175mg, approx. 830mg~approx. 1,170mg, approx. 835mg~approx. 1,165mg, approx. 840mg~approx. 1,160mg, approx. 845mg~approx. 1,155mg, approx. 850mg~approx. 1,150mg, approx. 855mg~approx. 1,145mg, about 860mg to about 1,140mg, about 865mg to about 1,135mg, about 870mg to about 1,130mg, about 875mg to about 1,125mg, about 880mg to about 1,120mg, about 885mg to about 1,115mg, about 890mg to about 1,110mg , about 895 mg to about 1,105 mg, about 900 mg to about 1,000 mg, about 905 mg to about 1,095 mg, about 910 mg to about 1,090 mg, about 915 mg to about 1,085 mg, about 920 mg to about 1,080 mg, about 925 mg to about 1,075 mg, about 930 The compound is administered to the subject in amounts ranging from approximately 1,070 mg to 9,070 mg, 935 mg to 1,065 mg, 940 mg to 1,060 mg, 945 mg to 1,055 mg, 950 mg to 1,050 mg, 955 mg to 1,045 mg, 960 mg to 1,040 mg, 965 mg to 1,035 mg, 970 mg to 1,030 mg, 975 mg to 1,025 mg, 980 mg to 1,020 mg, 985 mg to 1,015 mg, 990 mg to 1,010 mg, or 995 mg to 1,005 mg. In some embodiments, the compound is administered to the subject in amounts ranging from approximately 1,000 mg per dose.
[0018] In some embodiments, the compound is present in amounts of approximately 1,500 mg to approximately 2,500 mg per dose, for example, approximately 1,505 mg to approximately 2,495 mg, approximately 1,510 mg to approximately 2,490 mg, approximately 1,515 mg to approximately 2,485 mg, approximately 1,520 mg to approximately 2,480 mg, approximately 1,525 mg to approximately 2,475 mg, approximately 1,530 mg to approximately 2,470 mg, approximately 1,535 mg to approximately 2,465 mg, approximately 1,540 mg to approximately 2,460 mg, approximately 1,545 mg to approximately 2,455 mg, approximately 1,550 mg to approximately 2,450 mg, and approximately 1,555 mg to approximately 2,445 mg per dose. , about 1,560mg to about 2,440mg, about 1,565mg to about 2,435mg, about 1,570mg to about 2,430mg, about 1,575mg to about 2,425mg, about 1,580mg to about 2,420mg, about 1,585mg to about 2,415mg, about 1,590mg to about 2,410m g, approx. 1,595 mg ~ approx. 2,405 mg, approx. 1,600 mg ~ approx. 2,400 mg, approx. 1,605 mg ~ approx. 2,395 mg, approx. 1,610 mg ~ approx. 2,390 mg, approx. mg, approx. 1,630 mg ~ approx. 2,370 mg, approx. 1,635 mg ~ approx. 2,365 mg, approx. 1,640 mg ~ approx. 2,360 mg, approx. 1,645 mg ~ approx. 2,355 mg, approx. 0mg, about 1,665mg to about 2,335mg, about 1,670mg to about 2,330mg, about 1,675mg to about 2,325mg, about 1,680mg to about 2,320mg, about 1,685mg to about 2,315mg, about 1,690mg to about 2,310mg, about 1,695mg to about 2,3 05mg, about 1,700mg to about 2,300mg, about 1,705mg to about 2,295mg, about 1,710mg to about 2,290mg, about 1,715mg to about 2,285mg, about 1,720mg to about 2,280mg, about 1,725mg to about 2,275mg, about 1,730mg to about 2, 270mg, about 1,735mg to about 2,265mg, about 1,740mg to about 2,260mg, about 1,745mg to about 2,255mg, about 1,750mg to about 2,250mg, about 1,755mg to about 2,245mg, about 1,760mg to about 2,240mg, about 1,765mg to about 2,235mg, approximately 1,770mg to approximately 2,230mg, approximately 1,775mg to approximately 2,225mg, approximately 1,780mg to approximately 2,220mg, approximately 1,785mg to approximately 2,215mg, approximately 1,790mg to approximately 2,210mg, approximately 1,795mg to approximately 2,205mg, about 1,800mg to about 2,200mg, about 1,805mg to about 2,195mg, about 1,810mg to about 2,190mg, about 1,815mg to about 2,185mg, about 1,820mg to about 2,180mg, about 1,825mg ~2,175mg, 1,830mg~2,170mg, 1,835mg~2,165mg, 1,840mg~2,160mg, 1,845mg~2,155mg, 1,850mg~2,150mg, 1,855 mg ~ approx. 2,145 mg, approx. 1,860 mg ~ approx. 2,140 mg, approx. 1,865 mg ~ approx. 2,135 mg, approx. 1,870 mg ~ approx. 2,130 mg, approx. 85mg to about 2,115mg, about 1,890mg to about 2,110mg, about 1,895mg to about 2,105mg, about 1,900mg to about 2,100mg, about 1,905mg to about 2,095mg, about 1,910mg to about 2,090mg, about 1 , 915mg to about 2,085mg, about 1,920mg to about 2,080mg, about 1,925mg to about 2,075mg, about 1,930mg to about 2,070mg, about 1,935mg to about 2,065mg, about 1,940mg to about 2,060mg, The compound is administered to the subject in amounts of approximately 1,945 mg to 2,055 mg, 1,950 mg to 2,050 mg, 1,955 mg to 2,045 mg, 1,960 mg to 2,040 mg, 1,965 mg to 2,035 mg, 1,970 mg to 2,030 mg, 1,975 mg to 2,025 mg, 1,980 mg to 2,020 mg, 1,985 mg to 2,015 mg, 1,990 mg to 2,010 mg, or 1,995 mg to 2,005 mg. In some embodiments, the compound is administered to the subject in amounts of approximately 2,000 mg per dose.
[0019] For example, in some embodiments, the compound is used in doses of approximately 250 mg, 255 mg, 260 mg, 265 mg, 270 mg, 275 mg, 280 mg, 285 mg, 290 mg, 295 mg, 300 mg, 305 mg, 310 mg, 315 mg, 320 mg, 325 mg, 330 mg, 335 mg, 340 mg, 345 mg, 350 mg, 355 mg, 360 mg, 365 mg, 370 mg, 375 mg, 380 mg, 385 mg, 390 mg, 395 mg, 400 mg, 405 mg, 410 mg, 415 mg, 420 mg, 425 mg, and 430 mg per dose. g, 435mg, 440mg, 445mg, 450mg, 455mg, 460mg, 465mg, 470mg, 475mg, 480mg, 485mg, 490mg, 495mg, 500mg, 505mg, 510mg, 515mg, 520mg, 525mg, 530mg, 53 5mg, 540mg, 545mg, 550mg, 555mg, 560mg, 565mg, 570mg, 575mg, 580mg, 585mg, 590mg, 595mg, 600mg, 605mg, 610mg, 615mg, 620mg, 625mg, 630mg, 635mg, 6 40mg, 645mg, 650mg, 655mg, 660mg, 665mg, 670mg, 675mg, 680mg, 685mg, 690mg, 695mg, 700mg, 705mg, 710mg, 715mg, 720mg, 725mg, 730mg, 735mg, 740mg , 745mg, 750mg, 755mg, 760mg, 765mg, 770mg, 775mg, 780mg, 785mg, 790mg, 795mg, 800mg, 805mg, 810mg, 815mg, 820mg, 825mg, 830mg, 835mg, 840mg, 845 mg, 850mg, 855mg, 860mg, 865mg, 870mg, 875mg, 880mg, 885mg, 890mg, 895mg, 900mg, 905mg, 910mg, 915mg, 920mg, 925mg, 930mg, 935mg, 940mg, 945mg, 9 50mg, 955mg, 960mg, 965mg, 970mg, 975mg, 980mg, 985mg, 990mg, 995mg, 1,000mg, 1,005mg, 1,010mg, 1,015mg, 1,020mg, 1,025mg, 1,030mg, 1,035mg, 1,040mg、1,045mg、1,050mg、1,055mg、1,060mg、1,065mg、1,070mg、1,075mg、1,080mg、1,085mg、1,090mg、1,095mg、1,100mg、1,105mg、1,110mg、1,115mg、1,120mg、1,125mg、1,130mg、1,135mg、1,140mg、1,145mg、1,150mg、1,155mg、1,160mg、1,165mg、1,170mg、1,175mg、1,180mg、1,185mg、1,190mg、1,195mg、1,200mg、1,205mg、1,210mg、1,215mg、1,220mg、1,225mg、1,230mg、1,235mg、1,240mg、1,245mg、1,250mg、1,255mg、1,260mg、1,265mg、1,270mg、1,275mg、1,280mg、1,285mg、1,290mg、1,295mg、1,300mg、1,305mg、1,310mg、1,315mg、1,320mg、1,325mg、1,330mg、1,335mg、1,340mg、1,345mg、1,350mg、1,355mg、1,360mg、1,365mg、1,370mg、1,375mg、1,380mg、1,385mg、1,390mg、1,395mg、1,400mg、1,405mg、1,410mg、1,415mg、1,420mg、1,425mg、1,430mg、1,435mg、1,440mg、1,445mg、1,450mg、1,455mg、1,460mg、1,465mg、1,470mg、1,475mg、1,480mg、1,485mg、1,490mg、1,495mg、1,500mg、1,505mg、1,510mg、1,515mg、1,520mg、1,525mg、1,530mg、1,535mg、1,540mg、1,545mg、1,550mg、1,555mg、1,560mg、1,565mg、1,570mg、1,575mg、1,580mg、1,585mg、1,590mg、1,595mg、1,600mg、1,605mg、1,610mg、1,615mg、1,620mg、1,625mg、1,630mg、1,635mg、1,640mg、1,645mg、1,650mg、1,655mg、1,660mg、1,665mg、1,670mg、1,675mg、1,680mg、1,685mg、1,690mg、1,695mg、1,700mg、1,705mg、1,710mg、1,715mg、1,720mg、1,725mg、1,730mg、1,735mg、1,740mg、1,745mg、1,750mg、1,755mg、1,760mg、1,765mg、1,770mg、1,775mg、1,780mg、1,785mg、1,790mg、1,795mg、1,800mg、1,805mg、1,810mg、1,815mg、1,820mg、1,825mg、1,830mg、1,835mg、1,840mg、1,845mg、1,850mg、1,855mg、1,860mg、1,865mg、1,870mg、1,875mg、1,880mg、1,885mg、1,890mg、1,895mg、1,900mg、1,905mg、1,910mg、1,915mg、1,920mg、1,925mg、1,930mg、1,935mg、1,940mg、1,945mg、1,950mg、1,955mg、1,960mg、1,965mg、1,970mg、1,975mg、1,980mg、1,985mg、1,990mg、1,995mg、2,000mg、2,005mg、2,010mg、2,015mg、2,020mg、2,025mg、2,030mg、2,035mg、2,040mg、2,045mg、2,050mg、2,055mg、2,060mg、2,065mg、2,070mg、2,075mg、2,080mg、2,085mg、2,090mg、2,095mg、2,100mg、2,105mg、2,110mg、2,115mg、2,120mg、2,125mg、2,130mg、2,135mg、2,140mg、2,145mg、2,150mg、2,155mg、2,160mg、2,165mg、2,170mg、2,175mg、2,180mg、2,185mg、2,190mg、2,195mg、2,200mg、2,205mg、2,210mg、2,215mg、2,220mg、2,225mg、2,230mg、2,235mg、2,240mg、2,245mg、2,250mg、2,255mg、2,260mg、2,265mg、2,270mg、2,275mg、2,280mg、2,285mg、2,290mg, 2,295mg, 2,300mg, 2,305mg, 2,310mg, 2,315mg, 2,320mg, 2,325mg, 2,330mg, 2,335mg, 2,340mg, 2,3 45mg, 2,350mg, 2,355mg, 2,360mg, 2,365mg, 2,370mg, 2,375mg, 2,380mg, 2,385mg, 2,390mg, 2,395mg, 2,40 The drug is administered to the target individual in doses of 0 mg, 2,405 mg, 2,410 mg, 2,415 mg, 2,420 mg, 2,425 mg, 2,430 mg, 2,435 mg, 2,440 mg, 2,445 mg, 2,450 mg, 2,455 mg, 2,460 mg, 2,465 mg, 2,470 mg, 2,475 mg, 2,480 mg, 2,485 mg, 2,490 mg, 2,495 mg, or 2,500 mg.
[0020] In a further embodiment, the present disclosure relates to a therapeutically effective dose of atosiban and a PGF2α receptor antagonist, for example, a compound represented by formula (I), [ka] (wherein the formula, the Ar ring is an optionally condensed and optionally substituted aryl group, or an optionally condensed and optionally substituted heteroaryl group; The Cy ring is optionally condensed and optionally substituted aryl group, optionally condensed and optionally substituted heteroaryl group, optionally condensed and optionally substituted cycloalkyl group, or optionally condensed and optionally substituted heterocycloalkyl group; R 1H, carboxy, acyl, alkoxycarbonyl, C1~C5-alkylcarboxy, C1~C5-alkylacyl, C1~C5-alkylalkoxycarbonyl, C1~C5-alkylacyloxy, C1~C5-alkylsulfanyl, C1~C5-alkylsulfinyl, C1~C5-alkylsulfonyl, C1~C5-alkylsulfonyloxy, C1~C6-alkyl, C2~C6-alkenyl, C2~C6-alkynyl, aryl, heteroaryl, C3~C8-cycloalkyl, C1~C6-alkylaryl, C1~C6-alkylheteroaryl, C1~C6-alkylcycloalkyl, C2~C6-alkenylaryl, C2~C6-alkenylheteroaryl, C2~C6-alkynylaryl, C2~C6-alkynylheteroaryl, substituted carboxy, substituted acyl, substituted alkoxycarbonyl These are substituted C1-C5-alkylcarboxy, substituted C1-C5-alkylacyl, substituted C1-C5-alkylalkoxycarbonyl, substituted C1-C5-alkylacyloxy, substituted C1-C5-alkylsulfanyl, substituted C1-C5-alkylsulfinyl, substituted C1-C5-alkylsulfonyl, substituted C1-C5-alkylsulfonyloxy, substituted C1-C6-alkyl, substituted C2-C6-alkenyl, substituted C2-C6-alkynyl, substituted aryl, substituted heteroaryl, substituted C3-C8-cycloalkyl, substituted C1-C6-alkylaryl, substituted C1-C6-alkylheteroaryl, substituted C1-C6-alkylcycloalkyl, substituted C2-C6-alkenylaryl, substituted C2-C6-alkenylheteroaryl, substituted C2-C6-alkynylaryl, or substituted C2-C6-alkynylheteroaryl; Each R 2 These are independently C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, substituted C1-C6-alkyl, substituted C2-C6-alkenyl, or substituted C2-C6-alkynyl; n is an integer between 0 and 2. The method is characterized by administering either a pharmaceutically acceptable salt thereof to a pregnant subject, for example, a human subject in pregnancy, to prevent delivery before cesarean section.
[0021] According to the above-described embodiment, the compound can be administered to the subject in an amount of approximately 250 mg to approximately 2,500 mg per dose.
[0022] For example, the compound is present in amounts of approximately 250 mg to 750 mg per dose, for example, approximately 255 mg to 745 mg, approximately 260 mg to 740 mg, approximately 265 mg to 735 mg, approximately 270 mg to 730 mg, approximately 275 mg to 725 mg, approximately 280 mg to 720 mg, approximately 285 mg to 715 mg, approximately 290 mg to 710 mg, approximately 295 mg to 705 mg, approximately 300 mg to 700 mg, and approximately 305 mg per dose. mg ~ about 695mg, about 310mg - about 690mg, about 315mg - about 685mg, about 320mg - about 680mg, about 325mg - about 675mg, about 330mg - about 670mg, about 335mg - about 665mg , about 340 mg to about 660 mg, about 345 mg to about 655 mg, about 350 mg to about 650 mg, about 355 mg to about 645 mg, about 360 mg to about 640 mg, about 365 mg to about 635 mg, about 370 mg to about 630mg, about 375mg to about 625mg, about 380mg to about 620mg, about 385mg to about 615mg, about 390mg to about 610mg, about 395mg to about 605mg, about 400mg to about 600mg, about 4 05mg to about 595mg, about 410mg to about 590mg, about 415mg to about 585mg, about 420mg to about 580mg, about 425mg to about 575mg, about 430mg to about 570mg, about 435mg to about 565 The compound may be administered to the subject in amounts of mg, approximately 440 mg to 560 mg, approximately 445 mg to 555 mg, approximately 450 mg to 550 mg, approximately 455 mg to 545 mg, approximately 460 mg to 540 mg, approximately 465 mg to 535 mg, approximately 470 mg to 530 mg, approximately 475 mg to 525 mg, approximately 480 mg to 520 mg, approximately 485 mg to 515 mg, approximately 490 mg to 510 mg, or approximately 495 mg to 505 mg. In some embodiments, the compound is administered to the subject in amounts of approximately 500 mg per dose.
[0023] In some embodiments, the compound is present in amounts ranging from approximately 250 mg to approximately 2,000 mg per dose, for example, approximately 255 mg to approximately 1,990 mg, approximately 260 mg to approximately 1,980 mg, approximately 265 mg to approximately 1,970 mg, approximately 270 mg to approximately 1,960 mg, approximately 275 mg to approximately 1,950 mg, approximately 280 mg to approximately 1,940 mg, approximately 285 mg to approximately 1,930 mg, approximately 290 mg to approximately 1,920 mg, approximately 295 mg to approximately 1,910 mg, approximately 300 mg to approximately 1,900 mg, approximately 305 mg to approximately 1,890 mg, approximately 310 mg to approximately 1,880 mg, and approximately 315 mg per dose. mg ~ about 1,870 mg, about 320 mg - about 1,860 mg, about 325 mg - about 1,850 mg, about 330 mg - about 1,840 mg, about 335 mg - about 1,830 mg, about 340 mg - about 1,820 mg, about 345 mg - about 1,810 mg, about 350 mg - about 1,800 mg , about 355 mg to about 1,790 mg, about 360 mg to about 1,780 mg, about 365 mg to about 1,770 mg, about 370 mg to about 1,760 mg, about 375 mg to about 1,750 mg, about 380 mg to about 1,740 mg, about 385 mg to about 1,730 mg, about 390 mg to about 1,7 20mg, approximately 395mg to 1,710mg, approximately 400mg to 1,700mg, approximately 405mg to 1,690mg, approximately 410mg to 1,680mg, approximately 415mg to 1,670mg, approximately 420mg to 1,660mg, approximately 425mg to 1,650mg, approximately 430mg to 1,640mg, approximately 435mg to 1,630mg, approximately 440mg to 1,620mg, approximately 445mg to 1,610mg, approximately 450mg to 1,600mg, approximately 455mg to 1,590mg, approximately 460mg to 1,580mg, approximately 465mg to 1,570mg, approximately 4 70mg to about 1,560mg, about 475mg to about 1,550mg, about 480mg to about 1,540mg, about 485mg to about 1,530mg, about 490mg to about 1,520mg, about 495mg to about 1,510mg, about 500mg to about 1,500mg, about 505mg to about 1,495m g, approx. 510 mg ~ approx. 1,490 mg, approx. 515 mg ~ approx. 1,485 mg, approx. 520 mg ~ approx. 1,480 mg, approx. 525 mg ~ approx. 1,475 mg, approx.455mg, approximately 550mg to approximately 1,450mg, approximately 555mg to approximately 1,445mg, approximately 560mg to approximately 1,440mg, approximately 565mg to approximately 1,435mg, approximately 570mg to approximately 1,430mg, approximately 575mg to approximately 1,425mg, approximately 580mg to approximately 1,420mg, approximately 585mg to approximately 1,415mg, approximately 590mg to approximately 1,410mg, approximately 595mg to approximately 1,405mg, approximately 600mg to approximately 1,400mg, approximately 605mg to approximately 1,395mg, approximately 610mg to approximately 1,390mg, approximately 615mg to approximately 1,385mg, approximately 620mg to approximately 1,380mg, approximately 6 25mg~approx. 1,375mg, approx. 630mg~approx. 1,370mg, approx. 635mg~approx. 1,365mg, approx. 640mg~approx. 1,360mg, approx. 645mg~approx. 1,355mg, approx. 650mg~approx. 1,350mg, approx. 655mg~approx. 1,345mg, approx. 660mg~approx. 1,340mg, approx. 665mg~approx. 1,335mg, approx. 670mg~approx. 1,330mg, approx. 675mg~approx. 1,325mg, approx. 680mg~approx. 1,320mg, approx. 685mg~approx. 1,315mg, approx. 690mg~approx. 1,310mg, approx. 695mg~approx. 1,305mg, approx. 700mg~approx. 1, 300mg, approximately 705mg~approx. 1,295mg, approximately 710mg~approx. 1,290mg, approximately 715mg~approx. 1,285mg, approximately 720mg~approx. 1,280mg, approximately 725mg~approx. 1,275mg, approximately 730mg~approx. 1,270mg, approximately 735mg~approx. 1,265mg, approximately 740mg~approx. 1,260mg, approximately 745mg~approx. 1,255mg, approximately 750mg~approx. 1,250mg, approximately 755mg~approx. 1,245mg, approximately 760mg~approx. 1,240mg, approximately 765mg~approx. 1,235mg, approximately 770mg~approx. 1,230mg, approximately 775mg~approx. 1,225mg, approximately 7 80mg~approx. 1,220mg, approx. 785mg~approx. 1,215mg, approx. 790mg~approx. 1,210mg, approx. 795mg~approx. 1,205mg, approx. 800mg~approx. 1,200mg, approx. 805mg~approx. 1,195mg, approx. 810mg~approx. 1,190mg, approx. 815mg~approx. 1,185mg, approx. 820mg~approx. 1,180mg, approx. 825mg~approx. 1,175mg, approx. 830mg~approx. 1,170mg, approx. 835mg~approx. 1,165mg, approx. 840mg~approx. 1,160mg, approx. 845mg~approx. 1,155mg, approx. 850mg~approx. 1,150mg, approx. 855mg~approx. 1,145mg, about 860mg to about 1,140mg, about 865mg to about 1,135mg, about 870mg to about 1,130mg, about 875mg to about 1,125mg, about 880mg to about 1,120mg, about 885mg to about 1,115mg, about 890mg to about 1,110mg , about 895 mg to about 1,105 mg, about 900 mg to about 1,000 mg, about 905 mg to about 1,095 mg, about 910 mg to about 1,090 mg, about 915 mg to about 1,085 mg, about 920 mg to about 1,080 mg, about 925 mg to about 1,075 mg, about 930 The compound is administered to the subject in amounts ranging from approximately 1,070 mg to 9,070 mg, 935 mg to 1,065 mg, 940 mg to 1,060 mg, 945 mg to 1,055 mg, 950 mg to 1,050 mg, 955 mg to 1,045 mg, 960 mg to 1,040 mg, 965 mg to 1,035 mg, 970 mg to 1,030 mg, 975 mg to 1,025 mg, 980 mg to 1,020 mg, 985 mg to 1,015 mg, 990 mg to 1,010 mg, or 995 mg to 1,005 mg. In some embodiments, the compound is administered to the subject in amounts ranging from approximately 1,000 mg per dose.
[0024] In some embodiments, the compound is present in amounts of approximately 1,500 mg to approximately 2,500 mg per dose, for example, approximately 1,505 mg to approximately 2,495 mg, approximately 1,510 mg to approximately 2,490 mg, approximately 1,515 mg to approximately 2,485 mg, approximately 1,520 mg to approximately 2,480 mg, approximately 1,525 mg to approximately 2,475 mg, approximately 1,530 mg to approximately 2,470 mg, approximately 1,535 mg to approximately 2,465 mg, approximately 1,540 mg to approximately 2,460 mg, approximately 1,545 mg to approximately 2,455 mg, approximately 1,550 mg to approximately 2,450 mg, and approximately 1,555 mg to approximately 2,445 mg per dose. , about 1,560mg to about 2,440mg, about 1,565mg to about 2,435mg, about 1,570mg to about 2,430mg, about 1,575mg to about 2,425mg, about 1,580mg to about 2,420mg, about 1,585mg to about 2,415mg, about 1,590mg to about 2,410m g, approx. 1,595 mg ~ approx. 2,405 mg, approx. 1,600 mg ~ approx. 2,400 mg, approx. 1,605 mg ~ approx. 2,395 mg, approx. 1,610 mg ~ approx. 2,390 mg, approx. mg, approx. 1,630 mg ~ approx. 2,370 mg, approx. 1,635 mg ~ approx. 2,365 mg, approx. 1,640 mg ~ approx. 2,360 mg, approx. 1,645 mg ~ approx. 2,355 mg, approx. 0mg, about 1,665mg to about 2,335mg, about 1,670mg to about 2,330mg, about 1,675mg to about 2,325mg, about 1,680mg to about 2,320mg, about 1,685mg to about 2,315mg, about 1,690mg to about 2,310mg, about 1,695mg to about 2,3 05mg, about 1,700mg to about 2,300mg, about 1,705mg to about 2,295mg, about 1,710mg to about 2,290mg, about 1,715mg to about 2,285mg, about 1,720mg to about 2,280mg, about 1,725mg to about 2,275mg, about 1,730mg to about 2, 270mg, about 1,735mg to about 2,265mg, about 1,740mg to about 2,260mg, about 1,745mg to about 2,255mg, about 1,750mg to about 2,250mg, about 1,755mg to about 2,245mg, about 1,760mg to about 2,240mg, about 1,765mg to about 2,235mg, approximately 1,770mg to approximately 2,230mg, approximately 1,775mg to approximately 2,225mg, approximately 1,780mg to approximately 2,220mg, approximately 1,785mg to approximately 2,215mg, approximately 1,790mg to approximately 2,210mg, approximately 1,795mg to approximately 2,205mg, about 1,800mg to about 2,200mg, about 1,805mg to about 2,195mg, about 1,810mg to about 2,190mg, about 1,815mg to about 2,185mg, about 1,820mg to about 2,180mg, about 1,825mg ~2,175mg, 1,830mg~2,170mg, 1,835mg~2,165mg, 1,840mg~2,160mg, 1,845mg~2,155mg, 1,850mg~2,150mg, 1,855 mg ~ approx. 2,145 mg, approx. 1,860 mg ~ approx. 2,140 mg, approx. 1,865 mg ~ approx. 2,135 mg, approx. 1,870 mg ~ approx. 2,130 mg, approx. 85mg to about 2,115mg, about 1,890mg to about 2,110mg, about 1,895mg to about 2,105mg, about 1,900mg to about 2,100mg, about 1,905mg to about 2,095mg, about 1,910mg to about 2,090mg, about 1 , 915mg to about 2,085mg, about 1,920mg to about 2,080mg, about 1,925mg to about 2,075mg, about 1,930mg to about 2,070mg, about 1,935mg to about 2,065mg, about 1,940mg to about 2,060mg, The compound is administered to the subject in amounts of approximately 1,945 mg to 2,055 mg, 1,950 mg to 2,050 mg, 1,955 mg to 2,045 mg, 1,960 mg to 2,040 mg, 1,965 mg to 2,035 mg, 1,970 mg to 2,030 mg, 1,975 mg to 2,025 mg, 1,980 mg to 2,020 mg, 1,985 mg to 2,015 mg, 1,990 mg to 2,010 mg, or 1,995 mg to 2,005 mg. In some embodiments, the compound is administered to the subject in amounts of approximately 2,000 mg per dose.
[0025] For example, in some embodiments, the compound is used in doses of approximately 250 mg, 255 mg, 260 mg, 265 mg, 270 mg, 275 mg, 280 mg, 285 mg, 290 mg, 295 mg, 300 mg, 305 mg, 310 mg, 315 mg, 320 mg, 325 mg, 330 mg, 335 mg, 340 mg, 345 mg, 350 mg, 355 mg, 360 mg, 365 mg, 370 mg, 375 mg, 380 mg, 385 mg, 390 mg, 395 mg, 400 mg, 405 mg, 410 mg, 415 mg, 420 mg, 425 mg, and 430 mg per dose. g, 435mg, 440mg, 445mg, 450mg, 455mg, 460mg, 465mg, 470mg, 475mg, 480mg, 485mg, 490mg, 495mg, 500mg, 505mg, 510mg, 515mg, 520mg, 525mg, 530mg, 53 5mg, 540mg, 545mg, 550mg, 555mg, 560mg, 565mg, 570mg, 575mg, 580mg, 585mg, 590mg, 595mg, 600mg, 605mg, 610mg, 615mg, 620mg, 625mg, 630mg, 635mg, 6 40mg, 645mg, 650mg, 655mg, 660mg, 665mg, 670mg, 675mg, 680mg, 685mg, 690mg, 695mg, 700mg, 705mg, 710mg, 715mg, 720mg, 725mg, 730mg, 735mg, 740mg , 745mg, 750mg, 755mg, 760mg, 765mg, 770mg, 775mg, 780mg, 785mg, 790mg, 795mg, 800mg, 805mg, 810mg, 815mg, 820mg, 825mg, 830mg, 835mg, 840mg, 845 mg, 850mg, 855mg, 860mg, 865mg, 870mg, 875mg, 880mg, 885mg, 890mg, 895mg, 900mg, 905mg, 910mg, 915mg, 920mg, 925mg, 930mg, 935mg, 940mg, 945mg, 9 50mg, 955mg, 960mg, 965mg, 970mg, 975mg, 980mg, 985mg, 990mg, 995mg, 1,000mg, 1,005mg, 1,010mg, 1,015mg, 1,020mg, 1,025mg, 1,030mg, 1,035mg, 1,040mg、1,045mg、1,050mg、1,055mg、1,060mg、1,065mg、1,070mg、1,075mg、1,080mg、1,085mg、1,090mg、1,095mg、1,100mg、1,105mg、1,110mg、1,115mg、1,120mg、1,125mg、1,130mg、1,135mg、1,140mg、1,145mg、1,150mg、1,155mg、1,160mg、1,165mg、1,170mg、1,175mg、1,180mg、1,185mg、1,190mg、1,195mg、1,200mg、1,205mg、1,210mg、1,215mg、1,220mg、1,225mg、1,230mg、1,235mg、1,240mg、1,245mg、1,250mg、1,255mg、1,260mg、1,265mg、1,270mg、1,275mg、1,280mg、1,285mg、1,290mg、1,295mg、1,300mg、1,305mg、1,310mg、1,315mg、1,320mg、1,325mg、1,330mg、1,335mg、1,340mg、1,345mg、1,350mg、1,355mg、1,360mg、1,365mg、1,370mg、1,375mg、1,380mg、1,385mg、1,390mg、1,395mg、1,400mg、1,405mg、1,410mg、1,415mg、1,420mg、1,425mg、1,430mg、1,435mg、1,440mg、1,445mg、1,450mg、1,455mg、1,460mg、1,465mg、1,470mg、1,475mg、1,480mg、1,485mg、1,490mg、1,495mg、1,500mg、1,505mg、1,510mg、1,515mg、1,520mg、1,525mg、1,530mg、1,535mg、1,540mg、1,545mg、1,550mg、1,555mg、1,560mg、1,565mg、1,570mg、1,575mg、1,580mg、1,585mg、1,590mg、1,595mg、1,600mg、1,605mg、1,610mg、1,615mg、1,620mg、1,625mg、1,630mg、1,635mg、1,640mg、1,645mg、1,650mg、1,655mg、1,660mg、1,665mg、1,670mg、1,675mg、1,680mg、1,685mg、1,690mg、1,695mg、1,700mg、1,705mg、1,710mg、1,715mg、1,720mg、1,725mg、1,730mg、1,735mg、1,740mg、1,745mg、1,750mg、1,755mg、1,760mg、1,765mg、1,770mg、1,775mg、1,780mg、1,785mg、1,790mg、1,795mg、1,800mg、1,805mg、1,810mg、1,815mg、1,820mg、1,825mg、1,830mg、1,835mg、1,840mg、1,845mg、1,850mg、1,855mg、1,860mg、1,865mg、1,870mg、1,875mg、1,880mg、1,885mg、1,890mg、1,895mg、1,900mg、1,905mg、1,910mg、1,915mg、1,920mg、1,925mg、1,930mg、1,935mg、1,940mg、1,945mg、1,950mg、1,955mg、1,960mg、1,965mg、1,970mg、1,975mg、1,980mg、1,985mg、1,990mg、1,995mg、2,000mg、2,005mg、2,010mg、2,015mg、2,020mg、2,025mg、2,030mg、2,035mg、2,040mg、2,045mg、2,050mg、2,055mg、2,060mg、2,065mg、2,070mg、2,075mg、2,080mg、2,085mg、2,090mg、2,095mg、2,100mg、2,105mg、2,110mg、2,115mg、2,120mg、2,125mg、2,130mg、2,135mg、2,140mg、2,145mg、2,150mg、2,155mg、2,160mg、2,165mg、2,170mg、2,175mg、2,180mg、2,185mg、2,190mg、2,195mg、2,200mg、2,205mg、2,210mg、2,215mg、2,220mg、2,225mg、2,230mg、2,235mg、2,240mg、2,245mg、2,250mg、2,255mg、2,260mg、2,265mg、2,270mg、2,275mg、2,280mg、2,285mg、2,290mg, 2,295mg, 2,300mg, 2,305mg, 2,310mg, 2,315mg, 2,320mg, 2,325mg, 2,330mg, 2,335mg, 2,340mg, 2,3 45mg, 2,350mg, 2,355mg, 2,360mg, 2,365mg, 2,370mg, 2,375mg, 2,380mg, 2,385mg, 2,390mg, 2,395mg, 2,40 The drug is administered to the target individual in doses of 0 mg, 2,405 mg, 2,410 mg, 2,415 mg, 2,420 mg, 2,425 mg, 2,430 mg, 2,435 mg, 2,440 mg, 2,445 mg, 2,450 mg, 2,455 mg, 2,460 mg, 2,465 mg, 2,470 mg, 2,475 mg, 2,480 mg, 2,485 mg, 2,490 mg, 2,495 mg, or 2,500 mg.
[0026] In additional embodiments, the Disclosure relates to therapeutically effective doses of atosiban and a PGF2α receptor antagonist, for example, a compound represented by formula (I), [ka] (wherein the formula, the Ar ring is an optionally condensed and optionally substituted aryl group, or an optionally condensed and optionally substituted heteroaryl group; The Cy ring is optionally condensed and optionally substituted aryl group, optionally condensed and optionally substituted heteroaryl group, optionally condensed and optionally substituted cycloalkyl group, or optionally condensed and optionally substituted heterocycloalkyl group; R 1H, carboxy, acyl, alkoxycarbonyl, C1~C5-alkylcarboxy, C1~C5-alkylacyl, C1~C5-alkylalkoxycarbonyl, C1~C5-alkylacyloxy, C1~C5-alkylsulfanyl, C1~C5-alkylsulfinyl, C1~C5-alkylsulfonyl, C1~C5-alkylsulfonyloxy, C1~C6-alkyl, C2~C6-alkenyl, C2~C6-alkynyl, aryl, heteroaryl, C3~C8-cycloalkyl, C1~C6-alkylaryl, C1~C6-alkylheteroaryl, C1~C6-alkylcycloalkyl, C2~C6-alkenylaryl, C2~C6-alkenylheteroaryl, C2~C6-alkynylaryl, C2~C6-alkynylheteroaryl, substituted carboxy, substituted acyl, substituted alkoxycarbonyl These are substituted C1-C5-alkylcarboxy, substituted C1-C5-alkylacyl, substituted C1-C5-alkylalkoxycarbonyl, substituted C1-C5-alkylacyloxy, substituted C1-C5-alkylsulfanyl, substituted C1-C5-alkylsulfinyl, substituted C1-C5-alkylsulfonyl, substituted C1-C5-alkylsulfonyloxy, substituted C1-C6-alkyl, substituted C2-C6-alkenyl, substituted C2-C6-alkynyl, substituted aryl, substituted heteroaryl, substituted C3-C8-cycloalkyl, substituted C1-C6-alkylaryl, substituted C1-C6-alkylheteroaryl, substituted C1-C6-alkylcycloalkyl, substituted C2-C6-alkenylaryl, substituted C2-C6-alkenylheteroaryl, substituted C2-C6-alkynylaryl, or substituted C2-C6-alkynylheteroaryl; Each R 2 These are independently C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, substituted C1-C6-alkyl, substituted C2-C6-alkenyl, or substituted C2-C6-alkynyl; n is an integer between 0 and 2. The present invention features a method of reducing the frequency, peak amplitude, duration, and / or activity of uterine contractions in pregnant subjects, such as pregnant human subjects, by administering a pharmaceutically acceptable salt thereof to the subject.
[0027] According to the above-described embodiment, the compound can be administered to the subject in an amount of approximately 250 mg to approximately 2,500 mg per dose.
[0028] For example, the compound is present in amounts of approximately 250 mg to 750 mg per dose, for example, approximately 255 mg to 745 mg, approximately 260 mg to 740 mg, approximately 265 mg to 735 mg, approximately 270 mg to 730 mg, approximately 275 mg to 725 mg, approximately 280 mg to 720 mg, approximately 285 mg to 715 mg, approximately 290 mg to 710 mg, approximately 295 mg to 705 mg, approximately 300 mg to 700 mg, and approximately 305 mg per dose. mg ~ about 695mg, about 310mg - about 690mg, about 315mg - about 685mg, about 320mg - about 680mg, about 325mg - about 675mg, about 330mg - about 670mg, about 335mg - about 665mg , about 340 mg to about 660 mg, about 345 mg to about 655 mg, about 350 mg to about 650 mg, about 355 mg to about 645 mg, about 360 mg to about 640 mg, about 365 mg to about 635 mg, about 370 mg to about 630mg, about 375mg to about 625mg, about 380mg to about 620mg, about 385mg to about 615mg, about 390mg to about 610mg, about 395mg to about 605mg, about 400mg to about 600mg, about 4 05mg to about 595mg, about 410mg to about 590mg, about 415mg to about 585mg, about 420mg to about 580mg, about 425mg to about 575mg, about 430mg to about 570mg, about 435mg to about 565 The compound may be administered to the subject in amounts of mg, approximately 440 mg to 560 mg, approximately 445 mg to 555 mg, approximately 450 mg to 550 mg, approximately 455 mg to 545 mg, approximately 460 mg to 540 mg, approximately 465 mg to 535 mg, approximately 470 mg to 530 mg, approximately 475 mg to 525 mg, approximately 480 mg to 520 mg, approximately 485 mg to 515 mg, approximately 490 mg to 510 mg, or approximately 495 mg to 505 mg. In some embodiments, the compound is administered to the subject in amounts of approximately 500 mg per dose.
[0029] In some embodiments, the compound is present in amounts ranging from approximately 250 mg to approximately 2,000 mg per dose, for example, approximately 255 mg to approximately 1,990 mg, approximately 260 mg to approximately 1,980 mg, approximately 265 mg to approximately 1,970 mg, approximately 270 mg to approximately 1,960 mg, approximately 275 mg to approximately 1,950 mg, approximately 280 mg to approximately 1,940 mg, approximately 285 mg to approximately 1,930 mg, approximately 290 mg to approximately 1,920 mg, approximately 295 mg to approximately 1,910 mg, approximately 300 mg to approximately 1,900 mg, approximately 305 mg to approximately 1,890 mg, approximately 310 mg to approximately 1,880 mg, and approximately 315 mg per dose. mg ~ about 1,870 mg, about 320 mg - about 1,860 mg, about 325 mg - about 1,850 mg, about 330 mg - about 1,840 mg, about 335 mg - about 1,830 mg, about 340 mg - about 1,820 mg, about 345 mg - about 1,810 mg, about 350 mg - about 1,800 mg , about 355 mg to about 1,790 mg, about 360 mg to about 1,780 mg, about 365 mg to about 1,770 mg, about 370 mg to about 1,760 mg, about 375 mg to about 1,750 mg, about 380 mg to about 1,740 mg, about 385 mg to about 1,730 mg, about 390 mg to about 1,7 20mg, approximately 395mg to 1,710mg, approximately 400mg to 1,700mg, approximately 405mg to 1,690mg, approximately 410mg to 1,680mg, approximately 415mg to 1,670mg, approximately 420mg to 1,660mg, approximately 425mg to 1,650mg, approximately 430mg to 1,640mg, approximately 435mg to 1,630mg, approximately 440mg to 1,620mg, approximately 445mg to 1,610mg, approximately 450mg to 1,600mg, approximately 455mg to 1,590mg, approximately 460mg to 1,580mg, approximately 465mg to 1,570mg, approximately 4 70mg to about 1,560mg, about 475mg to about 1,550mg, about 480mg to about 1,540mg, about 485mg to about 1,530mg, about 490mg to about 1,520mg, about 495mg to about 1,510mg, about 500mg to about 1,500mg, about 505mg to about 1,495m g, approx. 510 mg ~ approx. 1,490 mg, approx. 515 mg ~ approx. 1,485 mg, approx. 520 mg ~ approx. 1,480 mg, approx. 525 mg ~ approx. 1,475 mg, approx.455mg, approximately 550mg to approximately 1,450mg, approximately 555mg to approximately 1,445mg, approximately 560mg to approximately 1,440mg, approximately 565mg to approximately 1,435mg, approximately 570mg to approximately 1,430mg, approximately 575mg to approximately 1,425mg, approximately 580mg to approximately 1,420mg, approximately 585mg to approximately 1,415mg, approximately 590mg to approximately 1,410mg, approximately 595mg to approximately 1,405mg, approximately 600mg to approximately 1,400mg, approximately 605mg to approximately 1,395mg, approximately 610mg to approximately 1,390mg, approximately 615mg to approximately 1,385mg, approximately 620mg to approximately 1,380mg, approximately 6 25mg~approx. 1,375mg, approx. 630mg~approx. 1,370mg, approx. 635mg~approx. 1,365mg, approx. 640mg~approx. 1,360mg, approx. 645mg~approx. 1,355mg, approx. 650mg~approx. 1,350mg, approx. 655mg~approx. 1,345mg, approx. 660mg~approx. 1,340mg, approx. 665mg~approx. 1,335mg, approx. 670mg~approx. 1,330mg, approx. 675mg~approx. 1,325mg, approx. 680mg~approx. 1,320mg, approx. 685mg~approx. 1,315mg, approx. 690mg~approx. 1,310mg, approx. 695mg~approx. 1,305mg, approx. 700mg~approx. 1, 300mg, approximately 705mg~approx. 1,295mg, approximately 710mg~approx. 1,290mg, approximately 715mg~approx. 1,285mg, approximately 720mg~approx. 1,280mg, approximately 725mg~approx. 1,275mg, approximately 730mg~approx. 1,270mg, approximately 735mg~approx. 1,265mg, approximately 740mg~approx. 1,260mg, approximately 745mg~approx. 1,255mg, approximately 750mg~approx. 1,250mg, approximately 755mg~approx. 1,245mg, approximately 760mg~approx. 1,240mg, approximately 765mg~approx. 1,235mg, approximately 770mg~approx. 1,230mg, approximately 775mg~approx. 1,225mg, approximately 7 80mg~approx. 1,220mg, approx. 785mg~approx. 1,215mg, approx. 790mg~approx. 1,210mg, approx. 795mg~approx. 1,205mg, approx. 800mg~approx. 1,200mg, approx. 805mg~approx. 1,195mg, approx. 810mg~approx. 1,190mg, approx. 815mg~approx. 1,185mg, approx. 820mg~approx. 1,180mg, approx. 825mg~approx. 1,175mg, approx. 830mg~approx. 1,170mg, approx. 835mg~approx. 1,165mg, approx. 840mg~approx. 1,160mg, approx. 845mg~approx. 1,155mg, approx. 850mg~approx. 1,150mg, approx. 855mg~approx. 1,145mg, about 860mg to about 1,140mg, about 865mg to about 1,135mg, about 870mg to about 1,130mg, about 875mg to about 1,125mg, about 880mg to about 1,120mg, about 885mg to about 1,115mg, about 890mg to about 1,110mg , about 895 mg to about 1,105 mg, about 900 mg to about 1,000 mg, about 905 mg to about 1,095 mg, about 910 mg to about 1,090 mg, about 915 mg to about 1,085 mg, about 920 mg to about 1,080 mg, about 925 mg to about 1,075 mg, about 930 The compound is administered to the subject in amounts ranging from approximately 1,070 mg to 9,070 mg, 935 mg to 1,065 mg, 940 mg to 1,060 mg, 945 mg to 1,055 mg, 950 mg to 1,050 mg, 955 mg to 1,045 mg, 960 mg to 1,040 mg, 965 mg to 1,035 mg, 970 mg to 1,030 mg, 975 mg to 1,025 mg, 980 mg to 1,020 mg, 985 mg to 1,015 mg, 990 mg to 1,010 mg, or 995 mg to 1,005 mg. In some embodiments, the compound is administered to the subject in amounts ranging from approximately 1,000 mg per dose.
[0030] In some embodiments, the compound is present in amounts of approximately 1,500 mg to approximately 2,500 mg per dose, for example, approximately 1,505 mg to approximately 2,495 mg, approximately 1,510 mg to approximately 2,490 mg, approximately 1,515 mg to approximately 2,485 mg, approximately 1,520 mg to approximately 2,480 mg, approximately 1,525 mg to approximately 2,475 mg, approximately 1,530 mg to approximately 2,470 mg, approximately 1,535 mg to approximately 2,465 mg, approximately 1,540 mg to approximately 2,460 mg, approximately 1,545 mg to approximately 2,455 mg, approximately 1,550 mg to approximately 2,450 mg, and approximately 1,555 mg to approximately 2,445 mg per dose. , about 1,560mg to about 2,440mg, about 1,565mg to about 2,435mg, about 1,570mg to about 2,430mg, about 1,575mg to about 2,425mg, about 1,580mg to about 2,420mg, about 1,585mg to about 2,415mg, about 1,590mg to about 2,410m g, approx. 1,595 mg ~ approx. 2,405 mg, approx. 1,600 mg ~ approx. 2,400 mg, approx. 1,605 mg ~ approx. 2,395 mg, approx. 1,610 mg ~ approx. 2,390 mg, approx. mg, approx. 1,630 mg ~ approx. 2,370 mg, approx. 1,635 mg ~ approx. 2,365 mg, approx. 1,640 mg ~ approx. 2,360 mg, approx. 1,645 mg ~ approx. 2,355 mg, approx. 0mg, about 1,665mg to about 2,335mg, about 1,670mg to about 2,330mg, about 1,675mg to about 2,325mg, about 1,680mg to about 2,320mg, about 1,685mg to about 2,315mg, about 1,690mg to about 2,310mg, about 1,695mg to about 2,3 05mg, about 1,700mg to about 2,300mg, about 1,705mg to about 2,295mg, about 1,710mg to about 2,290mg, about 1,715mg to about 2,285mg, about 1,720mg to about 2,280mg, about 1,725mg to about 2,275mg, about 1,730mg to about 2, 270mg, about 1,735mg to about 2,265mg, about 1,740mg to about 2,260mg, about 1,745mg to about 2,255mg, about 1,750mg to about 2,250mg, about 1,755mg to about 2,245mg, about 1,760mg to about 2,240mg, about 1,765mg to about 2,235mg, approximately 1,770mg to approximately 2,230mg, approximately 1,775mg to approximately 2,225mg, approximately 1,780mg to approximately 2,220mg, approximately 1,785mg to approximately 2,215mg, approximately 1,790mg to approximately 2,210mg, approximately 1,795mg to approximately 2,205mg, about 1,800mg to about 2,200mg, about 1,805mg to about 2,195mg, about 1,810mg to about 2,190mg, about 1,815mg to about 2,185mg, about 1,820mg to about 2,180mg, about 1,825mg ~2,175mg, 1,830mg~2,170mg, 1,835mg~2,165mg, 1,840mg~2,160mg, 1,845mg~2,155mg, 1,850mg~2,150mg, 1,855 mg ~ approx. 2,145 mg, approx. 1,860 mg ~ approx. 2,140 mg, approx. 1,865 mg ~ approx. 2,135 mg, approx. 1,870 mg ~ approx. 2,130 mg, approx. 85mg to about 2,115mg, about 1,890mg to about 2,110mg, about 1,895mg to about 2,105mg, about 1,900mg to about 2,100mg, about 1,905mg to about 2,095mg, about 1,910mg to about 2,090mg, about 1 , 915mg to about 2,085mg, about 1,920mg to about 2,080mg, about 1,925mg to about 2,075mg, about 1,930mg to about 2,070mg, about 1,935mg to about 2,065mg, about 1,940mg to about 2,060mg, The compound is administered to the subject in amounts of approximately 1,945 mg to 2,055 mg, 1,950 mg to 2,050 mg, 1,955 mg to 2,045 mg, 1,960 mg to 2,040 mg, 1,965 mg to 2,035 mg, 1,970 mg to 2,030 mg, 1,975 mg to 2,025 mg, 1,980 mg to 2,020 mg, 1,985 mg to 2,015 mg, 1,990 mg to 2,010 mg, or 1,995 mg to 2,005 mg. In some embodiments, the compound is administered to the subject in amounts of approximately 2,000 mg per dose.
[0031] For example, in some embodiments, the compound is used in doses of approximately 250 mg, 255 mg, 260 mg, 265 mg, 270 mg, 275 mg, 280 mg, 285 mg, 290 mg, 295 mg, 300 mg, 305 mg, 310 mg, 315 mg, 320 mg, 325 mg, 330 mg, 335 mg, 340 mg, 345 mg, 350 mg, 355 mg, 360 mg, 365 mg, 370 mg, 375 mg, 380 mg, 385 mg, 390 mg, 395 mg, 400 mg, 405 mg, 410 mg, 415 mg, 420 mg, 425 mg, and 430 mg per dose. g, 435mg, 440mg, 445mg, 450mg, 455mg, 460mg, 465mg, 470mg, 475mg, 480mg, 485mg, 490mg, 495mg, 500mg, 505mg, 510mg, 515mg, 520mg, 525mg, 530mg, 53 5mg, 540mg, 545mg, 550mg, 555mg, 560mg, 565mg, 570mg, 575mg, 580mg, 585mg, 590mg, 595mg, 600mg, 605mg, 610mg, 615mg, 620mg, 625mg, 630mg, 635mg, 6 40mg, 645mg, 650mg, 655mg, 660mg, 665mg, 670mg, 675mg, 680mg, 685mg, 690mg, 695mg, 700mg, 705mg, 710mg, 715mg, 720mg, 725mg, 730mg, 735mg, 740mg , 745mg, 750mg, 755mg, 760mg, 765mg, 770mg, 775mg, 780mg, 785mg, 790mg, 795mg, 800mg, 805mg, 810mg, 815mg, 820mg, 825mg, 830mg, 835mg, 840mg, 845 mg, 850mg, 855mg, 860mg, 865mg, 870mg, 875mg, 880mg, 885mg, 890mg, 895mg, 900mg, 905mg, 910mg, 915mg, 920mg, 925mg, 930mg, 935mg, 940mg, 945mg, 9 50mg, 955mg, 960mg, 965mg, 970mg, 975mg, 980mg, 985mg, 990mg, 995mg, 1,000mg, 1,005mg, 1,010mg, 1,015mg, 1,020mg, 1,025mg, 1,030mg, 1,035mg, 1,040mg、1,045mg、1,050mg、1,055mg、1,060mg、1,065mg、1,070mg、1,075mg、1,080mg、1,085mg、1,090mg、1,095mg、1,100mg、1,105mg、1,110mg、1,115mg、1,120mg、1,125mg、1,130mg、1,135mg、1,140mg、1,145mg、1,150mg、1,155mg、1,160mg、1,165mg、1,170mg、1,175mg、1,180mg、1,185mg、1,190mg、1,195mg、1,200mg、1,205mg、1,210mg、1,215mg、1,220mg、1,225mg、1,230mg、1,235mg、1,240mg、1,245mg、1,250mg、1,255mg、1,260mg、1,265mg、1,270mg、1,275mg、1,280mg、1,285mg、1,290mg、1,295mg、1,300mg、1,305mg、1,310mg、1,315mg、1,320mg、1,325mg、1,330mg、1,335mg、1,340mg、1,345mg、1,350mg、1,355mg、1,360mg、1,365mg、1,370mg、1,375mg、1,380mg、1,385mg、1,390mg、1,395mg、1,400mg、1,405mg、1,410mg、1,415mg、1,420mg、1,425mg、1,430mg、1,435mg、1,440mg、1,445mg、1,450mg、1,455mg、1,460mg、1,465mg、1,470mg、1,475mg、1,480mg、1,485mg、1,490mg、1,495mg、1,500mg、1,505mg、1,510mg、1,515mg、1,520mg、1,525mg、1,530mg、1,535mg、1,540mg、1,545mg、1,550mg、1,555mg、1,560mg、1,565mg、1,570mg、1,575mg、1,580mg、1,585mg、1,590mg、1,595mg、1,600mg、1,605mg、1,610mg、1,615mg、1,620mg、1,625mg、1,630mg、1,635mg、1,640mg、1,645mg、1,650mg、1,655mg、1,660mg、1,665mg、1,670mg、1,675mg、1,680mg、1,685mg、1,690mg、1,695mg、1,700mg、1,705mg、1,710mg、1,715mg、1,720mg、1,725mg、1,730mg、1,735mg、1,740mg、1,745mg、1,750mg、1,755mg、1,760mg、1,765mg、1,770mg、1,775mg、1,780mg、1,785mg、1,790mg、1,795mg、1,800mg、1,805mg、1,810mg、1,815mg、1,820mg、1,825mg、1,830mg、1,835mg、1,840mg、1,845mg、1,850mg、1,855mg、1,860mg、1,865mg、1,870mg、1,875mg、1,880mg、1,885mg、1,890mg、1,895mg、1,900mg、1,905mg、1,910mg、1,915mg、1,920mg、1,925mg、1,930mg、1,935mg、1,940mg、1,945mg、1,950mg、1,955mg、1,960mg、1,965mg、1,970mg、1,975mg、1,980mg、1,985mg、1,990mg、1,995mg、2,000mg、2,005mg、2,010mg、2,015mg、2,020mg、2,025mg、2,030mg、2,035mg、2,040mg、2,045mg、2,050mg、2,055mg、2,060mg、2,065mg、2,070mg、2,075mg、2,080mg、2,085mg、2,090mg、2,095mg、2,100mg、2,105mg、2,110mg、2,115mg、2,120mg、2,125mg、2,130mg、2,135mg、2,140mg、2,145mg、2,150mg、2,155mg、2,160mg、2,165mg、2,170mg、2,175mg、2,180mg、2,185mg、2,190mg、2,195mg、2,200mg、2,205mg、2,210mg、2,215mg、2,220mg、2,225mg、2,230mg、2,235mg、2,240mg、2,245mg、2,250mg、2,255mg、2,260mg、2,265mg、2,270mg、2,275mg、2,280mg、2,285mg、2,administered to a subject in an amount of 290 mg, 2,295 mg, 2,300 mg, 2,305 mg, 2,310 mg, 2,315 mg, 2,320 mg, 2,325 mg, 2,330 mg, 2,335 mg, 2,340 mg, 2,345 mg, 2,350 mg, 2,355 mg, 2,360 mg, 2,365 mg, 2,370 mg, 2,375 mg, 2,380 mg, 2,385 mg, 2,390 mg, 2,395 mg, 2,400 mg, 2,405 mg, 2,410 mg, 2,415 mg, 2,420 mg, 2,425 mg, 2,430 mg, 2,435 mg, 2,440 mg, 2,445 mg, 2,450 mg, 2,455 mg, 2,460 mg, 2,465 mg, 2,470 mg, 2,475 mg, 2,480 mg, 2,485 mg, 2,490 mg, 2,495 mg, or 2,500 mg.
[0032] In yet another aspect, the disclosure relates to a therapeutically effective amount of atosiban and a PGF2α receptor antagonist, for example, a compound represented by formula (I), [Chemical formula] (wherein the Ar ring is an optionally fused and optionally substituted aryl group or an optionally fused and optionally substituted heteroaryl group; the Cy ring is an optionally fused and optionally substituted aryl group, an optionally fused and optionally substituted heteroaryl group, an optionally fused and optionally substituted cycloalkyl group, or an optionally fused and optionally substituted heterocycloalkyl group; R 1H, carboxy, acyl, alkoxycarbonyl, C1~C5-alkylcarboxy, C1~C5-alkylacyl, C1~C5-alkylalkoxycarbonyl, C1~C5-alkylacyloxy, C1~C5-alkylsulfanyl, C1~C5-alkylsulfinyl, C1~C5-alkylsulfonyl, C1~C5-alkylsulfonyloxy, C1~C6-alkyl, C2~C6-alkenyl, C2~C6-alkynyl, aryl, heteroaryl, C3~C8-cycloalkyl, C1~C6-alkylaryl, C1~C6-alkylheteroaryl, C1~C6-alkylcycloalkyl, C2~C6-alkenylaryl, C2~C6-alkenylheteroaryl, C2~C6-alkynylaryl, C2~C6-alkynylheteroaryl, substituted carboxy, substituted acyl, substituted alkoxycarbonyl These are substituted C1-C5-alkylcarboxy, substituted C1-C5-alkylacyl, substituted C1-C5-alkylalkoxycarbonyl, substituted C1-C5-alkylacyloxy, substituted C1-C5-alkylsulfanyl, substituted C1-C5-alkylsulfinyl, substituted C1-C5-alkylsulfonyl, substituted C1-C5-alkylsulfonyloxy, substituted C1-C6-alkyl, substituted C2-C6-alkenyl, substituted C2-C6-alkynyl, substituted aryl, substituted heteroaryl, substituted C3-C8-cycloalkyl, substituted C1-C6-alkylaryl, substituted C1-C6-alkylheteroaryl, substituted C1-C6-alkylcycloalkyl, substituted C2-C6-alkenylaryl, substituted C2-C6-alkenylheteroaryl, substituted C2-C6-alkynylaryl, or substituted C2-C6-alkynylheteroaryl; Each R 2 These are independently C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, substituted C1-C6-alkyl, substituted C2-C6-alkenyl, or substituted C2-C6-alkynyl; n is an integer between 0 and 2. Alternatively, the method is characterized by reducing the expression of pro-inflammatory and / or contractile genes such as thyrooxygenase-2 (Cox2) in pregnant subjects, for example, in pregnant human subjects (e.g., in the uterine muscle of pregnant human subjects), by administering a pharmaceutically acceptable salt thereof to the subject.
[0033] According to the above-described embodiment, the compound can be administered to the subject in an amount of approximately 250 mg to approximately 2,500 mg per dose.
[0034] For example, the compound is present in amounts of approximately 250 mg to 750 mg per dose, for example, approximately 255 mg to 745 mg, approximately 260 mg to 740 mg, approximately 265 mg to 735 mg, approximately 270 mg to 730 mg, approximately 275 mg to 725 mg, approximately 280 mg to 720 mg, approximately 285 mg to 715 mg, approximately 290 mg to 710 mg, approximately 295 mg to 705 mg, approximately 300 mg to 700 mg, and approximately 305 mg per dose. mg ~ about 695mg, about 310mg - about 690mg, about 315mg - about 685mg, about 320mg - about 680mg, about 325mg - about 675mg, about 330mg - about 670mg, about 335mg - about 665mg , about 340 mg to about 660 mg, about 345 mg to about 655 mg, about 350 mg to about 650 mg, about 355 mg to about 645 mg, about 360 mg to about 640 mg, about 365 mg to about 635 mg, about 370 mg to about 630mg, about 375mg to about 625mg, about 380mg to about 620mg, about 385mg to about 615mg, about 390mg to about 610mg, about 395mg to about 605mg, about 400mg to about 600mg, about 4 05mg to about 595mg, about 410mg to about 590mg, about 415mg to about 585mg, about 420mg to about 580mg, about 425mg to about 575mg, about 430mg to about 570mg, about 435mg to about 565 The compound may be administered to the subject in amounts of mg, approximately 440 mg to 560 mg, approximately 445 mg to 555 mg, approximately 450 mg to 550 mg, approximately 455 mg to 545 mg, approximately 460 mg to 540 mg, approximately 465 mg to 535 mg, approximately 470 mg to 530 mg, approximately 475 mg to 525 mg, approximately 480 mg to 520 mg, approximately 485 mg to 515 mg, approximately 490 mg to 510 mg, or approximately 495 mg to 505 mg. In some embodiments, the compound is administered to the subject in amounts of approximately 500 mg per dose.
[0035] In some embodiments, the compound is present in amounts ranging from approximately 250 mg to approximately 2,000 mg per dose, for example, approximately 255 mg to approximately 1,990 mg, approximately 260 mg to approximately 1,980 mg, approximately 265 mg to approximately 1,970 mg, approximately 270 mg to approximately 1,960 mg, approximately 275 mg to approximately 1,950 mg, approximately 280 mg to approximately 1,940 mg, approximately 285 mg to approximately 1,930 mg, approximately 290 mg to approximately 1,920 mg, approximately 295 mg to approximately 1,910 mg, approximately 300 mg to approximately 1,900 mg, approximately 305 mg to approximately 1,890 mg, approximately 310 mg to approximately 1,880 mg, and approximately 315 mg per dose. mg ~ about 1,870 mg, about 320 mg - about 1,860 mg, about 325 mg - about 1,850 mg, about 330 mg - about 1,840 mg, about 335 mg - about 1,830 mg, about 340 mg - about 1,820 mg, about 345 mg - about 1,810 mg, about 350 mg - about 1,800 mg , about 355 mg to about 1,790 mg, about 360 mg to about 1,780 mg, about 365 mg to about 1,770 mg, about 370 mg to about 1,760 mg, about 375 mg to about 1,750 mg, about 380 mg to about 1,740 mg, about 385 mg to about 1,730 mg, about 390 mg to about 1,7 20mg, approximately 395mg to 1,710mg, approximately 400mg to 1,700mg, approximately 405mg to 1,690mg, approximately 410mg to 1,680mg, approximately 415mg to 1,670mg, approximately 420mg to 1,660mg, approximately 425mg to 1,650mg, approximately 430mg to 1,640mg, approximately 435mg to 1,630mg, approximately 440mg to 1,620mg, approximately 445mg to 1,610mg, approximately 450mg to 1,600mg, approximately 455mg to 1,590mg, approximately 460mg to 1,580mg, approximately 465mg to 1,570mg, approximately 4 70mg to about 1,560mg, about 475mg to about 1,550mg, about 480mg to about 1,540mg, about 485mg to about 1,530mg, about 490mg to about 1,520mg, about 495mg to about 1,510mg, about 500mg to about 1,500mg, about 505mg to about 1,495m g, approx. 510 mg ~ approx. 1,490 mg, approx. 515 mg ~ approx. 1,485 mg, approx. 520 mg ~ approx. 1,480 mg, approx. 525 mg ~ approx. 1,475 mg, approx.455mg, approximately 550mg to approximately 1,450mg, approximately 555mg to approximately 1,445mg, approximately 560mg to approximately 1,440mg, approximately 565mg to approximately 1,435mg, approximately 570mg to approximately 1,430mg, approximately 575mg to approximately 1,425mg, approximately 580mg to approximately 1,420mg, approximately 585mg to approximately 1,415mg, approximately 590mg to approximately 1,410mg, approximately 595mg to approximately 1,405mg, approximately 600mg to approximately 1,400mg, approximately 605mg to approximately 1,395mg, approximately 610mg to approximately 1,390mg, approximately 615mg to approximately 1,385mg, approximately 620mg to approximately 1,380mg, approximately 6 25mg~approx. 1,375mg, approx. 630mg~approx. 1,370mg, approx. 635mg~approx. 1,365mg, approx. 640mg~approx. 1,360mg, approx. 645mg~approx. 1,355mg, approx. 650mg~approx. 1,350mg, approx. 655mg~approx. 1,345mg, approx. 660mg~approx. 1,340mg, approx. 665mg~approx. 1,335mg, approx. 670mg~approx. 1,330mg, approx. 675mg~approx. 1,325mg, approx. 680mg~approx. 1,320mg, approx. 685mg~approx. 1,315mg, approx. 690mg~approx. 1,310mg, approx. 695mg~approx. 1,305mg, approx. 700mg~approx. 1, 300mg, approximately 705mg~approx. 1,295mg, approximately 710mg~approx. 1,290mg, approximately 715mg~approx. 1,285mg, approximately 720mg~approx. 1,280mg, approximately 725mg~approx. 1,275mg, approximately 730mg~approx. 1,270mg, approximately 735mg~approx. 1,265mg, approximately 740mg~approx. 1,260mg, approximately 745mg~approx. 1,255mg, approximately 750mg~approx. 1,250mg, approximately 755mg~approx. 1,245mg, approximately 760mg~approx. 1,240mg, approximately 765mg~approx. 1,235mg, approximately 770mg~approx. 1,230mg, approximately 775mg~approx. 1,225mg, approximately 7 80mg~approx. 1,220mg, approx. 785mg~approx. 1,215mg, approx. 790mg~approx. 1,210mg, approx. 795mg~approx. 1,205mg, approx. 800mg~approx. 1,200mg, approx. 805mg~approx. 1,195mg, approx. 810mg~approx. 1,190mg, approx. 815mg~approx. 1,185mg, approx. 820mg~approx. 1,180mg, approx. 825mg~approx. 1,175mg, approx. 830mg~approx. 1,170mg, approx. 835mg~approx. 1,165mg, approx. 840mg~approx. 1,160mg, approx. 845mg~approx. 1,155mg, approx. 850mg~approx. 1,150mg, approx. 855mg~approx. 1,145mg, about 860mg to about 1,140mg, about 865mg to about 1,135mg, about 870mg to about 1,130mg, about 875mg to about 1,125mg, about 880mg to about 1,120mg, about 885mg to about 1,115mg, about 890mg to about 1,110mg , about 895 mg to about 1,105 mg, about 900 mg to about 1,000 mg, about 905 mg to about 1,095 mg, about 910 mg to about 1,090 mg, about 915 mg to about 1,085 mg, about 920 mg to about 1,080 mg, about 925 mg to about 1,075 mg, about 930 The compound is administered to the subject in amounts ranging from approximately 1,070 mg to 9,070 mg, 935 mg to 1,065 mg, 940 mg to 1,060 mg, 945 mg to 1,055 mg, 950 mg to 1,050 mg, 955 mg to 1,045 mg, 960 mg to 1,040 mg, 965 mg to 1,035 mg, 970 mg to 1,030 mg, 975 mg to 1,025 mg, 980 mg to 1,020 mg, 985 mg to 1,015 mg, 990 mg to 1,010 mg, or 995 mg to 1,005 mg. In some embodiments, the compound is administered to the subject in amounts ranging from approximately 1,000 mg per dose.
[0036] In some embodiments, the compound is present in amounts of approximately 1,500 mg to approximately 2,500 mg per dose, for example, approximately 1,505 mg to approximately 2,495 mg, approximately 1,510 mg to approximately 2,490 mg, approximately 1,515 mg to approximately 2,485 mg, approximately 1,520 mg to approximately 2,480 mg, approximately 1,525 mg to approximately 2,475 mg, approximately 1,530 mg to approximately 2,470 mg, approximately 1,535 mg to approximately 2,465 mg, approximately 1,540 mg to approximately 2,460 mg, approximately 1,545 mg to approximately 2,455 mg, approximately 1,550 mg to approximately 2,450 mg, and approximately 1,555 mg to approximately 2,445 mg per dose. , about 1,560mg to about 2,440mg, about 1,565mg to about 2,435mg, about 1,570mg to about 2,430mg, about 1,575mg to about 2,425mg, about 1,580mg to about 2,420mg, about 1,585mg to about 2,415mg, about 1,590mg to about 2,410m g, approx. 1,595 mg ~ approx. 2,405 mg, approx. 1,600 mg ~ approx. 2,400 mg, approx. 1,605 mg ~ approx. 2,395 mg, approx. 1,610 mg ~ approx. 2,390 mg, approx. mg, approx. 1,630 mg ~ approx. 2,370 mg, approx. 1,635 mg ~ approx. 2,365 mg, approx. 1,640 mg ~ approx. 2,360 mg, approx. 1,645 mg ~ approx. 2,355 mg, approx. 0mg, about 1,665mg to about 2,335mg, about 1,670mg to about 2,330mg, about 1,675mg to about 2,325mg, about 1,680mg to about 2,320mg, about 1,685mg to about 2,315mg, about 1,690mg to about 2,310mg, about 1,695mg to about 2,3 05mg, about 1,700mg to about 2,300mg, about 1,705mg to about 2,295mg, about 1,710mg to about 2,290mg, about 1,715mg to about 2,285mg, about 1,720mg to about 2,280mg, about 1,725mg to about 2,275mg, about 1,730mg to about 2, 270mg, about 1,735mg to about 2,265mg, about 1,740mg to about 2,260mg, about 1,745mg to about 2,255mg, about 1,750mg to about 2,250mg, about 1,755mg to about 2,245mg, about 1,760mg to about 2,240mg, about 1,765mg to about 2,235mg, approximately 1,770mg to approximately 2,230mg, approximately 1,775mg to approximately 2,225mg, approximately 1,780mg to approximately 2,220mg, approximately 1,785mg to approximately 2,215mg, approximately 1,790mg to approximately 2,210mg, approximately 1,795mg to approximately 2,205mg, about 1,800mg to about 2,200mg, about 1,805mg to about 2,195mg, about 1,810mg to about 2,190mg, about 1,815mg to about 2,185mg, about 1,820mg to about 2,180mg, about 1,825mg ~2,175mg, 1,830mg~2,170mg, 1,835mg~2,165mg, 1,840mg~2,160mg, 1,845mg~2,155mg, 1,850mg~2,150mg, 1,855 mg ~ approx. 2,145 mg, approx. 1,860 mg ~ approx. 2,140 mg, approx. 1,865 mg ~ approx. 2,135 mg, approx. 1,870 mg ~ approx. 2,130 mg, approx. 85mg to about 2,115mg, about 1,890mg to about 2,110mg, about 1,895mg to about 2,105mg, about 1,900mg to about 2,100mg, about 1,905mg to about 2,095mg, about 1,910mg to about 2,090mg, about 1 , 915mg to about 2,085mg, about 1,920mg to about 2,080mg, about 1,925mg to about 2,075mg, about 1,930mg to about 2,070mg, about 1,935mg to about 2,065mg, about 1,940mg to about 2,060mg, The compound is administered to the subject in amounts of approximately 1,945 mg to 2,055 mg, 1,950 mg to 2,050 mg, 1,955 mg to 2,045 mg, 1,960 mg to 2,040 mg, 1,965 mg to 2,035 mg, 1,970 mg to 2,030 mg, 1,975 mg to 2,025 mg, 1,980 mg to 2,020 mg, 1,985 mg to 2,015 mg, 1,990 mg to 2,010 mg, or 1,995 mg to 2,005 mg. In some embodiments, the compound is administered to the subject in amounts of approximately 2,000 mg per dose.
[0037] For example, in some embodiments, the compound is used in doses of approximately 250 mg, 255 mg, 260 mg, 265 mg, 270 mg, 275 mg, 280 mg, 285 mg, 290 mg, 295 mg, 300 mg, 305 mg, 310 mg, 315 mg, 320 mg, 325 mg, 330 mg, 335 mg, 340 mg, 345 mg, 350 mg, 355 mg, 360 mg, 365 mg, 370 mg, 375 mg, 380 mg, 385 mg, 390 mg, 395 mg, 400 mg, 405 mg, 410 mg, 415 mg, 420 mg, 425 mg, and 430 mg per dose. g, 435mg, 440mg, 445mg, 450mg, 455mg, 460mg, 465mg, 470mg, 475mg, 480mg, 485mg, 490mg, 495mg, 500mg, 505mg, 510mg, 515mg, 520mg, 525mg, 530mg, 53 5mg, 540mg, 545mg, 550mg, 555mg, 560mg, 565mg, 570mg, 575mg, 580mg, 585mg, 590mg, 595mg, 600mg, 605mg, 610mg, 615mg, 620mg, 625mg, 630mg, 635mg, 6 40mg, 645mg, 650mg, 655mg, 660mg, 665mg, 670mg, 675mg, 680mg, 685mg, 690mg, 695mg, 700mg, 705mg, 710mg, 715mg, 720mg, 725mg, 730mg, 735mg, 740mg , 745mg, 750mg, 755mg, 760mg, 765mg, 770mg, 775mg, 780mg, 785mg, 790mg, 795mg, 800mg, 805mg, 810mg, 815mg, 820mg, 825mg, 830mg, 835mg, 840mg, 845 mg, 850mg, 855mg, 860mg, 865mg, 870mg, 875mg, 880mg, 885mg, 890mg, 895mg, 900mg, 905mg, 910mg, 915mg, 920mg, 925mg, 930mg, 935mg, 940mg, 945mg, 9 50mg, 955mg, 960mg, 965mg, 970mg, 975mg, 980mg, 985mg, 990mg, 995mg, 1,000mg, 1,005mg, 1,010mg, 1,015mg, 1,020mg, 1,025mg, 1,030mg, 1,035mg, 1,040mg、1,045mg、1,050mg、1,055mg、1,060mg、1,065mg、1,070mg、1,075mg、1,080mg、1,085mg、1,090mg、1,095mg、1,100mg、1,105mg、1,110mg、1,115mg、1,120mg、1,125mg、1,130mg、1,135mg、1,140mg、1,145mg、1,150mg、1,155mg、1,160mg、1,165mg、1,170mg、1,175mg、1,180mg、1,185mg、1,190mg、1,195mg、1,200mg、1,205mg、1,210mg、1,215mg、1,220mg、1,225mg、1,230mg、1,235mg、1,240mg、1,245mg、1,250mg、1,255mg、1,260mg、1,265mg、1,270mg、1,275mg、1,280mg、1,285mg、1,290mg、1,295mg、1,300mg、1,305mg、1,310mg、1,315mg、1,320mg、1,325mg、1,330mg、1,335mg、1,340mg、1,345mg、1,350mg、1,355mg、1,360mg、1,365mg、1,370mg、1,375mg、1,380mg、1,385mg、1,390mg、1,395mg、1,400mg、1,405mg、1,410mg、1,415mg、1,420mg、1,425mg、1,430mg、1,435mg、1,440mg、1,445mg、1,450mg、1,455mg、1,460mg、1,465mg、1,470mg、1,475mg、1,480mg、1,485mg、1,490mg、1,495mg、1,500mg、1,505mg、1,510mg、1,515mg、1,520mg、1,525mg、1,530mg、1,535mg、1,540mg、1,545mg、1,550mg、1,555mg、1,560mg、1,565mg、1,570mg、1,575mg、1,580mg、1,585mg、1,590mg、1,595mg、1,600mg、1,605mg、1,610mg、1,615mg、1,620mg、1,625mg、1,630mg、1,635mg、1,640mg、1,645mg、1,650mg、1,655mg、1,660mg、1,665mg、1,670mg、1,675mg、1,680mg、1,685mg、1,690mg、1,695mg、1,700mg、1,705mg、1,710mg、1,715mg、1,720mg、1,725mg、1,730mg、1,735mg、1,740mg、1,745mg、1,750mg、1,755mg、1,760mg、1,765mg、1,770mg、1,775mg、1,780mg、1,785mg、1,790mg、1,795mg、1,800mg、1,805mg、1,810mg、1,815mg、1,820mg、1,825mg、1,830mg、1,835mg、1,840mg、1,845mg、1,850mg、1,855mg、1,860mg、1,865mg、1,870mg、1,875mg、1,880mg、1,885mg、1,890mg、1,895mg、1,900mg、1,905mg、1,910mg、1,915mg、1,920mg、1,925mg、1,930mg、1,935mg、1,940mg、1,945mg、1,950mg、1,955mg、1,960mg、1,965mg、1,970mg、1,975mg、1,980mg、1,985mg、1,990mg、1,995mg、2,000mg、2,005mg、2,010mg、2,015mg、2,020mg、2,025mg、2,030mg、2,035mg、2,040mg、2,045mg、2,050mg、2,055mg、2,060mg、2,065mg、2,070mg、2,075mg、2,080mg、2,085mg、2,090mg、2,095mg、2,100mg、2,105mg、2,110mg、2,115mg、2,120mg、2,125mg、2,130mg、2,135mg、2,140mg、2,145mg、2,150mg、2,155mg、2,160mg、2,165mg、2,170mg、2,175mg、2,180mg、2,185mg、2,190mg、2,195mg、2,200mg、2,205mg、2,210mg、2,215mg、2,220mg、2,225mg、2,230mg、2,235mg、2,240mg、2,245mg、2,250mg、2,255mg、2,260mg、2,265mg、2,270mg、2,275mg、2,280mg、2,285mg、2,290mg, 2,295mg, 2,300mg, 2,305mg, 2,310mg, 2,315mg, 2,320mg, 2,325mg, 2,330mg, 2,335mg, 2,340mg, 2,3 45mg, 2,350mg, 2,355mg, 2,360mg, 2,365mg, 2,370mg, 2,375mg, 2,380mg, 2,385mg, 2,390mg, 2,395mg, 2,40 The drug is administered to the target individual in doses of 0 mg, 2,405 mg, 2,410 mg, 2,415 mg, 2,420 mg, 2,425 mg, 2,430 mg, 2,435 mg, 2,440 mg, 2,445 mg, 2,450 mg, 2,455 mg, 2,460 mg, 2,465 mg, 2,470 mg, 2,475 mg, 2,480 mg, 2,485 mg, 2,490 mg, 2,495 mg, or 2,500 mg.
[0038] In some embodiments of the above configuration, the Ar ring is selected from substituents (Ia) to (Iy), [ka] In the formula, each R 3These are, independently, halogens, haloalkyls, cyanos, optionally substituted aminos, hydroxyls, thiols, optionally substituted alkoxys, optionally substituted acyloxys, optionally substituted alkoxycarbonyls, carboxys, ureidos, alkylsulfonyls, arylsulfonyls, heteroarylsulfonyls, cycloalkylsulfonyls, heterocycloalkylsulfonyls, alkylsulfanyls, arylsulfanyls, heteroarylsulfanyls, cycloalkylsulfanyls, heterocycloalkylsulfanyls, alkylsulfinyls, arylsulfinyls, heteroarylsulfinyls, cycloalkylsulfinyls, heterocycloalkylsulfinyls, optionally substituted alkyls, optionally substituted alkenyls, optionally substituted alkynyls, optionally substituted and optionally condensed aryls, optionally substituted and optionally condensed heteroaryls, optionally substituted and optionally condensed cycloalkyls, or optionally substituted and optionally condensed heterocycloalkyls. Each m is an independent integer between 0 and 5. Each p is an independent integer between 0 and 3. Each q is an independent integer between 0 and 2. Each r is an independent integer between 0 and 1. Each s is an independent integer between 0 and 7.
[0039] Several embodiments, each R 3 This is selected independently of substituents (IIa) to (IIy). [ka]
[0040] In some embodiments, the Ar ring is a substituent represented by formula (Ia), [ka] Each R 3These are, independently, optionally substituted and optionally condensed aryls, optionally substituted and optionally condensed heteroaryls, optionally substituted and optionally condensed cycloalkyls, or optionally substituted and optionally condensed heterocycloalkyls.
[0041] In some embodiments, the Cy ring is selected from substituents (IIIa) to (IIIaa), [ka] [ka] In the formula, each R 4 These are, independently, halogens, haloalkyls, cyanos, optionally substituted aminos, hydroxyls, thiols, optionally substituted alkoxys, optionally substituted acyloxys, optionally substituted alkoxycarbonyls, carboxys, ureidos, alkylsulfonyls, arylsulfonyls, heteroarylsulfonyls, cycloalkylsulfonyls, heterocycloalkylsulfonyls, alkylsulfanyls, arylsulfanyls, heteroarylsulfanyls, cycloalkylsulfanyls, heterocycloalkylsulfanyls, alkylsulfinyls, arylsulfinyls, heteroarylsulfinyls, cycloalkylsulfinyls, heterocycloalkylsulfinyls, optionally substituted alkyls, optionally substituted alkenyls, optionally substituted alkynyls, optionally substituted and optionally condensed aryls, optionally substituted and optionally condensed heteroaryls, optionally substituted and optionally condensed cycloalkyls, or optionally substituted and optionally condensed heterocycloalkyls. Each G is independently -CH2-, -CR 4 H-, -NH-, -NR 4 -, -O- or -S-, Each t is an independent integer between 0 and 5. Each u is an independent integer between 0 and 3. Each v is an independent integer between 0 and 2. Each w is an independent integer between 0 and 1. Each x is an independent integer between 0 and 7. Each y is an independent integer between 0 and 4.
[0042] Substituent R 4 It should be understood that can be bound to G in equation (IIIb) or (IIIc). In such cases, G is -CH-, -CR 4 It should be understood that the selection is made from the group consisting of - and -N-.
[0043] In some embodiments, the Cy ring is an optionally substituted aryl group represented by formula (IVa). [ka]
[0044] In some embodiments, the Cy ring is a substituted aryl group represented by formula (IVb). [ka]
[0045] In some embodiments, R 1 is a C1-C5-alkylcarboxy, a C1-C5-alkylacyl, a C1-C5-alkylalkoxycarbonyl, a C1-C5-alkylacyloxy, a substituted C1-C5-alkylcarboxy, a substituted C1-C5-alkylacyl, a substituted C1-C5-alkylalkoxycarbonyl, or a substituted C1-C5-alkylacyloxy. In some embodiments, R 1 This is a C1-C5 alkyl acyloxy that has been optionally substituted.
[0046] In some embodiments, the compound is represented by formula (V), [ka] (In the formula, R 1 These are C1-C5-alkylcarboxy, C1-C5-alkylacyl, C1-C5-alkylalkoxycarbonyl, C1-C5-alkylacyloxy, substituted C1-C5-alkylcarboxy, substituted C1-C5-alkylacyl, substituted C1-C5-alkylalkoxycarbonyl, or substituted C1-C5-alkylacyloxy. Each R 3 These are, independently, halogens, haloalkyls, cyanos, optionally substituted aminos, hydroxyls, thiols, optionally substituted alkoxys, optionally substituted acyloxys, optionally substituted alkoxycarbonyls, carboxys, ureidos, alkylsulfonyls, arylsulfonyls, heteroarylsulfonyls, cycloalkylsulfonyls, heterocycloalkylsulfonyls, alkylsulfanyls, arylsulfanyls, heteroarylsulfanyls, cycloalkylsulfanyls, heterocycloalkylsulfanyls, alkylsulfinyls, arylsulfinyls, heteroarylsulfinyls, cycloalkylsulfinyls, heterocycloalkylsulfinyls, optionally substituted alkyls, optionally substituted alkenyls, optionally substituted alkynyls, optionally substituted and optionally condensed aryls, optionally substituted and optionally condensed heteroaryls, optionally substituted and optionally condensed cycloalkyls, or optionally substituted and optionally condensed heterocycloalkyls. Each R 4These are, independently, halogens, haloalkyls, cyanos, optionally substituted aminos, hydroxyls, thiols, optionally substituted alkoxys, optionally substituted acyloxys, optionally substituted alkoxycarbonyls, carboxys, ureidos, alkylsulfonyls, arylsulfonyls, heteroarylsulfonyls, cycloalkylsulfonyls, heterocycloalkylsulfonyls, alkylsulfanyls, arylsulfanyls, heteroarylsulfanyls, cycloalkylsulfanyls, heterocycloalkylsulfanyls, alkylsulfinyls, arylsulfinyls, heteroarylsulfinyls, cycloalkylsulfinyls, heterocycloalkylsulfinyls, optionally substituted alkyls, optionally substituted alkenyls, optionally substituted alkynyls, optionally substituted and optionally condensed aryls, optionally substituted and optionally condensed heteroaryls, optionally substituted and optionally condensed cycloalkyls, or optionally substituted and optionally condensed heterocycloalkyls. m is an integer between 0 and 5. t is an integer between 0 and 5. or a pharmaceutically acceptable salt thereof.
[0047] In some embodiments, the compound is represented by formula (Va), [ka] or a pharmaceutically acceptable salt thereof.
[0048] In some embodiments, the compound is represented by formula (VI), [ka] (In the formula, R 6 is a hydroxyl, an optionally substituted acyl, an optionally substituted alkoxycarbonyl, or an optionally substituted acyloxy. Each R 5These are, independently, halogens, haloalkyls, cyanos, optionally substituted aminos, hydroxyls, thiols, optionally substituted alkoxys, optionally substituted acyloxys, optionally substituted alkoxycarbonyls, carboxys, ureidos, alkylsulfonyls, arylsulfonyls, heteroarylsulfonyls, cycloalkylsulfonyls, heterocycloalkylsulfonyls, alkylsulfanyls, arylsulfanyls, heteroarylsulfanyls, cycloalkylsulfanyls, heterocycloalkylsulfanyls, alkylsulfinyls, arylsulfinyls, heteroarylsulfinyls, cycloalkylsulfinyls, heterocycloalkylsulfinyls, optionally substituted alkyls, optionally substituted alkenyls, optionally substituted alkynyls, optionally substituted and optionally condensed aryls, optionally substituted and optionally condensed heteroaryls, optionally substituted and optionally condensed cycloalkyls, or optionally substituted and optionally condensed heterocycloalkyls. Each R 4 These are halogens, haloalkyls, cyanos, optionally substituted aminos, hydroxyls, thiols, optionally substituted alkoxys, optionally substituted acyloxys, optionally substituted alkoxycarbonyls, carboxys, ureidos, alkylsulfonyls, arylsulfonyls, heteroarylsulfonyls, cycloalkylsulfonyls, heterocycloalkylsulfonyls, alkylsulfanyls, arylsulfanyls, heteroarylsulfanyls, cycloalkylsulfanyls, heterocycloalkylsulfanyls, alkylsulfinyls, arylsulfinyls, heteroarylsulfinyls, cycloalkylsulfinyls, heterocycloalkylsulfinyls, optionally substituted alkyls, optionally substituted alkenyls, optionally substituted alkynyls, optionally substituted and optionally condensed aryls, optionally substituted and optionally condensed heteroaryls, optionally substituted and optionally condensed cycloalkyls, or optionally substituted and optionally condensed heterocycloalkyls. i is an integer between 0 and 3. x is an integer between 0 and 5. or a pharmaceutically acceptable salt thereof.
[0049] In some embodiments, the compound is represented by formula (VIa), [ka] or a pharmaceutically acceptable salt thereof.
[0050] In some embodiments, the compound is represented by formula (VII), [ka] (In the formula, R 7 is an aminoacyl substituted with H or optionally, Each R 5 These are, independently, halogens, haloalkyls, cyanos, optionally substituted aminos, hydroxyls, thiols, optionally substituted alkoxys, optionally substituted acyloxys, optionally substituted alkoxycarbonyls, carboxys, ureidos, alkylsulfonyls, arylsulfonyls, heteroarylsulfonyls, cycloalkylsulfonyls, heterocycloalkylsulfonyls, alkylsulfanyls, arylsulfanyls, heteroarylsulfanyls, cycloalkylsulfanyls, heterocycloalkylsulfanyls, alkylsulfinyls, arylsulfinyls, heteroarylsulfinyls, cycloalkylsulfinyls, heterocycloalkylsulfinyls, optionally substituted alkyls, optionally substituted alkenyls, optionally substituted alkynyls, optionally substituted and optionally condensed aryls, optionally substituted and optionally condensed heteroaryls, optionally substituted and optionally condensed cycloalkyls, or optionally substituted and optionally condensed heterocycloalkyls. Each R 4These are halogens, haloalkyls, cyanos, optionally substituted aminos, hydroxyls, thiols, optionally substituted alkoxys, optionally substituted acyloxys, optionally substituted alkoxycarbonyls, carboxys, ureidos, alkylsulfonyls, arylsulfonyls, heteroarylsulfonyls, cycloalkylsulfonyls, heterocycloalkylsulfonyls, alkylsulfanyls, arylsulfanyls, heteroarylsulfanyls, cycloalkylsulfanyls, heterocycloalkylsulfanyls, alkylsulfinyls, arylsulfinyls, heteroarylsulfinyls, cycloalkylsulfinyls, heterocycloalkylsulfinyls, optionally substituted alkyls, optionally substituted alkenyls, optionally substituted alkynyls, optionally substituted and optionally condensed aryls, optionally substituted and optionally condensed heteroaryls, optionally substituted and optionally condensed cycloalkyls, or optionally substituted and optionally condensed heterocycloalkyls. i is an integer between 0 and 3. x is an integer between 0 and 5. or a pharmaceutically acceptable salt thereof.
[0051] In some embodiments, the compound is represented by formula (VIII), [ka] (In the formula, R 8 is an optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted and optionally condensed aryl, optionally substituted and optionally condensed heteroaryl, optionally substituted and optionally condensed cycloalkyl, or optionally substituted and optionally condensed heterocycloalkyl, preferably R 8This is an amino-substituted alkyl, for example, a 1-aminoC1~C6 alkyl (for example, (S)-1-aminoC1~C6 alkyl or (R)-1-aminoC1~C6 alkyl, for example, (S)-1-amino-2-methylpropyl, (S)-1-amino-2-methylbutyl, (S)-1-amino-3-methylbutyl, (R)-1-amino-2-methylpropyl, (R)-1-amino-2-methylbutyl, or (R)-1-amino-3-methylbutyl), Each R 5 These are, independently, halogens, haloalkyls, cyanos, optionally substituted aminos, hydroxyls, thiols, optionally substituted alkoxys, optionally substituted acyloxys, optionally substituted alkoxycarbonyls, carboxys, ureidos, alkylsulfonyls, arylsulfonyls, heteroarylsulfonyls, cycloalkylsulfonyls, heterocycloalkylsulfonyls, alkylsulfanyls, arylsulfanyls, heteroarylsulfanyls, cycloalkylsulfanyls, heterocycloalkylsulfanyls, alkylsulfinyls, arylsulfinyls, heteroarylsulfinyls, cycloalkylsulfinyls, heterocycloalkylsulfinyls, optionally substituted alkyls, optionally substituted alkenyls, optionally substituted alkynyls, optionally substituted and optionally condensed aryls, optionally substituted and optionally condensed heteroaryls, optionally substituted and optionally condensed cycloalkyls, or optionally substituted and optionally condensed heterocycloalkyls. Each R 4These are halogens, haloalkyls, cyanos, optionally substituted aminos, hydroxyls, thiols, optionally substituted alkoxys, optionally substituted acyloxys, optionally substituted alkoxycarbonyls, carboxys, ureidos, alkylsulfonyls, arylsulfonyls, heteroarylsulfonyls, cycloalkylsulfonyls, heterocycloalkylsulfonyls, alkylsulfanyls, arylsulfanyls, heteroarylsulfanyls, cycloalkylsulfanyls, heterocycloalkylsulfanyls, alkylsulfinyls, arylsulfinyls, heteroarylsulfinyls, cycloalkylsulfinyls, heterocycloalkylsulfinyls, optionally substituted alkyls, optionally substituted alkenyls, optionally substituted alkynyls, optionally substituted and optionally condensed aryls, optionally substituted and optionally condensed heteroaryls, optionally substituted and optionally condensed cycloalkyls, or optionally substituted and optionally condensed heterocycloalkyls. i is an integer between 0 and 3. t is an integer between 0 and 5. x is an integer between 0 and 5. or a pharmaceutically acceptable salt thereof.
[0052] In some embodiments, the method includes providing compound (1) as the subject. [ka]
[0053] In some embodiments, the method targets compound (2) [ka] or administering a pharmaceutically acceptable salt thereof, for example, a chloride salt represented by formula (3). [ka]
[0054] In some embodiments, the compound is in a crystalline state. For example, the compound may be a crystalline compound (3), (a) Characteristic X-ray powder diffraction peaks at approximately 7.0°2θ, 8.1°2θ, 10.0°2θ, 12.0°2θ, 13.1°2θ, 14.1°2θ, 16.4°2θ, 18.4°2θ, 20.1°2θ, 21.0°2θ, 23.5°2θ, and 29.5°2θ; (b) Centered around approximately 1.1 ppm, 3.3 ppm, 4.9 ppm, 5.4 ppm, 7.1 ppm, 7.7 ppm, 7.9 ppm, and 8.0 ppm 1 H nuclear magnetic resonance (NMR) peak ; (c) Endothermic heat of approximately 145°C to 147°C measured by differential scanning calorimetry; (d) Weight loss of approximately 0.2% to approximately 0.6% when heated from 25°C to 100°C, as measured by thermogravimetric analysis; and / or (e) When heated from 100°C to 160°C, as measured by thermogravimetric analysis, it may exhibit a weight loss of approximately 2.5% to 3.5%.
[0055] In some embodiments of any of the above-described aspects of this disclosure, the PGF2α receptor antagonist is present in an amount of approximately 300 mg to approximately 2,300 mg per dose, for example, approximately 300 mg per dose, 350 mg per dose, 400 mg per dose, 450 mg per dose, 500 mg per dose, 550 mg per dose, 600 mg per dose, 650 mg per dose, 700 mg per dose, 750 mg per dose, 800 mg per dose, 850 mg per dose, 900 mg per dose, 950 mg per dose, 1,000 mg per dose, 1,050 mg per dose, 1,100 mg per dose, 1,150 mg per dose, 1,200 mg per dose, and 1 The drug is administered to the target in amounts of 250 mg, 1,300 mg per dose, 1,350 mg per dose, 1,400 mg per dose, 1,450 mg per dose, 1,500 mg per dose, 1,550 mg per dose, 1,600 mg per dose, 1,650 mg per dose, 1,700 mg per dose, 1,750 mg per dose, 1,800 mg per dose, 1,850 mg per dose, 1,900 mg per dose, 1,950 mg per dose, 2,000 mg per dose, 2,050 mg per dose, 2,100 mg per dose, 2,150 mg per dose, 2,200 mg per dose, 2,250 mg per dose, or 2,300 mg per dose.PGF2α receptor antagonists are administered in doses of approximately 400 mg to 2,100 mg, for example, approximately 400 mg per dose, 450 mg per dose, 500 mg per dose, 550 mg per dose, 600 mg per dose, 650 mg per dose, 700 mg per dose, 750 mg per dose, 800 mg per dose, 850 mg per dose, 900 mg per dose, 950 mg per dose, 1,000 mg per dose, 1,050 mg per dose, 1,100 mg per dose, 1,150 mg per dose, 1,200 mg per dose. The drug may be administered to the target patient in amounts of 1,250 mg, 1,300 mg per dose, 1,350 mg per dose, 1,400 mg per dose, 1,450 mg per dose, 1,500 mg per dose, 1,550 mg per dose, 1,600 mg per dose, 1,650 mg per dose, 1,700 mg per dose, 1,750 mg per dose, 1,800 mg per dose, 1,850 mg per dose, 1,900 mg per dose, 1,950 mg per dose, 2,000 mg per dose, 2,050 mg per dose, or 2,100 mg per dose.In some embodiments, the PGF2α receptor antagonist is administered in amounts ranging from approximately 450 mg to approximately 2,050 mg per dose, for example, approximately 450 mg per dose, 500 mg per dose, 550 mg per dose, 600 mg per dose, 650 mg per dose, 700 mg per dose, 750 mg per dose, 800 mg per dose, 850 mg per dose, 900 mg per dose, 950 mg per dose, 1,000 mg per dose, 1,050 mg per dose, 1,100 mg per dose, 1,150 mg per dose, and 1,200 mg per dose. The drug is administered to the target patient in doses of 1,250 mg per dose, 1,300 mg per dose, 1,350 mg per dose, 1,400 mg per dose, 1,450 mg per dose, 1,500 mg per dose, 1,550 mg per dose, 1,600 mg per dose, 1,650 mg per dose, 1,700 mg per dose, 1,750 mg per dose, 1,800 mg per dose, 1,850 mg per dose, 1,900 mg per dose, 1,950 mg per dose, 2,000 mg per dose, or 2,050 mg per dose.
[0056] In some embodiments, the PGF2α receptor antagonist is administered to the subject in amounts ranging from approximately 100 mg to approximately 900 mg per dose, for example, approximately 100 mg per dose, 150 mg per dose, 200 mg per dose, 250 mg per dose, 300 mg per dose, 350 mg per dose, 400 mg per dose, 450 mg per dose, 500 mg per dose, 550 mg per dose, 600 mg per dose, 650 mg per dose, 700 mg per dose, 750 mg per dose, 800 mg per dose, 850 mg per dose, or 900 mg per dose. In some embodiments, the PGF2α receptor antagonist is administered to the subject in amounts ranging from approximately 200 mg to approximately 800 mg per dose, for example, approximately 200 mg per dose, 250 mg per dose, 300 mg per dose, 350 mg per dose, 400 mg per dose, 450 mg per dose, 500 mg per dose, 550 mg per dose, 600 mg per dose, 650 mg per dose, 700 mg per dose, 750 mg per dose, or 800 mg per dose. In some embodiments, the PGF2α receptor antagonist is administered to the subject in doses of approximately 300 mg to approximately 700 mg, for example, approximately 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, or 700 mg per dose. In some embodiments, the PGF2α receptor antagonist is administered to the subject in doses of approximately 400 mg to approximately 600 mg, for example, approximately 400 mg, 450 mg, 500 mg, 550 mg, or 600 mg per dose. In some embodiments, the PGF2α receptor antagonist is administered to the subject in amounts of approximately 450 mg to approximately 550 mg per dose, for example, approximately 450 mg per dose, 500 mg per dose, or 550 mg per dose.
[0057] In some embodiments, the PGF2α receptor antagonist is administered to the subject in amounts ranging from approximately 600 mg to approximately 1,400 mg per dose, for example, approximately 600 mg per dose, 650 mg per dose, 700 mg per dose, 750 mg per dose, 800 mg per dose, 850 mg per dose, 900 mg per dose, 950 mg per dose, 1,000 mg per dose, 1,050 mg per dose, 1,100 mg per dose, 1,150 mg per dose, 1,200 mg per dose, 1,250 mg per dose, 1,300 mg per dose, 1,350 mg per dose, or 1,400 mg per dose. In some embodiments, the PGF2α receptor antagonist is administered to the subject in amounts ranging from approximately 700 mg to approximately 1,300 mg per dose, for example, approximately 700 mg per dose, 750 mg per dose, 800 mg per dose, 850 mg per dose, 900 mg per dose, 950 mg per dose, 1,000 mg per dose, 1,050 mg per dose, 1,100 mg per dose, 1,150 mg per dose, 1,200 mg per dose, 1,250 mg per dose, or 1,300 mg per dose. In some embodiments, the PGF2α receptor antagonist is administered to the subject in amounts ranging from approximately 800 mg to approximately 1,200 mg per dose, for example, approximately 800 mg, 850 mg, 900 mg, 950 mg, 1,000 mg, 1,050 mg, 1,100 mg, 1,150 mg, or 1,200 mg per dose. In some embodiments, the PGF2α receptor antagonist is administered to the subject in amounts ranging from approximately 900 mg to approximately 1,100 mg per dose, for example, approximately 900 mg, 950 mg, 1,000 mg, 1,050 mg, or 1,100 mg per dose. In some embodiments, the PGF2α receptor antagonist is administered to the subject in amounts ranging from approximately 950 mg to approximately 1,050 mg per dose, for example, approximately 950 mg per dose, 1,000 mg per dose, or 1,050 mg per dose.
[0058] In some embodiments, among the other PGF2α receptor antagonists described herein, one of the compounds of formulas (I) to (VIII), such as compound (1), compound (2), or compound (3), is administered to the subject regularly in doses at 12, 24, 36, 48, 60, 72, 84, 96 hours, once or more times per week or month. For example, PGF2α receptor antagonists are administered in doses of 1 to 10 times every 12 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses), 1 to 10 times every 14 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses), 1 to 10 times every 16 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses), and 1 to 10 times every 18 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses). Dosage) 1 to 10 doses every 20 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 22 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 24 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 26 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 28 hours 10 doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 30 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 32 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 34 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 36 hours (e.g., 1, (2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 38 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 40 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 42 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 44 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8,9 or 10 doses), 1 to 10 doses every 46 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 48 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 60 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 72 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 84 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 96 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), It may be administered to the target in doses of 1 to 10 times every 108 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses), 1 to 10 times every 120 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses), 1 to 10 times every 132 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses), 1 to 10 times every 144 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses), 1 to 10 times every 156 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses), or 1 to 10 times weekly (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses).
[0059] In some embodiments, among the other PGF2α receptor antagonists described herein, one of the compounds of formulas (I) to (VIII), for example, compound (1), compound (2), or compound (3), is administered to the subject in doses of 1 to 6 times per day. For example, one of the compounds of formulas (I) to (VIII), for example, compound (1), compound (2), or compound (3), may be administered to the subject once daily. In some embodiments, the PGF2α receptor antagonist is administered to the subject twice daily.
[0060] In some embodiments, the PGF2α receptor antagonist is administered to the subject once every 4 to 12 hours, for example, once every 4 hours, once every 5 hours, once every 6 hours, once every 7 hours, once every 8 hours, once every 9 hours, once every 10 hours, once every 11 hours, or once every 12 hours.
[0061] Among the other PGF2α receptor antagonists described herein, any one compound of formulas (I) to (VIII), such as compound (1), compound (2), or compound (3), may be administered to a subject in one or more unit dosage forms that collectively constitute a single dose. For example, by administering one or more unit dosage forms of the compound to a subject, a specific amount of the compound can be administered as a single dose, such as 250 mg, 500 mg, 750 mg, 1,000 mg, 1,250 mg, 1,500 mg, 1,750 mg, 2,000 mg, or more. As a non-limiting example, a single dose of 1,000 mg of the compound may be administered to a subject by two separate 500 mg unit dosage forms of the compound. The two 500 mg unit dosage forms, when administered to the subject substantially simultaneously, collectively constitute a single 1,000 mg dose of the compound.
[0062] In some embodiments, among other PGF2α receptor antagonists described herein, any one compound of formulas (I) to (VIII), such as compound (1), compound (2), or compound (3), is administered in doses of approximately 250 mg to approximately 2,500 mg per day in total, for example, approximately 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg per day. The drug is administered to the target individual in doses of 0 mg, 900 mg, 1,000 mg, 1,050 mg, 1,100 mg, 1,150 mg, 1,200 mg, 1,250 mg, 1,300 mg, 1,350 mg, 1,400 mg, 1,450 mg, 1,500 mg, 1,550 mg, 1,600 mg, 1,650 mg, 1,700 mg, 1,750 mg, 1,800 mg, 1,850 mg, 1,900 mg, 1,950 mg, 2,000 mg, 2,050 mg, 2,100 mg, 2,150 mg, 2,200 mg, 2,250 mg, 2,300 mg, 2,350 mg, 2,400 mg, 2,450 mg, or 2,500 mg.
[0063] In some embodiments, the PGF2α receptor antagonist is administered in doses once or more times a day (e.g., 1 to 10 doses, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 times or more), totaling approximately 300 mg to approximately 2,000 mg per day, for example, approximately 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg per day. The drug is administered to the target population in amounts of g, 900 mg, 1,000 mg, 1,050 mg, 1,100 mg, 1,150 mg, 1,200 mg, 1,250 mg, 1,300 mg, 1,350 mg, 1,400 mg, 1,450 mg, 1,500 mg, 1,550 mg, 1,600 mg, 1,650 mg, 1,700 mg, 1,750 mg, 1,800 mg, 1,850 mg, 1,900 mg, 1,950 mg, or 2,000 mg.
[0064] In some embodiments, the PGF2α receptor antagonist is administered to the subject in doses once or more times a day (e.g., 1 to 10 doses, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 times or more), totaling approximately 400 mg to approximately 1,600 mg per day, for example, approximately 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 1,000 mg, 1,050 mg, 1,100 mg, 1,150 mg, 1,200 mg, 1,250 mg, 1,300 mg, 1,350 mg, 1,400 mg, 1,450 mg, 1,500 mg, 1,550 mg or 1,600 mg per day.
[0065] In some embodiments, the PGF2α receptor antagonist is administered to the subject in doses once or more times a day (e.g., 1 to 10 doses, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 times or more), totaling approximately 700 mg to approximately 1,300 mg per day, for example, approximately 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 1,000 mg, 1,050 mg, 1,100 mg, 1,150 mg, 1,200 mg, 1,250 mg or 1,300 mg per day.
[0066] In some embodiments, the PGF2α receptor antagonist is administered to the subject in doses once or more times a day (e.g., 1 to 10 doses, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 times or more), totaling approximately 800 mg to approximately 1,200 mg per day, for example, approximately 800 mg, 850 mg, 900 mg, 1,000 mg, 1,050 mg, 1,100 mg, 1,150 mg or 1,200 mg per day.
[0067] In some embodiments, the PGF2α receptor antagonist is administered to the subject in doses once or more times a day (e.g., 1 to 10 doses, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 times or more), totaling approximately 900 mg to approximately 1,100 mg per day, for example, approximately 900 mg, 1,000 mg, 1,050 mg or 1,100 mg per day.
[0068] In some embodiments, the PGF2α receptor antagonist is administered to the subject in doses once or more times a day (e.g., 1 to 10 doses, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 times or more), totaling approximately 950 mg to approximately 1,050 mg per day, for example, approximately 950 mg, 955 mg, 960 mg, 965 mg, 970 mg, 975 mg, 980 mg, 985 mg, 990 mg, 995 mg, 1,000 mg, 1,005 mg, 1,010 mg, 1,015 mg, 1,020 mg, 1,025 mg, 1,030 mg, 1,035 mg, 1,040 mg, 1,045 mg or 1,050 mg per day.
[0069] In some embodiments, among the other PGF2α receptor antagonists described herein, one of the compounds of formulas (I) to (VIII), such as compound (1), compound (2), or compound (3), is administered to the subject in a single dose per day. For example, the PGF2α receptor antagonist is administered in amounts of approximately 250 mg to approximately 2,500 mg per day (e.g., single dose), such as approximately 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 1,000 mg, 1,050 mg, 1,100 mg, 1,150 mg, 1,200 mg, 1,250 mg, 1,300 mg, 1,3 The drug may be administered to the subject in amounts of 50 mg, 1,400 mg, 1,450 mg, 1,500 mg, 1,550 mg, 1,600 mg, 1,650 mg, 1,700 mg, 1,750 mg, 1,800 mg, 1,850 mg, 1,900 mg, 1,950 mg, 2,000 mg, 2,050 mg, 2,100 mg, 2,150 mg, 2,200 mg, 2,250 mg, 2,300 mg, 2,350 mg, 2,400 mg, 2,450 mg, or 2,500 mg. In some embodiments, the PGF2α receptor antagonist is administered to the subject in amounts of approximately 1,000 mg per day (e.g., a single dose).
[0070] In some embodiments, a PGF2α receptor antagonist, such as any one of the compounds of formulas (I) to (VIII), e.g., compound (1), compound (2), or compound (3), among the other PGF2α receptor antagonists described herein, is administered to the subject once daily in a dose of approximately 800 mg to approximately 1,200 mg per dose during a first treatment period. Subsequently, the PGF2α receptor antagonist may be administered to the subject twice daily in a dose of approximately 300 mg to approximately 700 mg per dose during a second treatment period, i.e., a total dose of approximately 600 mg to approximately 1,400 mg per day during the second treatment period.
[0071] In some embodiments, the PGF2α receptor antagonist is administered in doses of approximately 850 mg to 1,150 mg per dose during the first treatment period, for example, approximately 850 mg, 855 mg, 860 mg, 865 mg, 870 mg, 875 mg, 880 mg, 885 mg, 890 mg, 895 mg, 900 mg, 905 mg, 910 mg, 915 mg, 920 mg, 925 mg, 930 mg, 935 mg, 940 mg, 945 mg, 950 mg, 955 mg, 960 mg, 965 mg, 970 mg, 975 mg, 980 mg, 985 mg per dose during the first treatment period. mg, 990mg, 995mg, 1,000mg, 1,005mg, 1,010mg, 1,015mg, 1,020mg, 1,025mg, 1,030mg, 1,035mg, 1,040mg, 1,045mg, 1,050mg, 1,055mg, 1,060mg, 1,0 65mg, 1,070mg, 1,075mg, 1,080mg, 1,085mg, 1,090mg, 1,095mg, 1,100mg, 1,105mg, 1,110mg, 1,115mg, 1,120mg, 1,125mg, 1,130mg, 1,135mg, 1,140 In doses of mg, 1,145 mg, or 1,150 mg (i.e., during the first treatment period, a total of approximately 850 mg, 855 mg, 860 mg, 865 mg, 870 mg, 875 mg, 880 mg, 885 mg, 890 mg, 895 mg, 900 mg, 905 mg, 910 mg, 915 mg, 920 mg, 925 mg, 930 mg, 935 mg, 940 mg, 945 mg, 950 mg, 955 mg, 960 mg, 965 mg, 970 mg, 975 mg, 980 mg, 985 mg, 990 mg, 995 mg, 1,000 mg, 1,005 mg, 1, It is administered to the target group in amounts of 0.10 mg, 1,015 mg, 1,020 mg, 1,025 mg, 1,030 mg, 1,035 mg, 1,040 mg, 1,045 mg, 1,050 mg, 1,055 mg, 1,060 mg, 1,065 mg, 1,070 mg, 1,075 mg, 1,080 mg, 1,085 mg, 1,090 mg, 1,095 mg, 1,100 mg, 1,105 mg, 1,110 mg, 1,115 mg, 1,120 mg, 1,125 mg, 1,130 mg, 1,135 mg, 1,140 mg, 1,145 mg, or 1,150 mg.
[0072] In some embodiments, the PGF2α receptor antagonist is administered in doses of approximately 900 mg to 1,100 mg per dose during the first treatment period, for example, approximately 900 mg, 905 mg, 910 mg, 915 mg, 920 mg, 925 mg, 930 mg, 935 mg, 940 mg, 945 mg, 950 mg, 955 mg, 960 mg, 965 mg, 970 mg, 975 mg per dose during the first treatment period. , 980mg, 985mg, 990mg, 995mg, 1,000mg, 1,005mg, 1,010mg, 1,015mg, 1,020mg, 1,025mg, 1,030mg, 1,035m g, 1,040mg, 1,045mg, 1,050mg, 1,055mg, 1,060mg, 1,065mg, 1,070mg, 1,075mg, 1,080mg, 1,085mg, 1,090 In doses of mg, 1,095 mg, or 1,100 mg (i.e., during the first treatment period, a total of approximately 900 mg, 905 mg, 910 mg, 915 mg, 920 mg, 925 mg, 930 mg, 935 mg, 940 mg, 945 mg, 950 mg, 955 mg, 960 mg, 965 mg, 970 mg, 975 mg, 980 mg, 985 mg, 990 mg, 995 mg, 1,000 mg per day), It is administered to the target group in doses of 1,005 mg, 1,010 mg, 1,015 mg, 1,020 mg, 1,025 mg, 1,030 mg, 1,035 mg, 1,040 mg, 1,045 mg, 1,050 mg, 1,055 mg, 1,060 mg, 1,065 mg, 1,070 mg, 1,075 mg, 1,080 mg, 1,085 mg, 1,090 mg, 1,095 mg, or 1,100 mg.
[0073] In some embodiments, the PGF2α receptor antagonist is administered in doses of approximately 950 mg to approximately 1,050 mg per dose during the first treatment period, for example, approximately 950 mg, 955 mg, 960 mg, 965 mg, 970 mg, 975 mg, 980 mg, 985 mg, 990 mg, 995 mg, 1,000 mg, 1,005 mg, 1,010 mg, 1,015 mg, 1,020 mg, 1,025 mg, 1,030 mg, 1,035 mg, 1,040 mg per dose during the first treatment period. The subject is administered a dose of mg, 1,045 mg, or 1,050 mg (i.e., a total of approximately 950 mg, 955 mg, 960 mg, 965 mg, 970 mg, 975 mg, 980 mg, 985 mg, 990 mg, 995 mg, 1,000 mg, 1,005 mg, 1,010 mg, 1,015 mg, 1,020 mg, 1,025 mg, 1,030 mg, 1,035 mg, 1,040 mg, 1,045 mg, or 1,050 mg per day during the first treatment period). In some embodiments, the PGF2α receptor antagonist is administered to the subject at a dose of approximately 1,000 mg per dose during the first treatment period.
[0074] In some embodiments, the PGF2α receptor antagonist is administered in doses of approximately 350 mg to 650 mg per dose during the second treatment period, for example, approximately 350 mg, 355 mg, 360 mg, 365 mg, 370 mg, 375 mg, 380 mg, 385 mg, 390 mg, 395 mg, 400 mg, 405 mg, 410 mg, 415 mg, 420 mg, 425 mg, 430 mg, 435 mg, 440 mg, 445 mg, 450 mg, 455 mg, 460 mg, 465 mg, 470 mg, 475 mg, and 480 mg per dose during the second treatment period. , in amounts of 485mg, 490mg, 495mg, 500mg, 505mg, 510mg, 515mg, 520mg, 525mg, 530mg, 535mg, 540mg, 545mg, 550mg, 555mg, 560mg, 565mg, 570mg, 575mg, 580mg, 585mg, 590mg, 595mg, 600mg, 605mg, 610mg, 615mg, 620mg, 625mg, 630mg, 635mg, 640mg, 645mg or 650mg (i.e., during the second treatment period, a total of approximately 700mg per day) For example, during the second treatment period, approximately 700mg, 710mg, 720mg, 730mg, 740mg, 750mg, 760mg, 770mg, 780mg, 790mg, 800mg, 800mg, 810mg, 820mg, 830mg, 840mg, 850mg, 860mg, 870mg, 880mg, 890mg, 900mg, 910mg, 920mg, 930mg, 940mg, 950mg, 960mg, 970mg, 980mg, 990mg, 1,000mg, 1,010mg, and 1,020mg per day. It is administered to the target group in amounts of 1,030 mg, 1,040 mg, 1,050 mg, 1,060 mg, 1,070 mg, 1,080 mg, 1,090 mg, 1,100 mg, 1,110 mg, 1,120 mg, 1,130 mg, 1,140 mg, 1,150 mg, 1,160 mg, 1,170 mg, 1,180 mg, 1,190 mg, 1,200 mg, 1,210 mg, 1,220 mg, 1,230 mg, 1,240 mg, 1,250 mg, 1,260 mg, 1,270 mg, 1,280 mg, 1,290 mg, or 1,300 mg.
[0075] In some embodiments, the PGF2α receptor antagonist is administered in doses of approximately 400 mg to 600 mg per dose during the second treatment period, for example, approximately 400 mg, 405 mg, 410 mg, 415 mg, 420 mg, 425 mg, 430 mg, 435 mg, 440 mg, 445 mg, 450 mg, 455 mg, 460 mg, 465 mg, 470 mg, 475 mg per dose during the second treatment period. In amounts of 480 mg, 485 mg, 490 mg, 495 mg, 500 mg, 505 mg, 510 mg, 515 mg, 520 mg, 525 mg, 530 mg, 535 mg, 540 mg, 545 mg, 550 mg, 555 mg, 560 mg, 565 mg, 570 mg, 575 mg, 580 mg, 585 mg, 590 mg, 595 mg, or 600 mg (i.e., per day during the second treatment period) The total amount is approximately 800mg to 1,200mg. For example, during the second treatment period, the daily doses would be approximately 800mg, 800mg, 810mg, 820mg, 830mg, 840mg, 850mg, 860mg, 870mg, 880mg, 890mg, 900mg, 910mg, 920mg, 930mg, 940mg, 950mg, 960mg, 970mg, 980mg, 990mg, and 1,000mg. It is administered to the target group in doses of 1,010 mg, 1,020 mg, 1,030 mg, 1,040 mg, 1,050 mg, 1,060 mg, 1,070 mg, 1,080 mg, 1,090 mg, 1,100 mg, 1,110 mg, 1,120 mg, 1,130 mg, 1,140 mg, 1,150 mg, 1,160 mg, 1,170 mg, 1,180 mg, 1,190 mg, or 1,200 mg.
[0076] In some embodiments, the PGF2α receptor antagonist is administered in amounts of approximately 450 mg to approximately 550 mg per dose during the second treatment period, for example, approximately 450 mg, 455 mg, 460 mg, 465 mg, 470 mg, 475 mg, 480 mg, 485 mg, 490 mg, 495 mg, 500 mg, 505 mg, 510 mg, 515 mg, 520 mg, 525 mg, 530 mg, 535 mg, 540 mg, 545 mg, or 550 mg per dose during the second treatment period (i.e., the second During the second treatment period, the subject is administered a total dose of approximately 900 mg to 1,100 mg per day, for example, approximately 900 mg, 910 mg, 920 mg, 930 mg, 940 mg, 950 mg, 960 mg, 970 mg, 980 mg, 990 mg, 1,000 mg, 1,010 mg, 1,020 mg, 1,030 mg, 1,040 mg, 1,050 mg, 1,060 mg, 1,070 mg, 1,080 mg, 1,090 mg, or 1,100 mg per day. In some embodiments, the PGF2α receptor antagonist is administered to the subject at a dose of approximately 500 mg per dose during the second treatment period.
[0077] In some embodiments, the PGF2α receptor antagonist is administered to the subject once every 10 to 14 hours during the second treatment period. In some embodiments, the PGF2α receptor antagonist is administered to the subject once every 11 to 13 hours during the second treatment period. In some embodiments, the PGF2α receptor antagonist is administered to the subject once every 12 hours during the second treatment period.
[0078] In some embodiments, the first treatment period is a period of 1 to 10 days (for example, a period of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days). In some embodiments, the first treatment period is a period of 1 to 5 days (for example, a period of 1, 2, 3, 4, or 5 days). In some embodiments, the first treatment period is a period of 1 day.
[0079] In some embodiments, the second treatment period is a period of 1 to 28 days (for example, a period of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28 days). In some embodiments, the second treatment period is a period of 4 to 14 days (for example, a period of 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days). In some embodiments, the second treatment period is a period of 5 to 10 days (for example, a period of 5, 6, 7, 8, 9, or 10 days). In some embodiments, the second treatment period is a period of 3 days. In some embodiments, the second treatment period is 4 days. In some embodiments, the second treatment period is 5 days. In some embodiments, the second treatment period is 6 days. In some embodiments, the second treatment period is 7 days. In some embodiments, the second treatment period is 8 days. In some embodiments, the second treatment period is 9 days. In some embodiments, the second treatment period is 10 days.
[0080] In some embodiments, the PGF2α receptor antagonist is administered to the subject until she reaches at least about 34 weeks of gestation (e.g., about 34 to about 40 weeks of gestation, e.g., 34, 35, 36, 37, 38, 39, or 40 weeks of gestation) or until she experiences childbirth. In some embodiments, the PGF2α receptor antagonist is administered to the subject until she reaches about 37 weeks of gestation.
[0081] In some embodiments, the PGF2α receptor antagonist is administered orally to the subject. The PGF2α receptor antagonist may be formulated, for example, as a tablet, gel capsule, powder, liquid solution, or liquid suspension.
[0082] In some embodiments, atosiban is administered regularly to the subject in doses at intervals of 12, 24, 36, 48, 60, 72, 84, 96 hours, or once or more times per week or month. For example, atosiban may be administered in 1 to 10 doses every 12 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses), 1 to 10 doses every 14 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses), 1 to 10 doses every 16 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses), 1 to 10 doses every 18 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses), or 1 to 10 doses every 20 hours (e.g., 1, 2, (3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 22 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 24 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 26 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 28 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 30 hours Dosages (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses), 1 to 10 doses every 32 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses), 1 to 10 doses every 34 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses), 1 to 10 doses every 36 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses), 1 to 10 doses every 38 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses), Doses of 1 to 10 times every 40 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 times every 42 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 times every 44 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 times every 46 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 times every 48 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8,9 or 10 doses), 1 to 10 doses every 60 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 72 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 84 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 96 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 108 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses) It may be administered to the target population in doses of 1 to 10 times every 120 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses), 1 to 10 times every 132 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses), 1 to 10 times every 144 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses), 1 to 10 times every 156 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses), or 1 to 10 times weekly (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses).
[0083] In some embodiments, atosiban is administered as a single bolus dose of approximately 4.0 mg to approximately 9.5 mg (e.g., approximately 4.0 mg, 4.1 mg, 4.2 mg, 4.3 mg, 4.4 mg, 4.5 mg, 4.6 mg, 4.7 mg, 4.8 mg, 4.9 mg, 5.0 mg, 5.1 mg, 5.2 mg, 5.3 mg, 5.4 mg, 5.5 mg, 5.6 mg, 5.7 mg, 5.8 mg, 5.9 mg, 6.0 mg, 6.1 mg, 6.2 mg, 6. It is administered to the target population as a single bolus dose of 3 mg, 6.4 mg, 6.5 mg, 6.6 mg, 6.7 mg, 6.8 mg, 6.9 mg, 7.0 mg, 7.1 mg, 7.2 mg, 7.3 mg, 7.4 mg, 7.5 mg, 7.6 mg, 7.7 mg, 7.8 mg, 7.9 mg, 8.0 mg, 8.1 mg, 8.2 mg, 8.3 mg, 8.4 mg, 8.5 mg, 8.6 mg, 8.7 mg, 8.8 mg, 8.9 mg, or 9.0 mg. In some embodiments, atosiban is administered to subjects in a single bolus dose of approximately 5.0 mg to approximately 8.5 mg (for example, a single bolus dose of approximately 5.0 mg, 5.1 mg, 5.2 mg, 5.3 mg, 5.4 mg, 5.5 mg, 5.6 mg, 5.7 mg, 5.8 mg, 5.9 mg, 6.0 mg, 6.1 mg, 6.2 mg, 6.3 mg, 6.4 mg, 6.5 mg, 6.6 mg, 6.7 mg, 6.8 mg, 6.9 mg, 7.0 mg, 7.1 mg, 7.2 mg, 7.3 mg, 7.4 mg, 7.5 mg, 7.6 mg, 7.7 mg, 7.8 mg, 7.9 mg, 8.0 mg, 8.1 mg, 8.2 mg, 8.3 mg, 8.4 mg, or 8.5 mg). In some embodiments, atosiban is administered to subjects in a single bolus dose of approximately 5.5 mg to approximately 8.0 mg (for example, a single bolus dose of approximately 5.5 mg, 5.6 mg, 5.7 mg, 5.8 mg, 5.9 mg, 6.0 mg, 6.1 mg, 6.2 mg, 6.3 mg, 6.4 mg, 6.5 mg, 6.6 mg, 6.7 mg, 6.8 mg, 6.9 mg, 7.0 mg, 7.1 mg, 7.2 mg, 7.3 mg, 7.4 mg, 7.5 mg, 7.6 mg, 7.7 mg, 7.8 mg, 7.9 mg, or 8.0 mg).In some embodiments, atosiban is administered to subjects in a single bolus dose of approximately 5.75 mg to approximately 7.75 mg (e.g., a single bolus dose of approximately 5.75 mg, 6.00 mg, 6.25 mg, 6.50 mg, 6.75 mg, 7.00 mg, 7.25 mg, 7.50 mg, or 7.75 mg). In some embodiments, atosiban is administered to subjects in a single bolus dose of approximately 6.0 mg to approximately 7.5 mg (e.g., a single bolus dose of approximately 6.0 mg, 6.1 mg, 6.2 mg, 6.3 mg, 6.4 mg, 6.5 mg, 6.6 mg, 6.7 mg, 6.8 mg, 6.9 mg, 7.0 mg, 7.1 mg, 7.2 mg, 7.3 mg, 7.4 mg, or 7.5 mg). In some embodiments, atosiban is administered to subjects in a single bolus dose of approximately 6.25 mg to approximately 7.25 mg (e.g., a single bolus dose of approximately 6.25 mg, 6.50 mg, 6.75 mg, 7.00 mg, or 7.25 mg). In some embodiments, atosiban is administered to subjects in a single bolus dose of approximately 6.5 mg to approximately 7.0 mg (e.g., a single bolus dose of approximately 6.50 mg, 6.75 mg, or 7.00 mg). In some embodiments, atosiban is administered to subjects in a single bolus dose of approximately 6.75 mg.
[0084] In some embodiments, a single bolus dose of atosiban is administered intravenously to the subject.
[0085] In some embodiments, following a single bolus administration of atosiban, the atosiban is subsequently administered to the subject by continuous intravenous infusion in amounts of approximately 40 mg to approximately 70 mg (for example, by continuous intravenous infusion in amounts of approximately 40 mg, 41 mg, 42 mg, 43 mg, 44 mg, 45 mg, 46 mg, 47 mg, 48 mg, 49 mg, 50 mg, 51 mg, 52 mg, 53 mg, 54 mg, 55 mg, 56 mg, 57 mg, 58 mg, 59 mg, 60 mg, 61 mg, 62 mg, 63 mg, 64 mg, 65 mg, 66 mg, 67 mg, 68 mg, 69 mg, or 70 mg). In some embodiments, following a single bolus dose of atosiban, the atosiban is subsequently administered to the subject by continuous intravenous infusion in amounts of approximately 45 mg to approximately 65 mg (for example, by continuous intravenous infusion in amounts of approximately 45 mg, 46 mg, 47 mg, 48 mg, 49 mg, 50 mg, 51 mg, 52 mg, 53 mg, 54 mg, 55 mg, 56 mg, 57 mg, 58 mg, 59 mg, 60 mg, 61 mg, 62 mg, 63 mg, 64 mg, or 65 mg). In some embodiments, following a single bolus dose of atosiban, the atosiban is subsequently administered to the subject by continuous intravenous infusion in amounts of approximately 50 mg to approximately 60 mg (for example, by continuous intravenous infusion in amounts of approximately 50 mg, 51 mg, 52 mg, 53 mg, 54 mg, 55 mg, 56 mg, 57 mg, 58 mg, 59 mg, or 60 mg). In some embodiments, following a single bolus dose of atosiban, the atosiban is subsequently administered to the subject by continuous intravenous infusion in amounts of approximately 52 mg to approximately 56 mg (for example, by continuous intravenous infusion in amounts of approximately 52 mg, 53 mg, 54 mg, 55 mg, or 56 mg). In some embodiments, following a single bolus dose of atosiban, the atosiban is subsequently administered to the subject by continuous intravenous infusion in amounts of approximately 54 mg.
[0086] In some embodiments, the aforementioned intravenous infusion is performed continuously over a period of about 1 to 5 hours, for example, about 1.0 hour, 1.25 hours, 1.5 hours, 1.75 hours, 2.0 hours, 2.25 hours, 2.5 hours, 2.75 hours, 3.0 hours, 3.25 hours, 3.5 hours, 3.5 hours, 3.75 hours, 4.0 hours, 4.25 hours, 4.5 hours, 4.75 hours, or 5.0 hours. In some embodiments, the aforementioned intravenous infusion is performed continuously over a period of about 1.5 to 4.5 hours, for example, about 1.5 hours, 1.75 hours, 2.0 hours, 2.25 hours, 2.5 hours, 2.75 hours, 3.0 hours, 3.25 hours, 3.5 hours, 3.5 hours, 3.75 hours, 4.0 hours, 4.25 hours, or 4.5 hours. In some embodiments, the aforementioned intravenous infusion is performed continuously over a period of about 2.0 hours to about 4.0 hours, for example, about 2.0 hours, 2.25 hours, 2.5 hours, 2.75 hours, 3.0 hours, 3.25 hours, 3.5 hours, 3.5 hours, 3.75 hours, or 4.0 hours. In some embodiments, the aforementioned intravenous infusion is performed continuously over a period of about 2.5 hours to about 3.5 hours, for example, about 2.5 hours, 2.75 hours, 3.0 hours, 3.25 hours, or 3.5 hours. In some embodiments, the aforementioned intravenous infusion is performed continuously over a period of about 3.0 hours.
[0087] In some embodiments, following the aforementioned sequential intravenous infusion, atosiban is subsequently administered to the subject by a second sequential intravenous infusion in amounts of approximately 240 mg to approximately 300 mg (for example, by a second sequential intravenous infusion in amounts of approximately 240 mg, 245 mg, 250 mg, 255 mg, 260 mg, 265 mg, 270 mg, 275 mg, 280 mg, 285 mg, 290 mg, 295 mg, or 300 mg). In some embodiments, following the aforementioned sequential intravenous infusion, atosiban is subsequently administered to the subject by a second sequential intravenous infusion in amounts of approximately 250 mg to approximately 290 mg (for example, by a second sequential intravenous infusion in amounts of approximately 250 mg, 255 mg, 260 mg, 265 mg, 270 mg, 275 mg, 280 mg, 285 mg, or 290 mg). In some embodiments, following the aforementioned sequential intravenous infusion, atosiban is subsequently administered to the subject by a second sequential intravenous infusion in an amount of approximately 250 mg to approximately 290 mg (for example, by a second sequential intravenous infusion in an amount of approximately 250 mg, 255 mg, 260 mg, 265 mg, 270 mg, 275 mg, 280 mg, 285 mg, or 290 mg). In some embodiments, following the aforementioned sequential intravenous infusion, atosiban is subsequently administered to the subject by a second sequential intravenous infusion in an amount of approximately 260 mg to approximately 280 mg (for example, by a second sequential intravenous infusion in an amount of approximately 260 mg, 265 mg, 270 mg, 275 mg, or 280 mg). In some embodiments, following the aforementioned sequential intravenous infusion, atosiban is subsequently administered to the subject by a second sequential intravenous infusion in an amount of approximately 265 mg to approximately 275 mg (for example, by a second sequential intravenous infusion in an amount of approximately 265 mg, 270 mg, or 275 mg). In some embodiments, following the aforementioned sequential intravenous infusion, atosiban is subsequently administered to the subject by a second sequential intravenous infusion in an amount of approximately 270 mg.
[0088] In some embodiments, the second intravenous infusion is performed continuously over a period of approximately 42 to 48 hours, for example, approximately 42.0 hours, 42.25 hours, 42.5 hours, 42.75 hours, 43.0 hours, 43.25 hours, 43.5 hours, 43.75 hours, 44.0 hours, 44.25 hours, 44.5 hours, 44.75 hours, 45.0 hours, 45.25 hours, 45.5 hours, 45.75 hours, 46.0 hours, 46.25 hours, 46.5 hours, 46.75 hours, 47.0 hours, 47.25 hours, 47.5 hours, 47.75 hours, or 48.0 hours. In some embodiments, the second intravenous infusion is performed continuously over a period of approximately 43 to 47 hours, for example, approximately 43.0 hours, 43.25 hours, 43.5 hours, 43.75 hours, 44.0 hours, 44.25 hours, 44.5 hours, 44.75 hours, 45.0 hours, 45.25 hours, 45.5 hours, 45.75 hours, 46.0 hours, 46.25 hours, 46.5 hours, 46.75 hours, or 47.0 hours. In some embodiments, the second intravenous infusion is performed continuously over a period of approximately 44 to 46 hours, for example, approximately 44.0 hours, 44.25 hours, 44.5 hours, 44.75 hours, 45.0 hours, 45.25 hours, 45.5 hours, 45.75 hours, or 46.0 hours. In some embodiments, the second intravenous infusion is performed continuously over a period of approximately 44.5 hours to approximately 45.5 hours, for example, approximately 44.5 hours, 44.75 hours, 45.0 hours, 45.25 hours, or 45.5 hours. In some embodiments, the second intravenous infusion is performed continuously over a period of approximately 44 hours.
[0089] In some embodiments, atosiban is administered to the subject until she reaches at least about 34 weeks of gestation (e.g., about 34 to about 40 weeks of gestation, e.g., 34, 35, 36, 37, 38, 39, or 40 weeks of gestation) or until she experiences childbirth. In some embodiments, atosiban is administered to the subject until she reaches about 37 weeks of gestation.
[0090] In some embodiments, the administration of the PGF2α receptor antagonist and the administration of atosiban are initiated within approximately 48 hours of each other. In some embodiments, the administration of the PGF2α receptor antagonist and the administration of atosiban are initiated within approximately 36 hours of each other. In some embodiments, the administration of the PGF2α receptor antagonist and the administration of atosiban are initiated within approximately 24 hours of each other. In some embodiments, the administration of the PGF2α receptor antagonist and the administration of atosiban are initiated within approximately 12 hours of each other. In some embodiments, the administration of the PGF2α receptor antagonist and the administration of atosiban are initiated within approximately 6 hours of each other. In some embodiments, the administration of the PGF2α receptor antagonist and the administration of atosiban are initiated substantially simultaneously.
[0091] In some embodiments, atosiban is formulated as an aqueous solution. The concentration of atosiban in the aqueous solution is, for example, about 5.0 mg / ml to about 10 mg / ml (for example, about 5.0 mg / ml, 5.1 mg / ml, 5.2 mg / ml, 5.3 mg / ml, 5.4 mg / ml, 5.5 mg / ml, 5.6 mg / ml, 5.7 mg / ml, 5.8 mg / ml, 5.9 mg / ml, 6.0 mg / ml, 6.1 mg / ml, 6.2 mg / ml, 6.3 mg / ml, 6.4 mg / ml, 6.5 mg / ml, 6.6 mg / ml, 6.7 mg / ml, 6.8 mg / ml, 6.9 mg / ml, 7.0 mg / ml, 7.1 mg / ml, 7.2 mg / ml, 7.3 mg It may be 7.4 mg / ml, 7.5 mg / ml, 7.6 mg / ml, 7.7 mg / ml, 7.8 mg / ml, 7.9 mg / ml, 8.0 mg / ml, 8.1 mg / ml, 8.2 mg / ml, 8.3 mg / ml, 8.4 mg / ml, 8.5 mg / ml, 8.6 mg / ml, 8.7 mg / ml, 8.8 mg / ml, 8.9 mg / ml, 9.0 mg / ml, 9.1 mg / ml, 9.2 mg / ml, 9.3 mg / ml, 9.4 mg / ml, 9.5 mg / ml, 9.6 mg / ml, 9.7 mg / ml, 9.8 mg / ml, 9.9 mg / ml, or 10.0 mg / ml. In some embodiments, the concentration of atosiban in the aqueous solution is, for example, about 5.5 mg / ml to about 9.5 mg / ml (for example, about 5.5 mg / ml, 5.6 mg / ml, 5.7 mg / ml, 5.8 mg / ml, 5.9 mg / ml, 6.0 mg / ml, 6.1 mg / ml, 6.2 mg / ml, 6.3 mg / ml, 6.4 mg / ml, 6.5 mg / ml, 6.6 mg / ml, 6.7 mg / ml, 6.8 mg / ml, 6.9 mg / ml, 7.0 mg / ml, 7.1 mg / ml, 7.2 mg / ml). ml, 7.3mg / ml, 7.4mg / ml, 7.5mg / ml, 7.6mg / ml, 7.7mg / ml, 7.8mg / ml, 7.9mg / ml, 8.0mg / ml, 8.1mg / ml, 8.2mg / ml, 8.3mg / ml, 8.4mg / ml, 8.5mg / ml, 8.6mg / ml, 8.7mg / ml, 8.8mg / ml, 8.9mg / ml, 9.0mg / ml, 9.1mg / ml, 9.2mg / ml, 9.3mg / ml, 9.4mg / ml or 9.5mg / ml).In some embodiments, the concentration of atosiban in the aqueous solution is, for example, about 6.0 mg / ml to about 9.0 mg / ml (for example, about 6.0 mg / ml, 6.1 mg / ml, 6.2 mg / ml, 6.3 mg / ml, 6.4 mg / ml, 6.5 mg / ml, 6.6 mg / ml, 6.7 mg / ml, 6.8 mg / ml, 6.9 mg / ml, 7.0 mg / ml, 7.1 mg / ml, 7.2 mg / ml). ml, 7.3mg / ml, 7.4mg / ml, 7.5mg / ml, 7.6mg / ml, 7.7mg / ml, 7.8mg / ml, 7.9mg / ml, 8.0mg / ml, 8.1mg / ml, 8 .2mg / ml, 8.3mg / ml, 8.4mg / ml, 8.5mg / ml, 8.6mg / ml, 8.7mg / ml, 8.8mg / ml, 8.9mg / ml or 9.0mg / ml). In some embodiments, the concentration of atosiban in the aqueous solution is, for example, about 6.5 mg / ml to about 8.5 mg / ml (for example, about 6.5 mg / ml, 6.6 mg / ml, 6.7 mg / ml, 6.8 mg / ml, 6.9 mg / ml, 7.0 mg / ml, 7.1 mg / ml, 7.2 mg / ml, 7.3 mg / ml, 7.4 mg / ml, 7.5 mg / ml, 7.6 mg / ml, 7.7 mg / ml, 7.8 mg / ml, 7.9 mg / ml, 8.0 mg / ml, 8.1 mg / ml, 8.2 mg / ml, 8.3 mg / ml, 8.4 mg / ml, or 8.5 mg / ml). In some embodiments, the concentration of atosiban in the aqueous solution is, for example, about 7.0 mg / ml to about 8.0 mg / ml (e.g., about 7.0 mg / ml, 7.1 mg / ml, 7.2 mg / ml, 7.3 mg / ml, 7.4 mg / ml, 7.5 mg / ml, 7.6 mg / ml, 7.7 mg / ml, 7.8 mg / ml, 7.9 mg / ml, or 8.0 mg / ml). In some embodiments, the concentration of atosiban in the aqueous solution is about 7.5 mg / ml.
[0092] The aqueous solution may further contain one or more pharmaceutically acceptable excipients, such as mannitol. In some embodiments, the concentration of mannitol in the aqueous solution is about 40 mg / ml to about 60 mg / ml, such as about 45 mg / ml to about 55 mg / ml (e.g., about 50 mg / ml).
[0093] In some embodiments, the aqueous solution has a pH of about 4.0 to about 5.0 (e.g., pH of about 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, or 5.0). In some embodiments, the aqueous solution has a pH of about 4.25 to about 4.75 (e.g., pH of about 4.25, 4.30, 4.35, 4.40, 4.45, 4.50, 4.55, 4.60, 4.65, 4.70, or 4.75). In some embodiments, the aqueous solution has a pH of about 4.5.
[0094] In some embodiments, the subject is a mononuclear pregnancy or a twin pregnancy.
[0095] In some embodiments, subjects have experienced or are at risk of experiencing preterm birth. Conditions that can identify subjects at risk of experiencing preterm birth include: (i) subjects whose gestational age prior to administration of atosiban and PGF2α receptor antagonist is approximately 24 to 36 weeks (e.g., gestational age approximately 24 to 34 weeks prior to administration of atosiban and PGF2α receptor antagonist, e.g., gestational age approximately 28 to 33 and 6 / 7 weeks); (ii) subjects exhibiting four or more uterine contractions per 30 minutes prior to administration of atosiban and PGF2α receptor antagonist (e.g., each lasting at least 30 seconds); (iii) subjects exhibiting cervical dilation of approximately 1 cm to 4 cm prior to administration of atosiban and PGF2α receptor antagonist; (iv) subjects exhibiting cervical dilation of approximately 1 cm to 4 cm prior to administration of atosiban and PGF2α receptor antagonist The subjects include (v) subjects who test positive for the presence of fetal fibronectin and / or insulin-like growth factor-binding protein-1 (IGFBP-1) in cervical secretion samples obtained from the subjects; (v) subjects who have a cervical length of approximately 25 mm or less before administration of atosiban and a PGF2α receptor antagonist; (vi) subjects who have progressive cervical dilation (e.g., a cervical dilation rate of approximately 0.5 cm to approximately 0.7 cm per hour before administration of atosiban and a PGF2α receptor antagonist); and (vii) subjects who have at least 50% effacement before administration of atosiban and a PGF2α receptor antagonist. Subjects may, for example, exhibit one or more or all of these characteristics before the first administration of atosiban and a PGF2α receptor antagonist to the subject. In some embodiments, the subject exhibits one or more or all of these characteristics up to 3 hours before administration of atosiban and / or a PGF2α receptor antagonist.
[0096] In some embodiments, labor in a subject is delayed by approximately 4 hours to approximately 6 weeks after the initial administration of atosiban and the PGF2α receptor antagonist to the subject. For example, labor may be delayed by approximately 12 hours to approximately 28 days, approximately 18 hours to approximately 21 days, approximately 24 hours to approximately 14 days, approximately 24 hours to approximately 14 days, approximately 48 hours, or approximately 7 days after the initial administration of atosiban and the PGF2α receptor antagonist to the subject. In some embodiments, after administration of atosiban and the PGF2α receptor antagonist to the subject, the subject experiences labor at a gestation period of at least approximately 34 weeks, for example, approximately 34, 35, 36, 37, 38, 39, or 40 weeks. In some embodiments, after administration of atosiban and the PGF2α receptor antagonist to the subject, the subject experiences labor at a gestation period of approximately 37 weeks. In some embodiments, after administration of atosiban and a PGF2α receptor antagonist to a subject, the subject experiences childbirth during a gestation period of approximately 36 to 40 weeks.
[0097] In a further embodiment, the Disclosure comprises a kit comprising a PGF2α receptor antagonist, such as one of the compounds of formulas (I) to (VIII), e.g., compound (1), compound (2), or compound (3), among other PGF2α receptor antagonists described herein, and a package insert instructing the user of the kit to administer the PGF2α receptor antagonist to a pregnant subject (e.g., a pregnant human subject) in accordance with any of the above embodiments or models described herein. In some embodiments, the PGF2α receptor antagonist is a compound represented by formula (1). [ka]
[0098] PGF2α receptor antagonists are compounds represented by formula (2). [ka] or a pharmaceutically acceptable salt thereof. For example, in some embodiments, the PGF2α receptor antagonist is a chloride salt of compound (2) represented by the following formula (3). [ka]
[0099] In some embodiments, the kit further comprises atosiban in the form of an aqueous solution having a concentration of about 5.0 mg / ml to about 10.0 mg / ml (e.g., a concentration of about 7.5 mg / ml). The aqueous solution may further contain one or more pharmaceutically acceptable excipients, such as mannitol, at a concentration of about 40 mg / ml to about 60 mg / ml, for example, about 45 mg / ml to about 55 mg / ml (e.g., about 50 mg / ml).
[0100] definition As used herein, the term "approximately" refers to a value that is 10% greater than or less than the stated value. For example, "approximately 5 mg" refers to an amount between 4.5 mg and 5.5 mg.
[0101] As used herein, the term "affinity" refers to the strength of the binding interaction between two molecules, such as a ligand and a receptor. i The term "K" is intended to refer to the inhibition constant of an antagonist against a specific molecule of interest, and is expressed as molar concentration (M). i The value can be determined, for example, using methods established in the art. K of an antagonist against a molecular target. i Methods that can be used to determine include, for example, competitive binding experiments such as the competitive radioligand binding assays described in US8,415,480, US9,447,055 and US9,834,528, the respective disclosures of which are incorporated herein by reference in their entirety. d The term "rate constant (k)" refers, for example, to the rate constant of association between two molecules. a The rate constant (k) for the dissociation of two molecules relative to ) d This refers to the dissociation constant that can be obtained from the ratio of ), and is expressed as molar concentration (M). K of receptor-ligand interaction dThe value can be determined, for example, using methods established in the art. K of receptor-ligand interaction d Methods that can be used to determine this include, for example, surface plasmon resonance using biosensor systems such as the BIACORE® system.
[0102] As used herein, the terms “effect” and “response” are interchangeable within the context of subjects such as pregnant human subjects receiving treatment for the treatment or prevention of preterm birth. These terms refer to any clinical improvement in the condition of the subject. Subjects experiencing or at risk of experiencing preterm birth, as well as atosiban and prostaglandin receptor F2α (PGF2α) antagonists as described herein (e.g., 1,3-thiazolidine-2-carboxamide compounds as described herein, e.g., (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidine-2-yl]carbonyl}amino)-3-(4-fluorophenyl)propyl L-valinate or its pharmaceutically acceptable salts, e.g., (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,Exemplary effects in the context of subjects being treated with 3-thiazolidinedione-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-vaphosphate include, but are not limited to, (i) delays after the first administration of atosiban and the PGF2α receptor antagonist to the subject, for example, more than 1 hour, more than 1 day or more than 1 week (e.g., delays of about 1 hour to about 16 weeks, e.g., particularly 1 hour, 6 hours, 12 hours, 18 hours, 24 hours, 48 hours, 72 hours, 1 week). (ii) Delay in the onset of labor in subjects (delay of 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks or 16 weeks), (ii) After administration of atosiban and a PGF2α receptor antagonist to a subject, the subject experiences labor at least approximately 34 weeks of gestation, for example, between approximately 34 and approximately 40 weeks of gestation (for example, at approximately 34, 35, 36, 37, 38, 39 or 40 weeks of gestation), (iii) Delay in the onset of labor, (iv) Reduction in vaginal bleeding in subjects after administration of atosiban and PGF2α receptor antagonists to subjects, (iv) Delay in the onset of rupture of membranes in subjects (for example, a delay of about 1 hour to about 16 weeks after the first administration of atosiban and PGF2α receptor antagonists to subjects, for example, particularly 1 hour, 6 hours, 12 hours, 18 hours, 24 hours, 48 hours, 72 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks) (v) a decrease in the expression of one or more pro-inflammatory genes, such as cyclooxygenase-2 (Cox2), in the subject after administration of atosiban and a PGF2α receptor antagonist (e.g., assessed by observing a decrease in Cox2 expression in the myometrium), and (vi) a decrease in the frequency, peak amplitude, duration, and / or activity of uterine contractions in the subject after administration of atosiban and a PGF2α receptor antagonist.
[0103] As used herein, the terms “bolus administration” and “bolus dose” are interchangeable and refer to the administration of a therapeutic agent to a subject in which the entire dose of the therapeutic agent is administered to the subject at a single, distinct time point. An example of a bolus administration is the administration of a 6.75 mg dose of an oxytocin receptor antagonist as described herein, such as atosiban, in which the entire 6.75 mg dose is administered to the patient at a single time point. In contrast, “sequential administration,” such as “sequential infusion,” refers to the administration of a therapeutic agent (e.g., an oxytocin receptor antagonist as described herein, such as atosiban) in which the entire dose of the therapeutic agent is administered to the patient at a steady rate over a time interval. An example of sequential administration is the administration of an oxytocin receptor antagonist as described herein, such as a 54 mg dose of atosiban, in which the entire 54 mg dose is administered to the patient at a steady rate over a time interval (e.g., over a period of one minute or more or over a period of one hour or more).
[0104] As used herein, the terms “crystalline” or “crystalline form” mean having a physical state that is a regular three-dimensional arrangement of atoms, ions, molecules, or molecular aggregates. A crystalline form is a lattice arrangement of building blocks called asymmetric units, which are arranged according to a clearly defined symmetry in repeating unit cells in three dimensions. In contrast, the terms “amorphous” or “amorphous form” refer to an unorganized (disorderly) structure. The physical state of a therapeutic compound can be determined by exemplary techniques such as X-ray diffraction, polarized light microscopy, and / or differential scanning calorimetry.
[0105] As used herein, the term “dose” refers to the amount of a therapeutic agent, such as atosiban and / or PGF2α receptor antagonists described herein, administered to a subject for the treatment of a disorder or condition, such as the treatment or prevention of premature birth in a pregnant subject (e.g., a human subject in pregnancy). The therapeutic agents described herein may be administered as a single dose or in multiple doses. In each case, the therapeutic agent may be administered using one or more unit dosage forms of the therapeutic agent. For example, a single dose of 1,000 mg of the therapeutic agent may be administered, for example, using two 500 mg unit dosage forms of the therapeutic agent.
[0106] As used herein, the terms “effacement” and “effaced” refer to the preparation of the cervix for delivery, the process that occurs in the progressive thinning of the cervix. Effacement can be expressed as a percentage, such as 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%. When effacement occurs, the cervix shortens and eventually becomes part of the lower uterine wall. Methods for measuring cervical effacement based on cervical thickness and dilation are known in the art, for example, described in US5,876,357, the disclosure of which is incorporated herein by reference as relating to the measurement of cervical dilation.
[0107] As used herein, the term “endogenous” refers to a molecule (e.g., polypeptide, nucleic acid, or cofactor) that is naturally found in a particular organism (e.g., a human) or in a particular location within an organism (e.g., an organ, tissue, or cell, e.g., a human cell).
[0108] As used herein, the term “exogenous” refers to a molecule (e.g., polypeptide, nucleic acid, or cofactor) that is not found naturally in a particular organism (e.g., human) or in a particular location within an organism (e.g., an organ, tissue, or cell, e.g., a human cell). Exogenous substances include substances supplied from an external source to an organism or a culture extracted therefrom.
[0109] As used herein, the term “gestational age” refers to how far a particular pregnancy has progressed, measured from the first day of the last menstrual cycle to the present for pregnant women. As used herein, the term “delivery” (also referred to as birth) refers to the expulsion of the fetus and placenta from the uterus for pregnant women. In a normal human pregnancy, delivery generally occurs at approximately 40 weeks of gestation. As used herein, “premature delivery” refers to the start of labor more than three weeks before the full gestational age, which is typically about 40 weeks in human subjects. In other words, premature delivery can occur at any stage before, for example, 38 weeks of gestation. If left untreated, premature delivery usually leads to the onset of labor or labor-related physiological changes in pregnant women. Premature delivery may or may not be associated with vaginal bleeding or rupture of the uterine membrane. Premature delivery may also be referred to as preterm labor.
[0110] As used herein, the term "once daily" refers to administering the therapeutic agent to the subject in a single dose each day. The date and time of administration of the therapeutic agent may be constant or variable. Similarly, terms such as "twice daily" and "three times daily" refer to administering the therapeutic agent to the subject in two or three doses per day, respectively.
[0111] As used herein, the term “progressive cervical dilation” refers to a uniform opening of the cervix in subjects such as pregnant human subjects who have experienced or are at risk of experiencing premature delivery. A subject is considered to have progressive cervical dilation if its cervix is opening (i.e., dilating) at a constant linear rate, for example, about 0.5 cm to about 0.7 cm per hour.
[0112] As used herein, the terms “prostaglandin F2α receptor antagonist” or “PGF2α receptor antagonist” refer to compounds that specifically and / or selectively bind to the PGF2α receptor and can inhibit receptor signaling, for example, in uterine myocytes. Inhibition of PGF2α receptor signaling can, for example, (i) cleavage of phosphatidylinositol-4,5-bisphosphate (PIP2), (ii) diacylglycerol (DAG) production, (iii) inositol-1,4,5-triphosphate (IP3) production, and / or (iv) intracellular calcium (Ca) by the sarcoplasmic reticulum. 2+ This can manifest as suppression of phospholipase C activity, which may be observed as a decrease in release. Inhibition of PGF2α receptor signaling may also manifest as a decrease in one or more downstream physiological events related to calcium mobilization, such as decreased uterine muscle contractions and / or decreased endothelial cell necrosis in the corpus luteum, a progesterone-secreting structure that supports the developing fetus. PGF2α receptor antagonists that can be used in conjunction with the compositions and methods described herein include, for example, 1,3-thiazolidine-2-carboxamide, e.g., (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidine-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valinate, or a pharmaceutically acceptable salt thereof (e.g., (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidine-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valinate), or in It contains another 1,3-thiazolidine-2-carboxamide that produces 3-([1,1'-biphenyl]-4-ylsulfonyl)-N-[1-(4-fluorophenyl)-3-hydroxypropyl]-1,3-thiazolidine-2-carboxamide in vivo.
[0113] When used in this specification, "IC 50The term "competitive ligand binding assay" refers to the concentration of a substance (antagonist) that reduces the efficacy of a reference agonist or the constitutive activity of a biological target by 50%, as measured, for example, in a competitive ligand binding assay. Examples of competitive ligand binding assays include, among others known in the art, competitive radioligand binding assays, competitive enzyme-linked immunosorbent assays (ELISAs), and fluorescence-based assays.
[0114] Where used herein in the context of providing or administering two or more therapeutic agents to a subject, the phrase “in combination with” means that two or more therapeutic agents are delivered to a subject (e.g., a mammalian subject such as a pregnant human subject) (i) simultaneously or (ii) at different times, so that while a detectable concentration of the previously administered agent or its metabolite remains in the subject’s plasma and / or one or more tissues (e.g., uterine muscle tissue), the subsequently administered agent is delivered to the subject. For example, one therapeutic agent may be administered to a subject in combination with another agent by administering both agents simultaneously to the subject, such as in a single pharmaceutical composition or in separate compositions administered simultaneously to the subject (e.g., by different routes of administration). In another example, one therapeutic agent may be administered to a subject in combination with another therapeutic agent by first administering one therapeutic agent to the subject, and then administering the other therapeutic agent by the same or different route of administration while a detectable amount of the first agent remains in the subject’s plasma and / or tissues (or tissues). After the initial administration of each agent (e.g., simultaneously or at different times), the subject does not need to receive the remaining agent(s) each time the first agent is administered. For example, if a patient receives a daily dose of the first medication and a weekly dose of the remaining medication(s), the two or more medications are said to be administered "in combination." The timing of administration of the two or more medications does not need to coincide.
[0115] As used herein, the term “menstrual cycle” refers to the recurring cycle of physiological changes in women, such as human females, that are related to fertility. While the length of the cycle may vary from woman to woman, 28 days is generally considered the typical average ovulatory cycle for human women.
[0116] As used herein, the term “pharmaceutical composition” means a mixture containing a therapeutic compound administered to a patient, such as a mammal, such as a human, for the purpose of preventing, treating, or controlling a specific disease or condition affecting a mammal, such as premature birth or dysmenorrhea.
[0117] As used herein, the term “pharmaceutically acceptable” means a compound, substance, composition and / or dosage form that is free from excessive toxicity, irritation, allergic reactions and other problematic disorders, has a reasonable efficacy / risk ratio and is suitable for contact with patient tissues, such as those of mammals (e.g., humans).
[0118] As used herein in the context of administering therapeutic drugs, the term “regularly” means administering the drug two or more times during the treatment period (for example, daily, weekly, monthly, or twice or more per year).
[0119] Where used herein in the context of therapeutic treatment, the terms “to provide” and “to provide” refer to the delivery of a therapeutic agent to a subject in need of treatment, such as a subject experiencing or at risk of experiencing premature birth (e.g., a mammalian subject such as a human). The therapeutic agent may be provided to a subject in need of treatment, for example, by direct administration of the therapeutic agent to the subject, or by administration of a prodrug that is converted to the therapeutic agent in vivo upon administration to the subject. Exemplary prodrugs include, but are not limited to, esters, phosphates, and other chemical functional groups that are susceptible to hydrolysis upon administration to the subject. Prodrugs include those known in the art, such as those described in Vig et al., Adv. Drug Deliv. Rev. 65:1370-1385 (2013) and Huttunen et al., Pharmacol. Rev. 63:750-771 (2011), whose respective disclosures are incorporated herein by reference.
[0120] As used herein, the term “sample” refers to specimens separated from a patient (e.g., blood, blood components (e.g., serum or plasma), urine, saliva, amniotic fluid, cerebrospinal fluid, tissue (e.g., placenta or uterine muscle), pancreatic juice, chorionic villi specimens, and cells).
[0121] As used herein, the terms “specifically bind” and “bind” refer to a binding reaction that determines the presence of a particular protein in a heterogeneous population of proteins and other biological molecules recognized by a specific ligand. Ligands that specifically bind to proteins (e.g., proteins, proteoglycans, or glycosaminoglycans) are, for example, those with a K content of less than 100 nM. D It binds to proteins. For example, ligands that specifically bind to proteins have a maximum K content of 100 nM (e.g., 1 pM to 100 nM). D Ligands that do not show specific binding to a protein or its domain are not suitable for binding to that particular protein or domain. Ligands are not suitable for binding to that protein or its domain. Ligands D This illustrates that various assay formats can be used to determine the affinity of a ligand to a specific protein. For example, solid-phase ELISA assays are commonly used to identify ligands that specifically bind to a target protein. For a description of assay formats and conditions that can be used to determine specific protein binding, see, for example, Harlow & Lane, Antibodies, A Laboratory Manual, Cold Spring Harbor Press, New York (1988) and Harlow & Lane, Using Antibodies, A Laboratory Manual, Cold Spring Harbor Press, New York (1999).
[0122] As used herein, the terms “subject” and “patient” are interchangeable and refer to organisms such as mammals (e.g., humans) receiving treatment for the treatment or prevention of preterm birth as described herein. Patients who are eligible for, or deemed to require, treatment for the treatment or prevention of preterm birth include subjects who have actually experienced preterm birth (e.g., pregnant human subjects) and subjects at risk of experiencing preterm birth. Various clinical indicators can be used to identify patients at “risk” of experiencing preterm birth. Examples of patients at “risk” of experiencing preterm birth (e.g., human patients) include: (i) subjects with a gestation period of approximately 24 to 36 weeks prior to administration of uterine contraction inhibitors such as atosiban and / or PGF2α receptor antagonists as described herein (e.g., a gestation period of approximately 24 to 34 weeks prior to administration of atosiban and PGF2α receptor antagonists, e.g., a gestation period of approximately 28 to 33 weeks and 6 / 7 weeks prior to administration of atosiban and PGF2α receptor antagonists); and (ii) subjects with four or more uterine contractions per 30 minutes prior to administration of the uterine contraction inhibitor(s)(e.g., uterine contractions of four or more). Subjects exhibiting contraction include (iii) subjects exhibiting cervical dilation of approximately 1 cm to approximately 4 cm prior to administration of a uterine contraction inhibitor(s), (iv) subjects exhibiting a positive test result for the presence of fetal fibronectin and / or insulin-like growth factor-binding protein-1 (IGFBP-1) in a sample of cervical secretions obtained from the subject prior to administration of a uterine contraction inhibitor(s), and (v) subjects exhibiting a cervical length of approximately 25 mm or less prior to administration of a uterine contraction inhibitor(s). Pregnant subjects at "risk" of experiencing premature birth may exhibit one or more or all of these characteristics prior to initial administration of atosiban and a PGF2α receptor antagonist according to the compositions and methods described herein.
[0123] As used herein, the term “substantially simultaneously” refers to the administration of two or more therapeutic agents to a subject within a few minutes of each other or exactly at the same time. The term “substantially simultaneously” is intended to encompass cases in which two or more therapeutic agents are administered to a subject without a significant delay between the administrations of each agent, such as cases in which a second or subsequent therapeutic agent is administered to a subject after the administration of a first therapeutic agent in the fastest manner permissible within any practical limitations observed by a healthcare professional. Examples of such practical limitations include the time required for a practitioner to prepare the patient for injection, such as intravenous infusion, following the administration of a first therapeutic agent, which may have been administered orally. To avoid misunderstanding, if a subject is first administered an oral therapeutic agent, and then immediately afterward, an injectable therapeutic agent is prepared and its dose is administered, both therapeutic agents are considered to have been administered “substantially simultaneously.”
[0124] Where used herein in the context of oxytocin receptor antagonists such as atosiban and PGF2α receptor antagonists such as any one of the compounds of formulas (I) to (VIII) herein, the term “therapeutic dose” refers to the amount of each drug that, when administered in combination with each other, can achieve a beneficial therapeutic outcome in a subject who is experiencing or at risk of experiencing preterm birth. For example, the “therapeutic dose” of the oxytocin receptor antagonists and PGF2α receptor antagonists described herein, when administered in combination with each other, is (i) a delay of more than one hour, more than one day, or more than one week after the first administration of each drug to the subject (e.g., a delay of about one hour to about 16 weeks, e.g., particularly one hour, six hours, twelve hours, eighteen hours, twenty-four hours, forty-eight hours, seventy-two hours, one week, two weeks, three weeks, four weeks, five weeks, six weeks). (ii) Delay in the onset of labor by a pregnant human subject (delay of 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 weeks), (ii) Delay in the onset of labor by a subject such that, after administration of each drug to the subject, the subject experiences labor at least approximately 34 weeks of gestation, for example, between approximately 34 and approximately 40 weeks of gestation (for example, at approximately 34, 35, 36, 37, 38, 39, or 40 weeks of gestation). (iii) delay of the onset of rupture of membranes, (iv) delay of the onset of rupture of membranes in the subject (e.g., a delay of about 1 hour to about 16 weeks after the first administration of each drug to the subject, e.g., a delay of 1 hour, 6 hours, 12 hours, 18 hours, 24 hours, 48 hours, 72 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks or 16 weeks), (v) decrease in the expression of one or more pro-inflammatory genes such as cyclooxygenase-2 (Cox2) in the subject after administration of each drug to the subject (e.g., assessed by observing a decrease in Cox2 expression in the myometrium), and (vi) decrease in the frequency, peak amplitude, duration, and / or activity of uterine contractions in the subject after administration of each drug to the subject, which together are the amounts of each drug that can achieve these results.
[0125] When two or more drugs are administered to a subject simultaneously (e.g., in single or separate compositions) or at different times, they are said to be administered "in combination" with each other, so that the subject receives a later-administered drug while a detectable concentration of the previously administered drug or its metabolite remains in the subject's plasma and / or one or more tissues (e.g., uterine muscle tissue). For example, one therapeutic agent may be administered to a subject in combination with another drug by administering both drugs simultaneously to the subject, such as in a single pharmaceutical composition or in separate compositions administered simultaneously to the subject (e.g., by different routes of administration). In another example, one therapeutic agent may be administered to a subject in combination with another therapeutic agent by administering one therapeutic agent first to the subject, and then administering the other therapeutic agent by the same or different routes of administration. After the initial administration of each drug (e.g., simultaneously or at different times), it is not necessary to administer the remaining drugs each time the subject receives a dose of the first drug. For example, if a subject receives a daily dose of the first drug and a weekly dose of the remaining drugs, the drugs are said to be administered "in combination" with each other. The timing of drug administration does not need to coincide.
[0126] As used herein, the term "uterine contraction inhibitor" refers to a substance that can delay the onset of labor in a subject (e.g., a mammalian subject such as a human subject). Uterine contraction inhibitors include, for example, intracellular Ca 2+They may function to suppress uterine contractions by inhibiting the mobilization of uterine cells. Examples of uterine contraction inhibitors are described, for example, in Haas et al. Int. J. Women's Health. 6:343-349 (2014), the disclosure of which is incorporated herein by reference. Uterine contraction inhibitors to be used in conjunction with the compositions and methods described herein include, but are not limited to, oxytocin receptor antagonists such as atosiban, and PGF2α receptor antagonists, such as the PGF2α receptor antagonists described herein (e.g., 1,3-thiazolidine-2-carboxamide compounds described herein, e.g., (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidine-2-yl]carbonyl)-amino)-3-(4-fluorophenyl)propyl L-valineate or a pharmaceutically acceptable salt thereof, e.g., (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidine-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valineate).
[0127] As used herein in the context of preterm birth, the terms “treat” or “treatment” refer to a therapeutic measure aimed at delaying the onset of labor in a pregnant subject (e.g., a pregnant human subject). Successful treatment of a pregnant subject with atosiban and the PGF2α receptor antagonists described herein (e.g., 1,3-thiazolidine-2-carboxamide compounds, e.g., (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidine-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valineate or a pharmaceutically acceptable salt thereof, e.g., (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidine-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valineate) may manifest in various forms. Desired therapeutic outcomes that can be achieved using the compositions and methods described herein include, but are not limited to, delays in the onset of labor by the subject after initial administration of atosiban and the PGF2α receptor antagonist, such as delays of 1 hour or more, 1 day or more, or 1 week or more (e.g., delays of about 1 hour to about 16 weeks, for example, particularly 1 hour, 6 hours, 12 hours, 18 hours, 24 hours, 48 hours, 72 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, or 16 weeks). Another clinical indicator of successful treatment is the observation of delayed onset of labor in subjects who experience labor at least at approximately 34 weeks of gestation after administration of atosiban and / or PGF2α receptor antagonists, for example, between approximately 34 and 40 weeks of gestation (e.g., at approximately 34, 35, 36, 37, 38, 39, or 40 weeks of gestation).Treatment success may also be indicated by a reduction in vaginal bleeding and a delay in the occurrence of rupture of membranes in the subject after administration of atosiban and PGF2α receptor antagonists (e.g., a delay of approximately 1 hour to approximately 16 weeks after the initial administration of atosiban and PGF2α receptor antagonists to the subject, e.g., a delay of 1 hour, 6 hours, 12 hours, 18 hours, 24 hours, 48 hours, 72 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, or 16 weeks). In another example, treatment success may be considered if, after administration of atosiban and PGF2α receptor antagonists to the subject, a reduction in the expression of one or more pro-inflammatory genes, such as cyclooxygenase-2 (Cox2), is observed in the subject (e.g., as assessed by observing a reduction in Cox2 expression in the myometrium). Additional clinical indicators of successful treatment of preterm birth include a reduction in the frequency, peak amplitude, duration, and / or activity of uterine contractions in subjects after administration of atosiban and PGF2α receptor antagonists.
[0128] As used herein, the term “treatment period” refers to the period during which a patient may be administered therapeutic agents such as atosiban and the PGF2α receptor antagonists described herein to treat or prevent premature birth. The treatment period described herein may be several hours, several days, or several weeks. For example, the duration of treatment for administering the 1,3-thiazolidine-2-carboxamide compounds described herein, e.g., (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidine-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valineate or a pharmaceutically acceptable salt thereof (e.g., (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidine-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valineate) may be about 1 hour per week to about 16 weeks, or until the subject experiences childbirth. In some embodiments, for example, atosiban is administered to the subject once or more every 12 to 72 hours, and the PGF2α receptor antagonist is administered to the subject once or twice a day.
[0129] As used herein, the term "C1-C6 alkyl" refers to a monovalent alkyl group having 1 to 6 carbon atoms. This term is exemplified by groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, and n-hexyl.
[0130] As used herein, the term "aryl" refers to an unsaturated aromatic carbocyclic group of 6 to 14 carbon atoms having one ring (e.g., phenyl) or multiple fused rings (e.g., naphthyl). Preferred aryls include phenyl, naphthyl, and phenantrenyl.
[0131] As used herein, the term "C1-C6 alkylaryl" refers to a C1-C6 alkyl group having an aryl substituent, including benzyl and phenethyl.
[0132] As used herein, the term "heteroaryl" refers to monocyclic heterocyclic aromatic groups, or bicyclic or tricyclic fused heterocyclic aromatic groups. Specific examples of heterocyclic aromatic groups include optionally substituted pyridyl, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,3,4-triazinyl, 1,2,3-triazinyl, benzofuryl, [2,3-dihydrodibenzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, isobenzothienyl Examples include ru, indolyl, isoindolyl, 3H-indolyl, benzimidazolyl, imidazo[1,2-a]pyridyl, benzothiazolyl, benzoxazolyl, quinolidinil, quinazolinil, phthalazinil, quinoxalinil, cinnolinil, naphthilidinil, pyrido[3,4-b]pyridyl, pyrido[3,2-b]pyridyl, pyrido[4,3-b]pyridyl, quinolyl, isoquinolyl, tetrazolyl, 5,6,7,8-tetrahydroquinolyl, 5,6,7,8-tetrahydroisoquinolyl, purinyl, pteridinil, carbazolyl, xanthenyl, or benzoquinolyl.
[0133] As used herein, the term "C1-C6 alkyl heteroaryl" means a C1-C6 alkyl group having a heteroaryl substituent, including 2-furylmethyl, 2-thienylmethyl, and 2-(1H-indole-3-yl)ethyl. The term "C2-C6 alkenyl" means an alkenyl group having preferably 2-6 carbon atoms and at least 1 or 2 alkenyl unsaturated moieties. Preferred alkenyl groups include ethenyl (-CH=CH2) and n-2-propenyl (allyl, -CH2CH=CH2).
[0134] As used herein, the term "C2-C6 alkenylaryl" means a C2-C6 alkenyl group having an aryl substituent, including 2-phenylvinyl.
[0135] As used herein, the term "C2-C6 alkenyl heteroaryl" means a C2-C6 alkenyl group having a heteroaryl substituent, including 2-(3-pyridinyl)vinyl.
[0136] As used herein, the term "C2-C6 alkynyl" refers to an alkynyl group having preferably 2-6 carbon atoms and at least 1-2 alkynyl unsaturated moieties. Preferred alkynyl groups include ethynyl (-C≡CH) and propargyl (-CH2C≡CH).
[0137] As used herein, the term "C2-C6 alkynylaryl" means a C2-C6 alkynyl group having an aryl substituent, including phenylethynyl.
[0138] As used herein, the term "C2-C6 alkynyl heteroaryl" means a C2-C6 alkynyl group having a heteroaryl substituent, including 2-thienylethynyl.
[0139] As used herein, the term "C3-C8 cycloalkyl" means a saturated carbocyclic group of 3 to 8 carbon atoms having a monocycle (e.g., cyclohexyl) or multiple fused rings (e.g., norbornyl). Preferred cycloalkyls include cyclopentyl, cyclohexyl, and norbornyl.
[0140] As used herein, the term "heterocycloalkyl" refers to a C3-C8 cycloalkyl group as defined above, where up to three carbon atoms are substituted with heteroatoms selected from the group consisting of O, S, and NR, where R is defined as hydrogen or methyl. Preferred heterocycloalkyls include pyrrolidine, piperidine, piperazine, 1-methylpiperazine, and morpholine.
[0141] As used herein, the term "C1-C6 alkylcycloalkyl" means a C1-C6 alkyl group having a cycloalkyl substituent, including cyclohexylmethyl and cyclopentylpropyl. The term "C1-C6 alkyl heterocycloalkyl" means a C1-C6 alkyl group having a heterocycloalkyl substituent, including 2-(1-pyrrolidinyl)ethyl, 4-morpholinylmethyl, and (1-methyl-4-piperidinyl)methyl.
[0142] As used herein, the term "carboxy" means the -C(O)OH group.
[0143] As used herein, the term "C1-C5 alkylcarboxy" means a C1-C5 alkyl group having a carboxyl substituent, including 2-carboxyethyl.
[0144] As used herein, the term "acyl" refers to a -C(O)R group, where R includes "C1-C6 alkyl," "aryl," "heteroaryl," "C1-C6 alkylaryl," or "C1-C6 alkylheteroaryl."
[0145] As used herein, the term "C1-C5 alkylacyl" means a C1-C5 alkyl group having an acyl substituent, including 2-acetylethyl.
[0146] As used herein, the term "acyloxy" refers to the -OC(O)R group, where R includes "C1-C6 alkyl," "aryl," "heteroaryl," "C1-C6 alkylaryl," or "C1-C6 alkylheteroaryl."
[0147] As used herein, the term "C1-C5 alkylacyloxy" means a C1-C5 alkyl group having an acyloxy substituent, including 2-(acetyloxy)ethyl.
[0148] As used herein, the term "alkoxy" refers to an -OR group, where R includes "C1-C6 alkyl," "aryl," "heteroaryl," "C1-C6 alkylaryl," or "C1-C6 alkylheteroaryl." Preferred alkoxy groups include, for example, methoxy, ethoxy, and phenoxy.
[0149] As used herein, the term "C1-C5 alkylalkoxy" means a C1-C5 alkyl group having an alkoxy substituent, including 2-ethoxyethyl.
[0150] As used herein, the term "alkoxycarbonyl" refers to a -C(O)OR group, where R is H, "C1-C6 alkyl" or "aryl" or "heteroaryl" or "C1-C6 alkylaryl" or "C1-C6 alkylheteroaryl".
[0151] As used herein, the term "C1-C5 alkylalkoxycarbonyl" means a C1-C5 alkyl group having an alkoxycarbonyl substituent, including 2-(benzyloxycarbonyl)ethyl.
[0152] As used herein, the term "aminocarbonyl" refers to the -C(O)NRR' group, where each R, R' independently comprises hydrogen, or a C1-C6 alkyl, or aryl, or heteroaryl, or a C1-C6 alkylaryl, or a C1-C6 alkylheteroaryl.
[0153] As used herein, the term "C1-C5 alkylaminocarbonyl" means a C1-C5 alkyl group having an aminocarbonyl substituent, including 2-(dimethylaminocarbonyl)ethyl.
[0154] As used herein, the term "acylamino" refers to the -NRC(O)R' group, where each R, R' is independently hydrogen, or "C1-C6 alkyl" or "aryl" or "heteroaryl" or "C1-C6 alkylaryl" or "C1-C6 alkylheteroaryl".
[0155] As used herein, the term "C1-C5 alkyl acylamino" means a C1-C5 alkyl group having an acylamino substituent, including 2-(propionylamino)ethyl.
[0156] As used herein, the term "ureid" refers to the -NRC(O)NR'R" group, where each R, R', and R'' is independently hydrogen or "C1-C6 alkyl" or "aryl" or "heteroaryl" or "C1-C6 alkylaryl" or "C1-C6 alkylheteroaryl", "cycloalkyl" or "heterocycloalkyl", where R' and R'' together with the nitrogen atom to which they are bonded can optionally form a 3- to 8-membered heterocycloalkyl ring.
[0157] As used herein, the term "C1-C5 alkylureide" means a C1-C5 alkyl group having a ureide substituent, including 2-(N'-methylureide)ethyl.
[0158] As used herein, the term "amino" refers to the -NRR' group, where each R and R' is independently a hydrogen atom or a "C1-C6 alkyl" or "aryl" or "heteroaryl" or "C1-C6 alkylaryl" or "C1-C6 alkylheteroaryl" or "cycloalkyl" or "heterocycloalkyl," and R and R' together with the nitrogen atom to which they are bonded can optionally form a 3- to 8-membered heterocycloalkyl ring.
[0159] As used herein, the term "C1-C5 alkylamino" means a C1-C5 alkyl group having an amino substituent, including 2-(1-pyrrolidinyl)ethyl.
[0160] As used herein, the term "ammonium" refers to positively charged -N + RR'R" refers to a group where each R, R', and R'' is independently a "C1-C6 alkyl," "C1-C6 alkylaryl," "C1-C6 alkylheteroaryl," "cycloalkyl," or "heterocycloalkyl," and R and R', together with the nitrogen atom to which they are bonded, can optionally form a 3- to 8-membered heterocycloalkyl ring.
[0161] As used herein, the term "halogen" means fluoro, chloro, bromo, and iodine atoms.
[0162] As used herein, the term "sulfonyloxy" means a -OSO2-R group, where R is selected from H, "C1-C6 alkyl", halogen-substituted "C1-C6 alkyl" (e.g., -OSO2-CF3 group), "aryl", "heteroaryl", "C1-C6 alkylaryl", or "C1-C6 alkylheteroaryl".
[0163] As used herein, the term "C1-C5 alkylsulfonyloxy" means a C1-C5 alkyl group having a sulfonyloxy substituent, including 2-(methylsulfonyloxy)ethyl.
[0164] As used herein, the term "sulfonyl" refers to a "-SO2-R" group, where R is selected from H, "aryl", "heteroaryl", "C1-C6 alkyl", halogen-substituted "C1-C6 alkyl" (e.g., -SO2-CF3 group), "C1-C6 alkylaryl", or "C1-C6 alkylheteroaryl".
[0165] As used herein, the term "C1-C5 alkylsulfonyl" means a C1-C5 alkyl group having a sulfonyl substituent, including 2-(methylsulfonyl)ethyl.
[0166] As used herein, the term "sulfinyl" refers to a "-S(O)-R" group, where R is selected from H, "C1-C6 alkyl", halogen-substituted "C1-C6 alkyl" (e.g., -SO-CF3 group), "aryl", "heteroaryl", "C1-C6 alkylaryl", or "C1-C6 alkylheteroaryl".
[0167] As used herein, the term "C1-C5 alkylsulfinyl" means a C1-C5 alkyl group having a sulfinyl substituent, including 2-(methylsulfinyl)ethyl.
[0168] As used herein, the term "sulfanyl" refers to an -SR group, where R includes "C1-C6 alkyl," "aryl," "heteroaryl," "C1-C6 alkylaryl," or "C1-C6 alkylheteroaryl." Preferred sulfanyl groups include methylsulfanyl and ethylsulfanyl.
[0169] As used herein, the term "C1-C5 alkylsulfanyl" means a C1-C5 alkyl group having a sulfanyl substituent, including 2-(methylsulfanyl)ethyl. The term "sulfonylamino" refers to the -NRSO2-R' group, where each R and R' is independently hydrogen, or "C1-C6 alkyl," "aryl," "heteroaryl," "C1-C6 alkylaryl," or "C1-C6 alkylheteroaryl."
[0170] As used herein, the term "C1-C5 alkylsulfonylamino" means a C1-C5 alkyl group having a sulfonylamino substituent, including 2-(ethylsulfonylamino)ethyl.
[0171] Unless otherwise restricted by the definition of individual substituents, the groups described above, such as "alkyl," "alkenyl," "alkynyl," "aryl," and "heteroaryl," can be optionally substituted with 1 to 5 substituents selected from the group consisting of "C1-C6 alkyl," "C2-C6 alkenyl," "C2-C6 alkynyl," "cycloalkyl," "heterocycloalkyl," "C1-C6 alkylaryl," "C1-C6 alkylheteroaryl," "C1-C6 alkylcycloalkyl," "C1-C6 alkylheterocycloalkyl," "amino," "ammonium," "acyl," "acyloxy," "acylamino," "aminocarbonyl," "alkoxycarbonyl," "ureido," "aryl," "heteroaryl," "sulfinyl," "sulfonyl," "alkoxy," "sulfanyl," "halogen," "carboxy," trihalomethyl, cyano, hydroxy, mercapto, nitro, etc. Alternatively, the substitution may also include situations in which adjacent substituents cyclize, particularly when adjacent functional substituents are involved, thereby forming, for example, lactams, lactones, or cyclic anhydrides, and further, for example, acetals, thioacetals, or aminals formed by cyclization to obtain a protecting group.
[0172] As used herein, the term “pharmaceutically acceptable salt or complex” refers to a salt or complex of a compound identified below of formulas (I) and (II) that retains the desired biological activity. Examples of such salts include, but are not limited to, acid addition salts formed by inorganic acids (e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, etc.), as well as salts formed by organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, fumaric acid, maleic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, naphthalenedisulfonic acid, and polygalacturonic acid. The compounds may also be administered as pharmaceutically acceptable quaternary salts known to those skilled in the art, in particular, of formula -NR,R',R" + Z -The compound comprises a quaternary ammonium salt, where R, R', and R'' are independently hydrogen, alkyl or benzyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkylaryl, C1-C6 alkylheteroaryl, cycloalkyl, and heterocycloalkyl, and Z is a counterion containing chloride, bromide, iodide, -O-alkyl, toluenesulfonate, methylsulfonate, sulfonate, phosphate, and carboxylate (e.g., benzoate, succinate, acetate, glycolate, maleate, fumarate, citrate, tartarate, ascorbate, cinnamoate, mandeloate, and diphenylacetate).
[0173] As used herein, the term “derivative” refers to a variant of a reference compound that differs from the reference compound by the inclusion and / or arrangement of one or more substituents, as well as structural variants of the reference compound, such as variants that are isomers of the reference compound, such as structural isomers (e.g., positional isomers) or stereoisomers (e.g., enantiomers or diastereomers).
[0174] Structural compositions described herein also include tautomers, their geometric isomers, enantiomers, diastereomers, and racemates, as well as pharmaceutically acceptable salts thereof. Such salts include, for example, acid addition salts formed with pharmaceutically acceptable acids such as hydrochlorides, hydrobroms, sulfates or bisulfates, phosphates or hydrogen phosphates, acetates, benzoates, succinates, fumarates, maleates, lactates, citrates, tartrates, glucons, methanesulfons, benzenesulfonic acid, and p-toluenesulfonates. [Brief explanation of the drawing]
[0175] [Figure 1] This graph shows the mean (plus / minus standard deviation) plasma concentrations of compound (2) when administered to pregnant human subjects receiving atosiban infusion therapy, as described in Part A of Example 1 below. [Figure 2]As described in Part A of Example 1 below, this is a graph showing the individual ductus arteriosus pulsation index of patients who were administered compound (2) in combination with atosiban. [Figure 3] As described in Part A of Example 1 below, this graph shows the mean (plus / minus standard deviation) amniotic fluid index of patients who were administered compound (2) in combination with atosiban. [Figure 4] This graph shows the proportion of subjects who experienced delivery within 48 hours of starting treatment with atosiban and compound (2) (in Part B of the experiment described in Example 1 below), compared to the proportion of subjects who experienced delivery within 48 hours of starting treatment with atosiban and placebo. The categories along the horizontal axis, from left to right, represent: (i) the total proportion of subjects in each treatment cohort who experienced delivery within 48 hours of starting treatment; (ii) the proportion of subjects in each cohort with a gestation period ("GA") of 24 to 30 weeks who experienced delivery within 48 hours of starting treatment; (iii) the proportion of subjects in each cohort with a gestation period of 30 to 34 weeks who experienced delivery within 48 hours of starting treatment; (iv) the proportion of subjects in each cohort of monoconceptions who experienced delivery within 48 hours of starting treatment; and (v) the proportion of subjects in each cohort of twin pregnancies who experienced delivery within 48 hours of starting treatment. Below the horizontal axis, odds ratios ("OR") are shown that quantify the association between including compound (2) in the treatment regimen and the delay in the onset of labor in each cohort. A 90% confidence interval ("CI") is provided for each odds ratio. [Figure 5]This graph shows the proportion of mononuclear pregnancies that occurred within 48 hours of the start of treatment with atosiban and compound (2) (in Part B of the experiment described in Example 1 below), compared to the proportion of mononuclear pregnancies that occurred within 48 hours of the start of treatment with atosiban and placebo. The categories along the horizontal axis, from left to right, represent: (i) the total proportion of subjects in each treatment cohort who experienced delivery within 48 hours of the start of treatment with mononuclear pregnancies; (ii) the proportion of subjects in each cohort who had a gestation period ("GA") between 24 and 30 weeks and experienced delivery within 48 hours of the start of treatment with mononuclear pregnancies; and (iii) the proportion of subjects in each cohort who had a gestation period between 30 and 34 weeks and experienced delivery within 48 hours of the start of treatment with mononuclear pregnancies. Below the horizontal axis, the odds ratio ("OR") is shown, which quantifies the association between including compound (2) in the treatment regimen and the delay in the onset of delivery in subjects in each cohort. A 90% confidence interval ("CI") is provided for each odds ratio. [Figure 6] This graph shows the proportion of mononuclear pregnancies that occurred within 7 days of the start of treatment with atosiban and compound (2) (in Part B of the experiment described in Example 1 below), compared to the proportion of mononuclear pregnancies that occurred within 7 days of the start of treatment with atosiban and placebo. The categories along the horizontal axis, from left to right, represent: (i) the total proportion of subjects in each treatment cohort who experienced delivery within 7 days of the start of treatment for mononuclear pregnancies; (ii) the proportion of subjects in each cohort who experienced delivery within 7 days of the start of treatment for mononuclear pregnancies with a gestational age ("GA") of 24 to 30 weeks; and (iii) the proportion of subjects in each cohort who experienced delivery within 7 days of the start of treatment for mononuclear pregnancies with a gestational age of 30 to 34 weeks. Below the horizontal axis, odds ratios ("OR") are shown, quantifying the association between including compound (2) in the treatment regimen and the delay in the onset of delivery in subjects in each cohort. A 90% confidence interval ("CI") is provided for each odds ratio. [Figure 7]This graph shows the reduction in uterine contractions experienced by subjects treated with atosiban and compound (2) compared to subjects treated with atosiban and placebo (Part B of the experiment described in Example 1 below). The values along the vertical axis represent the change from baseline in the amount of uterine contractions per 30-minute interval experienced by subjects in either cohort. The values along the horizontal axis represent the elapsed time (hours) since the start of treatment with either (i) atosiban and placebo or (ii) atosiban and compound (2). [Figure 8] This graph shows the effect of atosiban and compound (2) on delaying labor in pregnant human subjects, compared to the effect of atosiban and placebo. The data was obtained from Part B of the clinical trial described in Example 1 below. The values along the vertical axis represent the percentage of trial participants who experienced labor. The values along the horizontal axis represent the elapsed time (days) between the start of treatment with (i) atosiban and placebo (solid curve) or atosiban and compound (2) (dashed curve) and (ii) labor. [Modes for carrying out the invention]
[0176] This specification provides compositions and methods for the treatment and / or prevention of preterm labor in patients, such as mammalian patients (e.g., human female patients). Using the compositions and methods described herein, prostaglandin F2α (PGF2α) receptor antagonists can be administered to patients who have experienced or are at risk of experiencing preterm labor to delay the onset of labor, for example, by several hours, several days, or several weeks. PGF2α receptor antagonists can be administered to patients in combination with oxytocin receptor antagonists, such as atosiban. PGF2α receptor antagonists include, for example, the 1,3-thiazolidine-2-carboxamide compounds described herein, e.g., (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidine-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valineate or a pharmaceutically acceptable salt thereof, e.g., (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidine-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valineate, or in It may be another 1,3-thiazolidine-2-carboxamide that produces 3-([1,1'-biphenyl]-4-ylsulfonyl)-N-[1-(4-fluorophenyl)-3-hydroxypropyl]-1,3-thiazolidine-2-carboxamide in vivo.
[0177] The compositions and methods of this disclosure offer a variety of beneficial therapeutic outcomes. Using the compositions and methods of this disclosure, patients such as pregnant human female patients who are experiencing or at risk of experiencing premature birth can be treated to prolong gestation and grant the fetus additional time for the maturation of vital organs and tissue systems. In the early stages of pregnancy, such as approximately 24 to 34 weeks, the fetus is characterized by underdeveloped vital organ networks. The compositions and methods of this disclosure offer an opportunity to prolong gestation for a sufficient period, among other important developments, for the fetus to mature lung and nerve cells. This maturation, in turn, can significantly increase the chances of neonatal survival.
[0178] To obtain these beneficial pharmacological effects, patients may be administered therapeutically effective doses of a PGF2α receptor antagonist and atosiban, for example, simultaneously or at different times. Patients may receive multiple consecutive doses of the PGF2α receptor antagonist and / or atosiban. The same or different dosing schedules may be used for the administration of the PGF2α receptor antagonist and atosiban. For example, each time a patient receives one dose of these drugs, the patient may or may not receive a second dose of the drug. Patients may be administered the PGF2α receptor antagonist, for example, once or twice daily, and atosiban may be administered to the subject, for example, once or twice every 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 36 or 48 hours, or more. The combination therapy of atosiban and a PGF2α receptor antagonist may be administered once or more times a day, week, or month, as described herein, and may be continued, for example, until the patient experiences childbirth or reaches the full term of pregnancy.
[0179] The following sections describe atosiban formulations and PGF2α receptor antagonists that can be used in combination with the compositions and methods described herein, as well as dosages and schedules that can be used for administering these uterine contraction inhibitors.
[0180] PGF2α receptor antagonist PGF2α receptor antagonists that can be used in combination with the compositions and methods described herein include, for example, 1,3-thiazolidinedione-2-carboxamide compounds such as the PGF2α receptor antagonists described in US8,415,480, US9,447,055 and US9,834,528, the respective disclosures of which are incorporated herein in whole by reference. Exemplary PGF2α receptor antagonists include, for example, compounds represented by formula (I), [ka] (wherein the formula, the Ar ring is an optionally condensed and optionally substituted aryl group, or an optionally condensed and optionally substituted heteroaryl group; The Cy ring is optionally condensed and optionally substituted aryl group, optionally condensed and optionally substituted heteroaryl group, optionally condensed and optionally substituted cycloalkyl group, or optionally condensed and optionally substituted heterocycloalkyl group; R 1 H, carboxy, acyl, alkoxycarbonyl, C1~C5-alkylcarboxy, C1~C5-alkylacyl, C1~C5-alkylalkoxycarbonyl, C1~C5-alkylacyloxy, C1~C5-alkylsulfanyl, C1~C5-alkylsulfinyl, C1~C5-alkylsulfonyl, C1~C5-alkylsulfonyloxy, C1~C6-alkyl, C2~C6-alkenyl, C2~C6-alkynyl, aryl, heteroaryl, C3~C8-cycloalkyl, C1~C6-alkylaryl, C1~C6-alkylheteroaryl, C1~C6-alkylcycloalkyl, C2~C6-alkenylaryl, C2~C6-alkenylheteroaryl, C2~C6-alkynylaryl, C2~C6-alkynylheteroaryl, substituted carboxy, substituted acyl, substituted alkoxycarbonyl These are substituted C1-C5-alkylcarboxy, substituted C1-C5-alkylacyl, substituted C1-C5-alkylalkoxycarbonyl, substituted C1-C5-alkylacyloxy, substituted C1-C5-alkylsulfanyl, substituted C1-C5-alkylsulfinyl, substituted C1-C5-alkylsulfonyl, substituted C1-C5-alkylsulfonyloxy, substituted C1-C6-alkyl, substituted C2-C6-alkenyl, substituted C2-C6-alkynyl, substituted aryl, substituted heteroaryl, substituted C3-C8-cycloalkyl, substituted C1-C6-alkylaryl, substituted C1-C6-alkylheteroaryl, substituted C1-C6-alkylcycloalkyl, substituted C2-C6-alkenylaryl, substituted C2-C6-alkenylheteroaryl, substituted C2-C6-alkynylaryl, or substituted C2-C6-alkynylheteroaryl; Each R2 These are independently C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, substituted C1-C6-alkyl, substituted C2-C6-alkenyl, or substituted C2-C6-alkynyl; n is an integer between 0 and 2. or a pharmaceutically acceptable salt thereof.
[0181] In some embodiments, the Ar ring is selected from substituents (Ia) to (Iy), [ka] In the formula, each R 3 These are, independently, halogens, haloalkyls, cyanos, optionally substituted aminos, hydroxyls, thiols, optionally substituted alkoxys, optionally substituted acyloxys, optionally substituted alkoxycarbonyls, carboxys, ureidos, alkylsulfonyls, arylsulfonyls, heteroarylsulfonyls, cycloalkylsulfonyls, heterocycloalkylsulfonyls, alkylsulfanyls, arylsulfanyls, heteroarylsulfanyls, cycloalkylsulfanyls, heterocycloalkylsulfanyls, alkylsulfinyls, arylsulfinyls, heteroarylsulfinyls, cycloalkylsulfinyls, heterocycloalkylsulfinyls, optionally substituted alkyls, optionally substituted alkenyls, optionally substituted alkynyls, optionally substituted and optionally condensed aryls, optionally substituted and optionally condensed heteroaryls, optionally substituted and optionally condensed cycloalkyls, or optionally substituted and optionally condensed heterocycloalkyls. Each m is an independent integer between 0 and 5. Each p is an independent integer between 0 and 3. Each q is an independent integer between 0 and 2. Each r is an independent integer between 0 and 1. Each s is an independent integer between 0 and 7.
[0182] Several embodiments, each R 3 This is selected independently of substituents (IIa) to (IIy). [ka]
[0183] In some embodiments, the Ar ring is a substituent represented by formula (Ia), [ka] Each R 3 These are, independently, optionally substituted and optionally condensed aryls, optionally substituted and optionally condensed heteroaryls, optionally substituted and optionally condensed cycloalkyls, or optionally substituted and optionally condensed heterocycloalkyls.
[0184] In some embodiments, the Cy ring is selected from substituents (IIIa) to (IIIaa), [ka] [ka] Each R 4These are, independently, halogens, haloalkyls, cyanos, optionally substituted aminos, hydroxyls, thiols, optionally substituted alkoxys, optionally substituted acyloxys, optionally substituted alkoxycarbonyls, carboxys, ureidos, alkylsulfonyls, arylsulfonyls, heteroarylsulfonyls, cycloalkylsulfonyls, heterocycloalkylsulfonyls, alkylsulfanyls, arylsulfanyls, heteroarylsulfanyls, cycloalkylsulfanyls, heterocycloalkylsulfanyls, alkylsulfinyls, arylsulfinyls, heteroarylsulfinyls, cycloalkylsulfinyls, heterocycloalkylsulfinyls, optionally substituted alkyls, optionally substituted alkenyls, optionally substituted alkynyls, optionally substituted and optionally condensed aryls, optionally substituted and optionally condensed heteroaryls, optionally substituted and optionally condensed cycloalkyls, or optionally substituted and optionally condensed heterocycloalkyls. Each G is independently -CH2-, -CR 4 H-, -NH-, -NR 4 -, -O- or -S-, Each t is an independent integer between 0 and 5. Each u is an independent integer between 0 and 3. Each v is an independent integer between 0 and 2. Each w is an independent integer between 0 and 1. Each x is an independent integer between 0 and 7. Each y is an independent integer between 0 and 4.
[0185] In some embodiments, the Cy ring is an optionally substituted aryl group represented by formula (IVa). [ka]
[0186] In some embodiments, the Cy ring is a substituted aryl group represented by formula (IVb). [Chemical formula]
[0187] In some embodiments, R 1 is C1-C5-alkylcarboxy, C1-C5-alkylacyl, C1-C5-alkylalkoxycarbonyl, C1-C5-alkylacyloxy, substituted C1-C5-alkylcarboxy, substituted C1-C5-alkylacyl, substituted C1-C5-alkylalkoxycarbonyl, or substituted C1-C5-alkylacyloxy. In some embodiments, R 1 is optionally substituted C1-C5-alkylacyloxy.
[0188] In some embodiments, the compound is represented by formula (V), [Chemical formula] (wherein R 1 is C1-C5-alkylcarboxy, C1-C5-alkylacyl, C1-C5-alkylalkoxycarbonyl, C1-C5-alkylacyloxy, substituted C1-C5-alkylcarboxy, substituted C1-C5-alkylacyl, substituted C1-C5-alkylalkoxycarbonyl, or substituted C1-C5-alkylacyloxy, each R 3These are, independently, halogens, haloalkyls, cyanos, optionally substituted aminos, hydroxyls, thiols, optionally substituted alkoxys, optionally substituted acyloxys, optionally substituted alkoxycarbonyls, carboxys, ureidos, alkylsulfonyls, arylsulfonyls, heteroarylsulfonyls, cycloalkylsulfonyls, heterocycloalkylsulfonyls, alkylsulfanyls, arylsulfanyls, heteroarylsulfanyls, cycloalkylsulfanyls, heterocycloalkylsulfanyls, alkylsulfinyls, arylsulfinyls, heteroarylsulfinyls, cycloalkylsulfinyls, heterocycloalkylsulfinyls, optionally substituted alkyls, optionally substituted alkenyls, optionally substituted alkynyls, optionally substituted and optionally condensed aryls, optionally substituted and optionally condensed heteroaryls, optionally substituted and optionally condensed cycloalkyls, or optionally substituted and optionally condensed heterocycloalkyls. Each R 4 These are, independently, halogens, haloalkyls, cyanos, optionally substituted aminos, hydroxyls, thiols, optionally substituted alkoxys, optionally substituted acyloxys, optionally substituted alkoxycarbonyls, carboxys, ureidos, alkylsulfonyls, arylsulfonyls, heteroarylsulfonyls, cycloalkylsulfonyls, heterocycloalkylsulfonyls, alkylsulfanyls, arylsulfanyls, heteroarylsulfanyls, cycloalkylsulfanyls, heterocycloalkylsulfanyls, alkylsulfinyls, arylsulfinyls, heteroarylsulfinyls, cycloalkylsulfinyls, heterocycloalkylsulfinyls, optionally substituted alkyls, optionally substituted alkenyls, optionally substituted alkynyls, optionally substituted and optionally condensed aryls, optionally substituted and optionally condensed heteroaryls, optionally substituted and optionally condensed cycloalkyls, or optionally substituted and optionally condensed heterocycloalkyls. m is an integer between 0 and 5. t is an integer between 0 and 5. or a pharmaceutically acceptable salt thereof.
[0189] In some embodiments, the compound is represented by formula (Va), [ka] or a pharmaceutically acceptable salt thereof.
[0190] In some embodiments, the compound is represented by formula (VI), [ka] (In the formula, R 6 is a hydroxyl, an optionally substituted acyl, an optionally substituted alkoxycarbonyl, or an optionally substituted acyloxy. Each R 5 These are, independently, halogens, haloalkyls, cyanos, optionally substituted aminos, hydroxyls, thiols, optionally substituted alkoxys, optionally substituted acyloxys, optionally substituted alkoxycarbonyls, carboxys, ureidos, alkylsulfonyls, arylsulfonyls, heteroarylsulfonyls, cycloalkylsulfonyls, heterocycloalkylsulfonyls, alkylsulfanyls, arylsulfanyls, heteroarylsulfanyls, cycloalkylsulfanyls, heterocycloalkylsulfanyls, alkylsulfinyls, arylsulfinyls, heteroarylsulfinyls, cycloalkylsulfinyls, heterocycloalkylsulfinyls, optionally substituted alkyls, optionally substituted alkenyls, optionally substituted alkynyls, optionally substituted and optionally condensed aryls, optionally substituted and optionally condensed heteroaryls, optionally substituted and optionally condensed cycloalkyls, or optionally substituted and optionally condensed heterocycloalkyls. Each R 4These are halogens, haloalkyls, cyanos, optionally substituted aminos, hydroxyls, thiols, optionally substituted alkoxys, optionally substituted acyloxys, optionally substituted alkoxycarbonyls, carboxys, ureidos, alkylsulfonyls, arylsulfonyls, heteroarylsulfonyls, cycloalkylsulfonyls, heterocycloalkylsulfonyls, alkylsulfanyls, arylsulfanyls, heteroarylsulfanyls, cycloalkylsulfanyls, heterocycloalkylsulfanyls, alkylsulfinyls, arylsulfinyls, heteroarylsulfinyls, cycloalkylsulfinyls, heterocycloalkylsulfinyls, optionally substituted alkyls, optionally substituted alkenyls, optionally substituted alkynyls, optionally substituted and optionally condensed aryls, optionally substituted and optionally condensed heteroaryls, optionally substituted and optionally condensed cycloalkyls, or optionally substituted and optionally condensed heterocycloalkyls. i is an integer between 0 and 3. x is an integer between 0 and 5. or a pharmaceutically acceptable salt thereof.
[0191] In some embodiments, the compound is represented by formula (VII), [ka] (In the formula, R 7 is an aminoacyl substituted with H or optionally, Each R 5These are, independently, halogens, haloalkyls, cyanos, optionally substituted aminos, hydroxyls, thiols, optionally substituted alkoxys, optionally substituted acyloxys, optionally substituted alkoxycarbonyls, carboxys, ureidos, alkylsulfonyls, arylsulfonyls, heteroarylsulfonyls, cycloalkylsulfonyls, heterocycloalkylsulfonyls, alkylsulfanyls, arylsulfanyls, heteroarylsulfanyls, cycloalkylsulfanyls, heterocycloalkylsulfanyls, alkylsulfinyls, arylsulfinyls, heteroarylsulfinyls, cycloalkylsulfinyls, heterocycloalkylsulfinyls, optionally substituted alkyls, optionally substituted alkenyls, optionally substituted alkynyls, optionally substituted and optionally condensed aryls, optionally substituted and optionally condensed heteroaryls, optionally substituted and optionally condensed cycloalkyls, or optionally substituted and optionally condensed heterocycloalkyls. Each R 4 These are halogens, haloalkyls, cyanos, optionally substituted aminos, hydroxyls, thiols, optionally substituted alkoxys, optionally substituted acyloxys, optionally substituted alkoxycarbonyls, carboxys, ureidos, alkylsulfonyls, arylsulfonyls, heteroarylsulfonyls, cycloalkylsulfonyls, heterocycloalkylsulfonyls, alkylsulfanyls, arylsulfanyls, heteroarylsulfanyls, cycloalkylsulfanyls, heterocycloalkylsulfanyls, alkylsulfinyls, arylsulfinyls, heteroarylsulfinyls, cycloalkylsulfinyls, heterocycloalkylsulfinyls, optionally substituted alkyls, optionally substituted alkenyls, optionally substituted alkynyls, optionally substituted and optionally condensed aryls, optionally substituted and optionally condensed heteroaryls, optionally substituted and optionally condensed cycloalkyls, or optionally substituted and optionally condensed heterocycloalkyls. i is an integer between 0 and 3. x is an integer between 0 and 5. or a pharmaceutically acceptable salt thereof.
[0192] In some embodiments, the compound is represented by formula (VII), [ka] (In the formula, R 8 is an optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted and optionally condensed aryl, optionally substituted and optionally condensed heteroaryl, optionally substituted and optionally condensed cycloalkyl, or optionally substituted and optionally condensed heterocycloalkyl, preferably R 8 This is an amino-substituted alkyl, for example, a 1-aminoC1~C6 alkyl (for example, (S)-1-aminoC1~C6 alkyl or (R)-1-aminoC1~C6 alkyl, for example, (S)-1-amino-2-methylpropyl, (S)-1-amino-2-methylbutyl, (S)-1-amino-3-methylbutyl, (R)-1-amino-2-methylpropyl, (R)-1-amino-2-methylbutyl, or (R)-1-amino-3-methylbutyl). Each R 5These are, independently, halogens, haloalkyls, cyanos, optionally substituted aminos, hydroxyls, thiols, optionally substituted alkoxys, optionally substituted acyloxys, optionally substituted alkoxycarbonyls, carboxys, ureidos, alkylsulfonyls, arylsulfonyls, heteroarylsulfonyls, cycloalkylsulfonyls, heterocycloalkylsulfonyls, alkylsulfanyls, arylsulfanyls, heteroarylsulfanyls, cycloalkylsulfanyls, heterocycloalkylsulfanyls, alkylsulfinyls, arylsulfinyls, heteroarylsulfinyls, cycloalkylsulfinyls, heterocycloalkylsulfinyls, optionally substituted alkyls, optionally substituted alkenyls, optionally substituted alkynyls, optionally substituted and optionally condensed aryls, optionally substituted and optionally condensed heteroaryls, optionally substituted and optionally condensed cycloalkyls, or optionally substituted and optionally condensed heterocycloalkyls. Each R 4 These are halogens, haloalkyls, cyanos, optionally substituted aminos, hydroxyls, thiols, optionally substituted alkoxys, optionally substituted acyloxys, optionally substituted alkoxycarbonyls, carboxys, ureidos, alkylsulfonyls, arylsulfonyls, heteroarylsulfonyls, cycloalkylsulfonyls, heterocycloalkylsulfonyls, alkylsulfanyls, arylsulfanyls, heteroarylsulfanyls, cycloalkylsulfanyls, heterocycloalkylsulfanyls, alkylsulfinyls, arylsulfinyls, heteroarylsulfinyls, cycloalkylsulfinyls, heterocycloalkylsulfinyls, optionally substituted alkyls, optionally substituted alkenyls, optionally substituted alkynyls, optionally substituted and optionally condensed aryls, optionally substituted and optionally condensed heteroaryls, optionally substituted and optionally condensed cycloalkyls, or optionally substituted and optionally condensed heterocycloalkyls. i is an integer from 0 to 3, t is an integer from 0 to 5, x is an integer from 0 to 5), or a pharmaceutically acceptable salt thereof.
[0193] (3S)-3-({[(2S)-3-(Biphenyl-4-ylsulfonyl)-1,3-thiazolidin-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valinate (Compound 2) Specific PGF2α receptor antagonists that can be administered to a patient (e.g., a pregnant human patient) to treat or prevent preterm birth include (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidin-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valinate represented by the following formula (2) and its pharmaceutically acceptable salts. This compound is converted in vivo to 3-([1,1'-biphenyl]-4-ylsulfonyl)-N-[1-(4-fluorophenyl)-3-hydroxypropyl]-1,3-thiazolidine-2-carboxamide (represented by the following formula (1)). Compound 1 described in US8,415,480 is an antagonist of the prostaglandin F receptor, and this compound exhibits an inhibition constant (Ki) of 6 nM for the human PGF2α receptor as determined by a competitive radioligand binding assay (experimental details of the competitive radioligand binding assay useful for determining Ki values are described, for example, in US8,415,480, Example 51). After administration to a subject, Compound 2 is deesterified in vivo by the activity of endogenous esterases such as those present in the gastrointestinal tract to form Compound 1.
Chemical formula
[0194] Compound 2 was found to be an inhibitor of the prostaglandin F2α receptor because it inhibits the receptor at a Ki of 1 nM. Compound 2 exhibits several improvements in physicochemical properties compared to Compound 1, including solubility in water, as well as being a medium that simulates small intestinal contents under feeding (FeSSIF) and fasting (FaSSIF) conditions. These data are described, for example, in US9,447,055 and US9,843,528.
[0195] In addition to exhibiting improved water solubility, compound 2 and its salts feature a particularly beneficial absorption mechanism. Compound 2 is deesterified by surrounding esterases in the small intestine and subsequently passively penetrates the small intestinal epithelium. Compound 2 and its salts are not substrates of the Pept1 transporter protein, a proton-coupled cotransporter that mediates the absorption of peptide nutrients. Pept1 is known to mediate the absorption of various ballinate esters, as described, for example, in Vig et al., Adv. Drug Deliv. Rev. 65:1370-1385 (2013). Pept1 exhibits broad substrate specificity, as evidenced by the structural diversity of compounds transported across the intestinal epithelium by this protein. Despite the presence of ballinate ester functional groups, compound 2 and its salts are independent of this transporter for absorption across the small intestinal epithelium. This is an advantageous property because compound 2 and its salts (e.g., its chloride salt represented by formula (3)) do not compete with the natural substrates of Pept1, such as peptide nutrients, for binding to and transport by this protein. Rather, compound 2 and its salts are readily converted in vivo into a form that can be absorbed independently of energy and local proton gradients. This beneficial property, coupled with the high water solubility of compound 1 and its salts, promotes a pharmacokinetic profile in which compound 2 and its salts readily dissolve in aqueous environments and are converted into a form that can be absorbed independently of transport.
[0196] (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidined-2-yl]carbonyl}amino)-3-(4-fluorophenyl)propyl L-vaphosphate (compound 3) The chloride salt of compound 2, (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidined-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-vaphosphate (referred to herein as compound 3), exhibits additional advantageous characteristics. For example, this compound is readily crystallized using several different experimental procedures. When compound 3 is crystallized from various media and under various ambient conditions, it yields a reproducible single crystalline form. Furthermore, this crystalline form of compound 3 exhibits long-term stability under ambient conditions and in the presence of high relative humidity. Compound 3 exhibits low hygroscopicity and therefore does not tend to absorb moisture from the local atmosphere. Thus, compound 3 exhibits resistance to chemical changes such as hydrolysis caused by the presence of water, and resistance to the incorporation of impurities. For example, impurities related to atmospheric moisture are not readily integrated into the crystalline form of compound 3. [ka]
[0197] Further PGF2α receptor antagonists PGF2α receptor antagonists that can be used in combination with the compositions and methods described herein include additional 1,3-thiazolidine-2-carboxamides, such as additional 1,3-thiazolidine-2-carboxamides that produce compound (1) in vivo (e.g., by deesterification of the compound of formula (VIII) by the activity of endogenous esterases in vivo). Examples of additional PGF2α receptor antagonists that can be used in combination with the compositions and methods described herein include the compounds shown in Table 1 below. The synthesis of these compounds is described in US8,415,480, the disclosure thereof is incorporated herein by reference in its entirety. [Table 1-1] Table 1-2 Table 1-3 Table 1-4 Table 1-5 Table 1-6 Table 1-7 Table 1-8 Table 1-9 Table 1-10 Table 1-11 Table 1-12 Table 1-13 Table 1-14 Table 1-15 Table 1-16 Table 1-17 Table 1-18 [Table 1-19] [Table 1-20] [Table 1-21] [Table 1-22] [Table 1-23] [Table 1-24] [Table 1-25]
[0198] Atosiban Atosiban, marketed under the name TRACTOCILE®, is an oxytocin receptor antagonist that inhibits the release of calcium ions from the sarcoplasmic reticulum into the cytoplasm of uterine myocytes. Uterine contractions are partially dependent on the recruitment of these divalent calcium ions. Atosiban can inhibit the influx of calcium ions into uterine myocytes without altering serum calcium levels. Atosiban is structurally represented as the following compound (4). [ka]
[0199] Exemplary methods for the preparation of atosiban are described, for example, in U.S. Patents 4,504,469 and 4,402,942, and may include solid-phase peptide synthesis and liquid-phase cyclization, for example, by disulfide bond formation. It should be understood that the aforementioned compounds can also be synthesized by other methods, for example, by substituting one of the amide bond-forming agents shown in U.S. Patents 4,504,469 or 4,402,942 with another amide bond-forming agent described herein or known in the art.
[0200] Oxytocin antagonists useful in combination with the compositions and methods described herein include atosiban, as well as its salts, derivatives, variants, crystalline forms, and formulations, such as the salts, derivatives, variants, crystalline forms, or formulations described herein, for example, the respective disclosures of which are incorporated herein by reference in whole in U.S. Patent No. 4,504,469 or U.S. Patent No. 4,402,942.
[0201] Treatment methods Combination therapy PGF2α receptor antagonists, such as the 1,3-thiazolidine-2-carboxamide compounds described herein, can be administered in combination with atosiban to subjects (e.g., pregnant human subjects) to treat or prevent preterm labor. The concomitant administration of these agents, such as in accordance with the above-described dosing regimen, provides significant clinical benefits. For example, the compositions and methods described herein enable the extension of pregnancy by more than one hour, more than one day, or more than one week.Specific examples of the clinical benefits provided by the compositions and methods described herein include (i) delays after the first administration of atosiban and the PGF2α receptor antagonist to the subject, for example, more than 1 hour, more than 1 day or more than 1 week (for example, delays of about 1 hour to about 16 weeks, for example, particularly 1 hour, 6 hours, 12 hours, 18 hours, 24 hours, 48 hours, 72 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 1 (ii) Delay in the onset of labor by subjects (delay of 2 weeks, 13 weeks, 14 weeks, 15 weeks or 16 weeks), (ii) Delay in the onset of labor by subjects such that, after administration of atosiban and a PGF2α receptor antagonist to subjects, the subjects experience labor at least at approximately 34 weeks of gestation, for example, between approximately 34 and approximately 40 weeks of gestation (for example, at approximately 34, 35, 36, 37, 38, 39 or 40 weeks of gestation), (iii) Delay in the onset of labor by subjects receiving atosiban and a PGF2α receptor antagonist (iv) Decreased vaginal bleeding in subjects after administration of a systemic antagonist, (iv) Delayed onset of rupture of membranes in subjects (e.g., a delay of approximately 1 hour to approximately 16 weeks after the first administration of atosiban and a PGF2α receptor antagonist to the subject, e.g., a delay of 1 hour, 6 hours, 12 hours, 18 hours, 24 hours, 48 hours, 72 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks or 16 weeks), (v) a decrease in the expression of one or more pro-inflammatory genes, such as cyclooxygenase-2 (Cox2), in the subject after administration of atosiban and a PGF2α receptor antagonist (e.g., assessed by observing a decrease in Cox2 expression in the myometrium), and (vi) a decrease in the frequency, peak amplitude, duration, and / or activity of uterine contractions in the subject after administration of atosiban and a PGF2α receptor antagonist, including but not limited to these.
[0202] Prenatal corticosteroids Furthermore, PGF2α receptor antagonists, such as atosiban and the PGF2α receptor antagonists described herein, can be administered in combination with corticosteroids to patients (e.g., patients who have experienced or are at risk of experiencing preterm birth). Prenatal corticosteroids such as betamethasone, dexamethasone, and hydrocortisone represent a class of therapeutic agents that can be administered to subjects to promote prenatal fetal lung maturation. Treatment with prenatal corticosteroids has been associated with an overall reduction in neonatal mortality within 48 hours of birth, respiratory distress syndrome, intraventricular hemorrhage, necrotizing enterocolitis, respiratory support, intensive care hospitalization, and systemic infections. In addition, prenatal corticosteroid therapy is effective in women with premature rupture of membranes (PROM) and pregnancy-related hypertension. In particular, there is evidence suggesting efficacy over a wide range of gestational periods, such as from approximately 26 to 34 weeks (Miracle et al. J. Perinat. Med. 36:191-196 (2008), the disclosure of which is incorporated herein by reference). Therefore, using the compositions and methods described herein, a patient may be administered atosiban and a PGF2α receptor antagonist (such as a compound represented by any one of formulas (I) to (VIII), e.g., compound (1), (2), or (3)) to delay the onset of labor, thereby providing additional time for administering prenatal corticosteroids to promote prenatal fetal lung development.
[0203] Evaluation of patient response Using various methods known in the art and described herein, it is possible to determine whether a patient (e.g., a patient who has experienced or is at risk of experiencing premature birth) is responding favorably to uterine contraction inhibitory treatment. For example, the success of treatment with PGF2α receptor antagonists such as atosiban and 1,3-thiazolidinedione-2-carboxamide compounds described herein is (a) Delays in the onset of labor in patients, including but not limited to delays of 1 hour or more, 1 day or more, or 1 week or more, after the initial administration of atosiban and PGF2α receptor antagonists (e.g., delays of approximately 1 hour to approximately 16 weeks, e.g., particularly delays of 1 hour, 6 hours, 12 hours, 18 hours, 24 hours, 48 hours, 72 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks or 16 weeks); (b) Delay in the onset of labor in subjects who experience labor at least approximately 34 weeks of gestation after administration of atosiban and / or a PGF2α receptor antagonist, for example between approximately 34 and 40 weeks of gestation (e.g., approximately 34, 35, 36, 37, 38, 39, or 40 weeks of gestation); (c) Reduction in vaginal bleeding in subjects after administration of atosiban and PGF2α receptor antagonists; (d) Delay in the onset of rupture of membranes by the subject (for example, a delay of about 1 hour to about 16 weeks after the initial administration of atosiban and PGF2α receptor antagonist to the subject, for example, a delay of 1 hour, 6 hours, 12 hours, 18 hours, 24 hours, 48 hours, 72 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks or 16 weeks); (e) A decrease in the expression of one or more pro-inflammatory genes, such as cyclooxygenase-2 (Cox2), in the subject after administration of atosiban and a PGF2α receptor antagonist (e.g., as assessed by observing a decrease in Cox2 expression in the myometrium); and / or (f) A decrease in the frequency, peak amplitude, duration, and / or activity of uterine contractions in subjects after administration of atosiban and / or PGF2α receptor antagonists; This can be shown by:
[0204] Route of administration and dosage The compositions and methods described herein may be used to administer atosiban and PGF2α receptor antagonists to subjects (e.g., pregnant humans) for the treatment or prevention of preterm birth. Exemplary dosages and schedules that may be used for the administration of atosiban and the PGF2α receptor antagonists of this disclosure are described in the following sections.
[0205] Atosiban According to the compositions and methods of this disclosure, atosiban may be administered to a subject in a single dose or regularly to a subject in doses of one or more, for example, every 12 hours, 24 hours, 36 hours, 48 hours, 60 hours, 72 hours, 84 hours, 96 hours, weekly, or monthly. For example, atosiban may be administered in 1 to 10 doses every 12 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses), 1 to 10 doses every 14 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses), 1 to 10 doses every 16 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses), 1 to 10 doses every 18 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses), or 1 to 10 doses every 20 hours. (For example, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 22 hours (for example, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 24 hours (for example, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 26 hours (for example, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 28 hours (for example, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses) (1 dose), 1 to 10 doses every 30 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 32 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 34 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 36 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 38 hours (e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 40 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 42 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 44 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 46 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses),Doses can be taken in the following ways: 1 to 10 doses every 48 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 60 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 72 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 84 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 96 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 108 hours (e.g., 1, 2, 3, 4, 5 It may be administered to the subject in doses of 6, 7, 8, 9, or 10 times, 1 to 10 times every 120 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times), 1 to 10 times every 132 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times), 1 to 10 times every 144 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times), 1 to 10 times every 156 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times), or 1 to 10 times weekly (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times).
[0206] In some embodiments, atosiban is administered as a single bolus dose of approximately 4.0 mg to approximately 9.5 mg (e.g., approximately 4.0 mg, 4.1 mg, 4.2 mg, 4.3 mg, 4.4 mg, 4.5 mg, 4.6 mg, 4.7 mg, 4.8 mg, 4.9 mg, 5.0 mg, 5.1 mg, 5.2 mg, 5.3 mg, 5.4 mg, 5.5 mg, 5.6 mg, 5.7 mg, 5.8 mg, 5.9 mg, 6.0 mg, 6.1 mg, 6.2 mg, 6. It is administered to the target population as a single bolus dose of 3 mg, 6.4 mg, 6.5 mg, 6.6 mg, 6.7 mg, 6.8 mg, 6.9 mg, 7.0 mg, 7.1 mg, 7.2 mg, 7.3 mg, 7.4 mg, 7.5 mg, 7.6 mg, 7.7 mg, 7.8 mg, 7.9 mg, 8.0 mg, 8.1 mg, 8.2 mg, 8.3 mg, 8.4 mg, 8.5 mg, 8.6 mg, 8.7 mg, 8.8 mg, 8.9 mg, or 9.0 mg. In some embodiments, atosiban is administered to subjects in a single bolus dose of approximately 5.0 mg to approximately 8.5 mg (for example, a single bolus dose of approximately 5.0 mg, 5.1 mg, 5.2 mg, 5.3 mg, 5.4 mg, 5.5 mg, 5.6 mg, 5.7 mg, 5.8 mg, 5.9 mg, 6.0 mg, 6.1 mg, 6.2 mg, 6.3 mg, 6.4 mg, 6.5 mg, 6.6 mg, 6.7 mg, 6.8 mg, 6.9 mg, 7.0 mg, 7.1 mg, 7.2 mg, 7.3 mg, 7.4 mg, 7.5 mg, 7.6 mg, 7.7 mg, 7.8 mg, 7.9 mg, 8.0 mg, 8.1 mg, 8.2 mg, 8.3 mg, 8.4 mg, or 8.5 mg). In some embodiments, atosiban is administered to subjects in a single bolus dose of approximately 5.5 mg to approximately 8.0 mg (for example, a single bolus dose of approximately 5.5 mg, 5.6 mg, 5.7 mg, 5.8 mg, 5.9 mg, 6.0 mg, 6.1 mg, 6.2 mg, 6.3 mg, 6.4 mg, 6.5 mg, 6.6 mg, 6.7 mg, 6.8 mg, 6.9 mg, 7.0 mg, 7.1 mg, 7.2 mg, 7.3 mg, 7.4 mg, 7.5 mg, 7.6 mg, 7.7 mg, 7.8 mg, 7.9 mg, or 8.0 mg).In some embodiments, atosiban is administered to subjects in a single bolus dose of approximately 5.75 mg to approximately 7.75 mg (e.g., a single bolus dose of approximately 5.75 mg, 6.00 mg, 6.25 mg, 6.50 mg, 6.75 mg, 7.00 mg, 7.25 mg, 7.50 mg, or 7.75 mg). In some embodiments, atosiban is administered to subjects in a single bolus dose of approximately 6.0 mg to approximately 7.5 mg (e.g., a single bolus dose of approximately 6.0 mg, 6.1 mg, 6.2 mg, 6.3 mg, 6.4 mg, 6.5 mg, 6.6 mg, 6.7 mg, 6.8 mg, 6.9 mg, 7.0 mg, 7.1 mg, 7.2 mg, 7.3 mg, 7.4 mg, or 7.5 mg). In some embodiments, atosiban is administered to subjects in a single bolus dose of approximately 6.25 mg to approximately 7.25 mg (e.g., a single bolus dose of approximately 6.25 mg, 6.50 mg, 6.75 mg, 7.00 mg, or 7.25 mg). In some embodiments, atosiban is administered to subjects in a single bolus dose of approximately 6.5 mg to approximately 7.0 mg (e.g., a single bolus dose of approximately 6.50 mg, 6.75 mg, or 7.00 mg). In some embodiments, atosiban is administered to subjects in a single bolus dose of approximately 6.75 mg.
[0207] In some embodiments, a single bolus dose of atosiban is administered intravenously to the subject.
[0208] In some embodiments, following a single bolus administration of atosiban, the atosiban is subsequently administered to the subject by continuous intravenous infusion in amounts of approximately 40 mg to approximately 70 mg (for example, by continuous intravenous infusion in amounts of approximately 40 mg, 41 mg, 42 mg, 43 mg, 44 mg, 45 mg, 46 mg, 47 mg, 48 mg, 49 mg, 50 mg, 51 mg, 52 mg, 53 mg, 54 mg, 55 mg, 56 mg, 57 mg, 58 mg, 59 mg, 60 mg, 61 mg, 62 mg, 63 mg, 64 mg, 65 mg, 66 mg, 67 mg, 68 mg, 69 mg, or 70 mg). In some embodiments, following a single bolus dose of atosiban, the atosiban is subsequently administered to the subject by continuous intravenous infusion in amounts of approximately 45 mg to approximately 65 mg (for example, by continuous intravenous infusion in amounts of approximately 45 mg, 46 mg, 47 mg, 48 mg, 49 mg, 50 mg, 51 mg, 52 mg, 53 mg, 54 mg, 55 mg, 56 mg, 57 mg, 58 mg, 59 mg, 60 mg, 61 mg, 62 mg, 63 mg, 64 mg, or 65 mg). In some embodiments, following a single bolus dose of atosiban, the atosiban is subsequently administered to the subject by continuous intravenous infusion in amounts of approximately 50 mg to approximately 60 mg (for example, by continuous intravenous infusion in amounts of approximately 50 mg, 51 mg, 52 mg, 53 mg, 54 mg, 55 mg, 56 mg, 57 mg, 58 mg, 59 mg, or 60 mg). In some embodiments, following a single bolus dose of atosiban, the atosiban is subsequently administered to the subject by continuous intravenous infusion in amounts of approximately 52 mg to approximately 56 mg (for example, by continuous intravenous infusion in amounts of approximately 52 mg, 53 mg, 54 mg, 55 mg, or 56 mg). In some embodiments, following a single bolus dose of atosiban, the atosiban is subsequently administered to the subject by continuous intravenous infusion in amounts of approximately 54 mg.
[0209] In some embodiments, the aforementioned intravenous infusion is performed continuously over a period of about 1 to 5 hours, for example, about 1.0 hour, 1.25 hours, 1.5 hours, 1.75 hours, 2.0 hours, 2.25 hours, 2.5 hours, 2.75 hours, 3.0 hours, 3.25 hours, 3.5 hours, 3.5 hours, 3.75 hours, 4.0 hours, 4.25 hours, 4.5 hours, 4.75 hours, or 5.0 hours. In some embodiments, the aforementioned intravenous infusion is performed continuously over a period of about 1.5 to 4.5 hours, for example, about 1.5 hours, 1.75 hours, 2.0 hours, 2.25 hours, 2.5 hours, 2.75 hours, 3.0 hours, 3.25 hours, 3.5 hours, 3.5 hours, 3.75 hours, 4.0 hours, 4.25 hours, or 4.5 hours. In some embodiments, the aforementioned intravenous infusion is performed continuously over a period of about 2.0 hours to about 4.0 hours, for example, about 2.0 hours, 2.25 hours, 2.5 hours, 2.75 hours, 3.0 hours, 3.25 hours, 3.5 hours, 3.5 hours, 3.75 hours, or 4.0 hours. In some embodiments, the aforementioned intravenous infusion is performed continuously over a period of about 2.5 hours to about 3.5 hours, for example, about 2.5 hours, 2.75 hours, 3.0 hours, 3.25 hours, or 3.5 hours. In some embodiments, the aforementioned intravenous infusion is performed continuously over a period of about 3.0 hours.
[0210] In some embodiments, following the aforementioned sequential intravenous infusion, atosiban is subsequently administered to the subject by a second sequential intravenous infusion in amounts of approximately 240 mg to approximately 300 mg (for example, by a second sequential intravenous infusion in amounts of approximately 240 mg, 245 mg, 250 mg, 255 mg, 260 mg, 265 mg, 270 mg, 275 mg, 280 mg, 285 mg, 290 mg, 295 mg, or 300 mg). In some embodiments, following the aforementioned sequential intravenous infusion, atosiban is subsequently administered to the subject by a second sequential intravenous infusion in amounts of approximately 250 mg to approximately 290 mg (for example, by a second sequential intravenous infusion in amounts of approximately 250 mg, 255 mg, 260 mg, 265 mg, 270 mg, 275 mg, 280 mg, 285 mg, or 290 mg). In some embodiments, following the aforementioned sequential intravenous infusion, atosiban is subsequently administered to the subject by a second sequential intravenous infusion in an amount of approximately 250 mg to approximately 290 mg (for example, by a second sequential intravenous infusion in an amount of approximately 250 mg, 255 mg, 260 mg, 265 mg, 270 mg, 275 mg, 280 mg, 285 mg, or 290 mg). In some embodiments, following the aforementioned sequential intravenous infusion, atosiban is subsequently administered to the subject by a second sequential intravenous infusion in an amount of approximately 260 mg to approximately 280 mg (for example, by a second sequential intravenous infusion in an amount of approximately 260 mg, 265 mg, 270 mg, 275 mg, or 280 mg). In some embodiments, following the aforementioned sequential intravenous infusion, atosiban is subsequently administered to the subject by a second sequential intravenous infusion in an amount of approximately 265 mg to approximately 275 mg (for example, by a second sequential intravenous infusion in an amount of approximately 265 mg, 270 mg, or 275 mg). In some embodiments, following the aforementioned sequential intravenous infusion, atosiban is subsequently administered to the subject by a second sequential intravenous infusion in an amount of approximately 270 mg.
[0211] In some embodiments, the second intravenous infusion is performed continuously over a period of approximately 42 to 48 hours, for example, approximately 42.0 hours, 42.25 hours, 42.5 hours, 42.75 hours, 43.0 hours, 43.25 hours, 43.5 hours, 43.75 hours, 44.0 hours, 44.25 hours, 44.5 hours, 44.75 hours, 45.0 hours, 45.25 hours, 45.5 hours, 45.75 hours, 46.0 hours, 46.25 hours, 46.5 hours, 46.75 hours, 47.0 hours, 47.25 hours, 47.5 hours, 47.75 hours, or 48.0 hours. In some embodiments, the second intravenous infusion is performed continuously over a period of approximately 43 to 47 hours, for example, approximately 43.0 hours, 43.25 hours, 43.5 hours, 43.75 hours, 44.0 hours, 44.25 hours, 44.5 hours, 44.75 hours, 45.0 hours, 45.25 hours, 45.5 hours, 45.75 hours, 46.0 hours, 46.25 hours, 46.5 hours, 46.75 hours, or 47.0 hours. In some embodiments, the second intravenous infusion is performed continuously over a period of approximately 44 to 46 hours, for example, approximately 44.0 hours, 44.25 hours, 44.5 hours, 44.75 hours, 45.0 hours, 45.25 hours, 45.5 hours, 45.75 hours, or 46.0 hours. In some embodiments, the second intravenous infusion is performed continuously over a period of approximately 44.5 hours to approximately 45.5 hours, for example, approximately 44.5 hours, 44.75 hours, 45.0 hours, 45.25 hours, or 45.5 hours. In some embodiments, the second intravenous infusion is performed continuously over a period of approximately 44 hours.
[0212] In some embodiments, atosiban is administered to the subject until she reaches at least about 34 weeks of gestation (e.g., about 34 to about 40 weeks of gestation, e.g., 34, 35, 36, 37, 38, 39, or 40 weeks of gestation) or until she experiences labor. In some embodiments, atosiban is administered to the subject until she reaches about 37 weeks of gestation.
[0213] In some embodiments, the administration of the PGF2α receptor antagonist and the administration of atosiban are initiated within approximately 48 hours of each other. In some embodiments, the administration of the PGF2α receptor antagonist and the administration of atosiban are initiated within approximately 36 hours of each other. In some embodiments, the administration of the PGF2α receptor antagonist and the administration of atosiban are initiated within approximately 24 hours of each other. In some embodiments, the administration of the PGF2α receptor antagonist and the administration of atosiban are initiated within approximately 12 hours of each other. In some embodiments, the administration of the PGF2α receptor antagonist and the administration of atosiban are initiated within approximately 6 hours of each other. In some embodiments, the administration of the PGF2α receptor antagonist and the administration of atosiban are initiated substantially simultaneously.
[0214] In some embodiments, atosiban is formulated as an aqueous solution. The concentration of atosiban in the aqueous solution is, for example, about 5.0 mg / ml to about 10 mg / ml (for example, about 5.0 mg / ml, 5.1 mg / ml, 5.2 mg / ml, 5.3 mg / ml, 5.4 mg / ml, 5.5 mg / ml, 5.6 mg / ml, 5.7 mg / ml, 5.8 mg / ml, 5.9 mg / ml, 6.0 mg / ml, 6.1 mg / ml, 6.2 mg / ml, 6.3 mg / ml, 6.4 mg / ml, 6.5 mg / ml, 6.6 mg / ml, 6.7 mg / ml, 6.8 mg / ml, 6.9 mg / ml, 7.0 mg / ml, 7.1 mg / ml, 7.2 mg / ml, 7.3 mg It may be 7.4 mg / ml, 7.5 mg / ml, 7.6 mg / ml, 7.7 mg / ml, 7.8 mg / ml, 7.9 mg / ml, 8.0 mg / ml, 8.1 mg / ml, 8.2 mg / ml, 8.3 mg / ml, 8.4 mg / ml, 8.5 mg / ml, 8.6 mg / ml, 8.7 mg / ml, 8.8 mg / ml, 8.9 mg / ml, 9.0 mg / ml, 9.1 mg / ml, 9.2 mg / ml, 9.3 mg / ml, 9.4 mg / ml, 9.5 mg / ml, 9.6 mg / ml, 9.7 mg / ml, 9.8 mg / ml, 9.9 mg / ml, or 10.0 mg / ml. In some embodiments, the concentration of atosiban in the aqueous solution is, for example, about 5.5 mg / ml to about 9.5 mg / ml (for example, about 5.5 mg / ml, 5.6 mg / ml, 5.7 mg / ml, 5.8 mg / ml, 5.9 mg / ml, 6.0 mg / ml, 6.1 mg / ml, 6.2 mg / ml, 6.3 mg / ml, 6.4 mg / ml, 6.5 mg / ml, 6.6 mg / ml, 6.7 mg / ml, 6.8 mg / ml, 6.9 mg / ml, 7.0 mg / ml, 7.1 mg / ml, 7.2 mg / ml). ml, 7.3mg / ml, 7.4mg / ml, 7.5mg / ml, 7.6mg / ml, 7.7mg / ml, 7.8mg / ml, 7.9mg / ml, 8.0mg / ml, 8.1mg / ml, 8.2mg / ml, 8.3mg / ml, 8.4mg / ml, 8.5mg / ml, 8.6mg / ml, 8.7mg / ml, 8.8mg / ml, 8.9mg / ml, 9.0mg / ml, 9.1mg / ml, 9.2mg / ml, 9.3mg / ml, 9.4mg / ml or 9.5mg / ml).In some embodiments, the concentration of atosiban in the aqueous solution is, for example, about 6.0 mg / ml to about 9.0 mg / ml (for example, about 6.0 mg / ml, 6.1 mg / ml, 6.2 mg / ml, 6.3 mg / ml, 6.4 mg / ml, 6.5 mg / ml, 6.6 mg / ml, 6.7 mg / ml, 6.8 mg / ml, 6.9 mg / ml, 7.0 mg / ml, 7.1 mg / ml, 7.2 mg / ml). ml, 7.3mg / ml, 7.4mg / ml, 7.5mg / ml, 7.6mg / ml, 7.7mg / ml, 7.8mg / ml, 7.9mg / ml, 8.0mg / ml, 8.1mg / ml, 8 .2mg / ml, 8.3mg / ml, 8.4mg / ml, 8.5mg / ml, 8.6mg / ml, 8.7mg / ml, 8.8mg / ml, 8.9mg / ml or 9.0mg / ml). In some embodiments, the concentration of atosiban in the aqueous solution is, for example, about 6.5 mg / ml to about 8.5 mg / ml (for example, about 6.5 mg / ml, 6.6 mg / ml, 6.7 mg / ml, 6.8 mg / ml, 6.9 mg / ml, 7.0 mg / ml, 7.1 mg / ml, 7.2 mg / ml, 7.3 mg / ml, 7.4 mg / ml, 7.5 mg / ml, 7.6 mg / ml, 7.7 mg / ml, 7.8 mg / ml, 7.9 mg / ml, 8.0 mg / ml, 8.1 mg / ml, 8.2 mg / ml, 8.3 mg / ml, 8.4 mg / ml, or 8.5 mg / ml). In some embodiments, the concentration of atosiban in the aqueous solution is, for example, about 7.0 mg / ml to about 8.0 mg / ml (e.g., about 7.0 mg / ml, 7.1 mg / ml, 7.2 mg / ml, 7.3 mg / ml, 7.4 mg / ml, 7.5 mg / ml, 7.6 mg / ml, 7.7 mg / ml, 7.8 mg / ml, 7.9 mg / ml, or 8.0 mg / ml). In some embodiments, the concentration of atosiban in the aqueous solution is about 7.5 mg / ml.
[0215] The aqueous solution may further contain one or more pharmaceutically acceptable excipients, such as mannitol. In some embodiments, the concentration of mannitol in the aqueous solution is about 40 mg / ml to about 60 mg / ml, such as about 45 mg / ml to about 55 mg / ml (e.g., about 50 mg / ml).
[0216] In some embodiments, the aqueous solution has a pH of about 4.0 to about 5.0 (e.g., pH of about 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, or 5.0). In some embodiments, the aqueous solution has a pH of about 4.25 to about 4.75 (e.g., pH of about 4.25, 4.30, 4.35, 4.40, 4.45, 4.50, 4.55, 4.60, 4.65, 4.70, or 4.75). In some embodiments, the aqueous solution has a pH of about 4.5.
[0217] PGF2α receptor antagonist The PGF2α receptor antagonists described herein are available in doses of approximately 300 mg to 2,300 mg, for example, approximately 300 mg per dose, 350 mg per dose, 400 mg per dose, 450 mg per dose, 500 mg per dose, 550 mg per dose, 600 mg per dose, 650 mg per dose, 700 mg per dose, 750 mg per dose, 800 mg per dose, 850 mg per dose, 900 mg per dose, 950 mg per dose, 1,000 mg per dose, 1,050 mg per dose, 1,100 mg per dose, 1,150 mg per dose, 1,200 mg per dose, 1,250 mg per dose, and 1,000 mg per dose. The drug may be administered to the target in amounts of 1,300 mg per dose, 1,350 mg per dose, 1,400 mg per dose, 1,450 mg per dose, 1,500 mg per dose, 1,550 mg per dose, 1,600 mg per dose, 1,650 mg per dose, 1,700 mg per dose, 1,750 mg per dose, 1,800 mg per dose, 1,850 mg per dose, 1,900 mg per dose, 1,950 mg per dose, 2,000 mg per dose, 2,050 mg per dose, 2,100 mg per dose, 2,150 mg per dose, 2,200 mg per dose, 2,250 mg per dose, or 2,300 mg per dose.PGF2α receptor antagonists are administered in doses of approximately 400 mg to 2,100 mg, for example, approximately 400 mg per dose, 450 mg per dose, 500 mg per dose, 550 mg per dose, 600 mg per dose, 650 mg per dose, 700 mg per dose, 750 mg per dose, 800 mg per dose, 850 mg per dose, 900 mg per dose, 950 mg per dose, 1,000 mg per dose, 1,050 mg per dose, 1,100 mg per dose, 1,150 mg per dose, 1,200 mg per dose. The drug may be administered to the target patient in amounts of 1,250 mg, 1,300 mg per dose, 1,350 mg per dose, 1,400 mg per dose, 1,450 mg per dose, 1,500 mg per dose, 1,550 mg per dose, 1,600 mg per dose, 1,650 mg per dose, 1,700 mg per dose, 1,750 mg per dose, 1,800 mg per dose, 1,850 mg per dose, 1,900 mg per dose, 1,950 mg per dose, 2,000 mg per dose, 2,050 mg per dose, or 2,100 mg per dose.In some embodiments, the PGF2α receptor antagonist is administered in amounts ranging from approximately 450 mg to approximately 2,050 mg per dose, for example, approximately 450 mg per dose, 500 mg per dose, 550 mg per dose, 600 mg per dose, 650 mg per dose, 700 mg per dose, 750 mg per dose, 800 mg per dose, 850 mg per dose, 900 mg per dose, 950 mg per dose, 1,000 mg per dose, 1,050 mg per dose, 1,100 mg per dose, 1,150 mg per dose, and 1,200 mg per dose. The drug is administered to the target patient in doses of 1,250 mg per dose, 1,300 mg per dose, 1,350 mg per dose, 1,400 mg per dose, 1,450 mg per dose, 1,500 mg per dose, 1,550 mg per dose, 1,600 mg per dose, 1,650 mg per dose, 1,700 mg per dose, 1,750 mg per dose, 1,800 mg per dose, 1,850 mg per dose, 1,900 mg per dose, 1,950 mg per dose, 2,000 mg per dose, or 2,050 mg per dose.
[0218] In some embodiments, the PGF2α receptor antagonist is administered to the subject in amounts ranging from approximately 100 mg to approximately 900 mg per dose, for example, approximately 100 mg per dose, 150 mg per dose, 200 mg per dose, 250 mg per dose, 300 mg per dose, 350 mg per dose, 400 mg per dose, 450 mg per dose, 500 mg per dose, 550 mg per dose, 600 mg per dose, 650 mg per dose, 700 mg per dose, 750 mg per dose, 800 mg per dose, 850 mg per dose, or 900 mg per dose. In some embodiments, the PGF2α receptor antagonist is administered to the subject in amounts ranging from approximately 200 mg to approximately 800 mg per dose, for example, approximately 200 mg per dose, 250 mg per dose, 300 mg per dose, 350 mg per dose, 400 mg per dose, 450 mg per dose, 500 mg per dose, 550 mg per dose, 600 mg per dose, 650 mg per dose, 700 mg per dose, 750 mg per dose, or 800 mg per dose. In some embodiments, the PGF2α receptor antagonist is administered to the subject in doses of approximately 300 mg to approximately 700 mg, for example, approximately 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, or 700 mg per dose. In some embodiments, the PGF2α receptor antagonist is administered to the subject in doses of approximately 400 mg to approximately 600 mg, for example, approximately 400 mg, 450 mg, 500 mg, 550 mg, or 600 mg per dose. In some embodiments, the PGF2α receptor antagonist is administered to the subject in amounts of approximately 450 mg to approximately 550 mg per dose, for example, approximately 450 mg per dose, 500 mg per dose, or 550 mg per dose.
[0219] In some embodiments, the PGF2α receptor antagonist is administered to the subject in amounts ranging from approximately 600 mg to approximately 1,400 mg per dose, for example, approximately 600 mg per dose, 650 mg per dose, 700 mg per dose, 750 mg per dose, 800 mg per dose, 850 mg per dose, 900 mg per dose, 950 mg per dose, 1,000 mg per dose, 1,050 mg per dose, 1,100 mg per dose, 1,150 mg per dose, 1,200 mg per dose, 1,250 mg per dose, 1,300 mg per dose, 1,350 mg per dose, or 1,400 mg per dose. In some embodiments, the PGF2α receptor antagonist is administered to the subject in amounts ranging from approximately 700 mg to approximately 1,300 mg per dose, for example, approximately 700 mg per dose, 750 mg per dose, 800 mg per dose, 850 mg per dose, 900 mg per dose, 950 mg per dose, 1,000 mg per dose, 1,050 mg per dose, 1,100 mg per dose, 1,150 mg per dose, 1,200 mg per dose, 1,250 mg per dose, or 1,300 mg per dose. In some embodiments, the PGF2α receptor antagonist is administered to the subject in amounts ranging from approximately 800 mg to approximately 1,200 mg per dose, for example, approximately 800 mg, 850 mg, 900 mg, 950 mg, 1,000 mg, 1,050 mg, 1,100 mg, 1,150 mg, or 1,200 mg per dose. In some embodiments, the PGF2α receptor antagonist is administered to the subject in amounts ranging from approximately 900 mg to approximately 1,100 mg per dose, for example, approximately 900 mg, 950 mg, 1,000 mg, 1,050 mg, or 1,100 mg per dose. In some embodiments, the PGF2α receptor antagonist is administered to the subject in amounts ranging from approximately 950 mg to approximately 1,050 mg per dose, for example, approximately 950 mg per dose, 1,000 mg per dose, or 1,050 mg per dose.
[0220] In some embodiments, among the other PGF2α receptor antagonists described herein, one of the compounds of formulas (I) to (VIII), such as compound (1), compound (2), or compound (3), is administered to the subject regularly in doses at 12, 24, 36, 48, 60, 72, 84, 96 hours, once or more times per week or month. For example, PGF2α receptor antagonists are administered in doses of 1 to 10 times every 12 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses), 1 to 10 times every 14 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses), 1 to 10 times every 16 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses), and 1 to 10 times every 18 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses). Dosage) 1 to 10 doses every 20 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 22 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 24 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 26 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 28 hours 10 doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 30 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 32 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 34 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 36 hours (e.g., 1, (2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 38 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 40 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 42 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 44 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8,9 or 10 doses), 1 to 10 doses every 46 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 48 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 60 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 72 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 84 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), 1 to 10 doses every 96 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses), It may be administered to the target in doses of 1 to 10 times every 108 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses), 1 to 10 times every 120 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses), 1 to 10 times every 132 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses), 1 to 10 times every 144 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses), 1 to 10 times every 156 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses), or 1 to 10 times weekly (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses).
[0221] In some embodiments, among the other PGF2α receptor antagonists described herein, one of the compounds of formulas (I) to (VIII), for example, compound (1), compound (2), or compound (3), is administered to the subject in doses of 1 to 6 times per day. For example, one of the compounds of formulas (I) to (VIII), for example, compound (1), compound (2), or compound (3), may be administered to the subject once daily. In some embodiments, the PGF2α receptor antagonist is administered to the subject twice daily.
[0222] In some embodiments, the PGF2α receptor antagonist is administered to the subject once every 4 to 12 hours, for example, once every 4 hours, once every 5 hours, once every 6 hours, once every 7 hours, once every 8 hours, once every 9 hours, once every 10 hours, once every 11 hours, or once every 12 hours.
[0223] Among the other PGF2α receptor antagonists described herein, any one compound of formulas (I) to (VIII), such as compound (1), compound (2), or compound (3), may be administered to a subject in one or more unit dosage forms that collectively constitute a single dose. For example, by administering one or more unit dosage forms of the compound to a subject, a specific amount of the compound can be administered as a single dose, such as 250 mg, 500 mg, 750 mg, 1,000 mg, 1,250 mg, 1,500 mg, 1,750 mg, 2,000 mg, or more. As a non-limiting example, a single dose of 1,000 mg of the compound may be administered to a subject by two separate 500 mg unit dosage forms of the compound. The two 500 mg unit dosage forms, when administered to the subject substantially simultaneously, collectively constitute a single 1,000 mg dose of the compound.
[0224] In some embodiments, among other PGF2α receptor antagonists described herein, any one compound of formulas (I) to (VIII), such as compound (1), compound (2), or compound (3), is administered in doses of approximately 250 mg to approximately 2,500 mg per day in total, for example, approximately 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg per day. The drug is administered to the target individual in doses of 0 mg, 900 mg, 1,000 mg, 1,050 mg, 1,100 mg, 1,150 mg, 1,200 mg, 1,250 mg, 1,300 mg, 1,350 mg, 1,400 mg, 1,450 mg, 1,500 mg, 1,550 mg, 1,600 mg, 1,650 mg, 1,700 mg, 1,750 mg, 1,800 mg, 1,850 mg, 1,900 mg, 1,950 mg, 2,000 mg, 2,050 mg, 2,100 mg, 2,150 mg, 2,200 mg, 2,250 mg, 2,300 mg, 2,350 mg, 2,400 mg, 2,450 mg, or 2,500 mg.
[0225] In some embodiments, the PGF2α receptor antagonist is administered in doses once or more times a day (e.g., 1 to 10 doses, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 times or more), totaling approximately 300 mg to approximately 2,000 mg per day, for example, approximately 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg per day. The drug is administered to the target population in amounts of g, 900 mg, 1,000 mg, 1,050 mg, 1,100 mg, 1,150 mg, 1,200 mg, 1,250 mg, 1,300 mg, 1,350 mg, 1,400 mg, 1,450 mg, 1,500 mg, 1,550 mg, 1,600 mg, 1,650 mg, 1,700 mg, 1,750 mg, 1,800 mg, 1,850 mg, 1,900 mg, 1,950 mg, or 2,000 mg.
[0226] In some embodiments, the PGF2α receptor antagonist is administered to the subject in doses once or more times a day (e.g., 1 to 10 doses, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 times or more), totaling approximately 400 mg to approximately 1,600 mg per day, for example, approximately 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 1,000 mg, 1,050 mg, 1,100 mg, 1,150 mg, 1,200 mg, 1,250 mg, 1,300 mg, 1,350 mg, 1,400 mg, 1,450 mg, 1,500 mg, 1,550 mg or 1,600 mg per day.
[0227] In some embodiments, the PGF2α receptor antagonist is administered to the subject in doses once or more times a day (e.g., 1 to 10 doses, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 times or more), totaling approximately 700 mg to approximately 1,300 mg per day, for example, approximately 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 1,000 mg, 1,050 mg, 1,100 mg, 1,150 mg, 1,200 mg, 1,250 mg or 1,300 mg per day.
[0228] In some embodiments, the PGF2α receptor antagonist is administered to the subject in doses once or more times a day (e.g., 1 to 10 doses, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 times or more), totaling approximately 800 mg to approximately 1,200 mg per day, for example, approximately 800 mg, 850 mg, 900 mg, 1,000 mg, 1,050 mg, 1,100 mg, 1,150 mg or 1,200 mg per day.
[0229] In some embodiments, the PGF2α receptor antagonist is administered to the subject in doses once or more times a day (e.g., 1 to 10 doses, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 times or more), totaling approximately 900 mg to approximately 1,100 mg per day, for example, approximately 900 mg, 1,000 mg, 1,050 mg or 1,100 mg per day.
[0230] In some embodiments, the PGF2α receptor antagonist is administered to the subject in doses once or more times a day (e.g., 1 to 10 doses, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 times or more), totaling approximately 950 mg to approximately 1,050 mg per day, for example, approximately 950 mg, 955 mg, 960 mg, 965 mg, 970 mg, 975 mg, 980 mg, 985 mg, 990 mg, 995 mg, 1,000 mg, 1,005 mg, 1,010 mg, 1,015 mg, 1,020 mg, 1,025 mg, 1,030 mg, 1,035 mg, 1,040 mg, 1,045 mg or 1,050 mg per day.
[0231] In some embodiments, among the other PGF2α receptor antagonists described herein, one of the compounds of formulas (I) to (VIII), such as compound (1), compound (2), or compound (3), is administered to the subject in a single dose per day. For example, the PGF2α receptor antagonist is administered in amounts of approximately 250 mg to approximately 2,500 mg per day (e.g., single dose), such as approximately 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 1,000 mg, 1,050 mg, 1,100 mg, 1,150 mg, 1,200 mg, 1,250 mg, 1,300 mg, 1,3 The drug may be administered to the subject in amounts of 50 mg, 1,400 mg, 1,450 mg, 1,500 mg, 1,550 mg, 1,600 mg, 1,650 mg, 1,700 mg, 1,750 mg, 1,800 mg, 1,850 mg, 1,900 mg, 1,950 mg, 2,000 mg, 2,050 mg, 2,100 mg, 2,150 mg, 2,200 mg, 2,250 mg, 2,300 mg, 2,350 mg, 2,400 mg, 2,450 mg, or 2,500 mg. In some embodiments, the PGF2α receptor antagonist is administered to the subject in amounts of approximately 1,000 mg per day (e.g., a single dose).
[0232] In some embodiments, a PGF2α receptor antagonist, such as any one of the compounds of formulas (I) to (VIII), e.g., compound (1), compound (2), or compound (3), among the other PGF2α receptor antagonists described herein, is administered to the subject once daily in a dose of approximately 800 mg to approximately 1,200 mg per dose during a first treatment period. Subsequently, the PGF2α receptor antagonist may be administered to the subject twice daily in a dose of approximately 300 mg to approximately 700 mg per dose during a second treatment period, i.e., a total dose of approximately 600 mg to approximately 1,400 mg per day during the second treatment period.
[0233] In some embodiments, the PGF2α receptor antagonist is administered in doses of approximately 850 mg to 1,150 mg per dose during the first treatment period, for example, approximately 850 mg, 855 mg, 860 mg, 865 mg, 870 mg, 875 mg, 880 mg, 885 mg, 890 mg, 895 mg, 900 mg, 905 mg, 910 mg, 915 mg, 920 mg, 925 mg, 930 mg, 935 mg, 940 mg, 945 mg, 950 mg, 955 mg, 960 mg, 965 mg, 970 mg, 975 mg, 980 mg, 985 mg per dose during the first treatment period. mg, 990mg, 995mg, 1,000mg, 1,005mg, 1,010mg, 1,015mg, 1,020mg, 1,025mg, 1,030mg, 1,035mg, 1,040mg, 1,045mg, 1,050mg, 1,055mg, 1,060mg, 1,0 65mg, 1,070mg, 1,075mg, 1,080mg, 1,085mg, 1,090mg, 1,095mg, 1,100mg, 1,105mg, 1,110mg, 1,115mg, 1,120mg, 1,125mg, 1,130mg, 1,135mg, 1,140 In doses of mg, 1,145 mg, or 1,150 mg (i.e., during the first treatment period, a total of approximately 850 mg, 855 mg, 860 mg, 865 mg, 870 mg, 875 mg, 880 mg, 885 mg, 890 mg, 895 mg, 900 mg, 905 mg, 910 mg, 915 mg, 920 mg, 925 mg, 930 mg, 935 mg, 940 mg, 945 mg, 950 mg, 955 mg, 960 mg, 965 mg, 970 mg, 975 mg, 980 mg, 985 mg, 990 mg, 995 mg, 1,000 mg, 1,005 mg, 1, It is administered to the target group in amounts of 0.10 mg, 1,015 mg, 1,020 mg, 1,025 mg, 1,030 mg, 1,035 mg, 1,040 mg, 1,045 mg, 1,050 mg, 1,055 mg, 1,060 mg, 1,065 mg, 1,070 mg, 1,075 mg, 1,080 mg, 1,085 mg, 1,090 mg, 1,095 mg, 1,100 mg, 1,105 mg, 1,110 mg, 1,115 mg, 1,120 mg, 1,125 mg, 1,130 mg, 1,135 mg, 1,140 mg, 1,145 mg, or 1,150 mg.
[0234] In some embodiments, the PGF2α receptor antagonist is administered in doses of approximately 900 mg to 1,100 mg per dose during the first treatment period, for example, approximately 900 mg, 905 mg, 910 mg, 915 mg, 920 mg, 925 mg, 930 mg, 935 mg, 940 mg, 945 mg, 950 mg, 955 mg, 960 mg, 965 mg, 970 mg, 975 mg per dose during the first treatment period. , 980mg, 985mg, 990mg, 995mg, 1,000mg, 1,005mg, 1,010mg, 1,015mg, 1,020mg, 1,025mg, 1,030mg, 1,035m g, 1,040mg, 1,045mg, 1,050mg, 1,055mg, 1,060mg, 1,065mg, 1,070mg, 1,075mg, 1,080mg, 1,085mg, 1,090 In doses of mg, 1,095 mg, or 1,100 mg (i.e., during the first treatment period, a total of approximately 900 mg, 905 mg, 910 mg, 915 mg, 920 mg, 925 mg, 930 mg, 935 mg, 940 mg, 945 mg, 950 mg, 955 mg, 960 mg, 965 mg, 970 mg, 975 mg, 980 mg, 985 mg, 990 mg, 995 mg, 1,000 mg per day), It is administered to the target group in doses of 1,005 mg, 1,010 mg, 1,015 mg, 1,020 mg, 1,025 mg, 1,030 mg, 1,035 mg, 1,040 mg, 1,045 mg, 1,050 mg, 1,055 mg, 1,060 mg, 1,065 mg, 1,070 mg, 1,075 mg, 1,080 mg, 1,085 mg, 1,090 mg, 1,095 mg, or 1,100 mg.
[0235] In some embodiments, the PGF2α receptor antagonist is administered in doses of approximately 950 mg to approximately 1,050 mg per dose during the first treatment period, for example, approximately 950 mg, 955 mg, 960 mg, 965 mg, 970 mg, 975 mg, 980 mg, 985 mg, 990 mg, 995 mg, 1,000 mg, 1,005 mg, 1,010 mg, 1,015 mg, 1,020 mg, 1,025 mg, 1,030 mg, 1,035 mg, 1,040 mg per dose during the first treatment period. The subject is administered a dose of mg, 1,045 mg, or 1,050 mg (i.e., a total of approximately 950 mg, 955 mg, 960 mg, 965 mg, 970 mg, 975 mg, 980 mg, 985 mg, 990 mg, 995 mg, 1,000 mg, 1,005 mg, 1,010 mg, 1,015 mg, 1,020 mg, 1,025 mg, 1,030 mg, 1,035 mg, 1,040 mg, 1,045 mg, or 1,050 mg per day during the first treatment period). In some embodiments, the PGF2α receptor antagonist is administered to the subject at a dose of approximately 1,000 mg per dose during the first treatment period.
[0236] In some embodiments, the PGF2α receptor antagonist is administered in doses of approximately 350 mg to 650 mg per dose during the second treatment period, for example, approximately 350 mg, 355 mg, 360 mg, 365 mg, 370 mg, 375 mg, 380 mg, 385 mg, 390 mg, 395 mg, 400 mg, 405 mg, 410 mg, 415 mg, 420 mg, 425 mg, 430 mg, 435 mg, 440 mg, 445 mg, 450 mg, 455 mg, 460 mg, 465 mg, 470 mg, 475 mg, and 480 mg per dose during the second treatment period. , in amounts of 485mg, 490mg, 495mg, 500mg, 505mg, 510mg, 515mg, 520mg, 525mg, 530mg, 535mg, 540mg, 545mg, 550mg, 555mg, 560mg, 565mg, 570mg, 575mg, 580mg, 585mg, 590mg, 595mg, 600mg, 605mg, 610mg, 615mg, 620mg, 625mg, 630mg, 635mg, 640mg, 645mg or 650mg (i.e., during the second treatment period, a total of approximately 700mg per day) For example, during the second treatment period, approximately 700mg, 710mg, 720mg, 730mg, 740mg, 750mg, 760mg, 770mg, 780mg, 790mg, 800mg, 800mg, 810mg, 820mg, 830mg, 840mg, 850mg, 860mg, 870mg, 880mg, 890mg, 900mg, 910mg, 920mg, 930mg, 940mg, 950mg, 960mg, 970mg, 980mg, 990mg, 1,000mg, 1,010mg, and 1,020mg per day. It is administered to the target group in amounts of 1,030 mg, 1,040 mg, 1,050 mg, 1,060 mg, 1,070 mg, 1,080 mg, 1,090 mg, 1,100 mg, 1,110 mg, 1,120 mg, 1,130 mg, 1,140 mg, 1,150 mg, 1,160 mg, 1,170 mg, 1,180 mg, 1,190 mg, 1,200 mg, 1,210 mg, 1,220 mg, 1,230 mg, 1,240 mg, 1,250 mg, 1,260 mg, 1,270 mg, 1,280 mg, 1,290 mg, or 1,300 mg.
[0237] In some embodiments, the PGF2α receptor antagonist is administered in doses of approximately 400 mg to 600 mg per dose during the second treatment period, for example, approximately 400 mg, 405 mg, 410 mg, 415 mg, 420 mg, 425 mg, 430 mg, 435 mg, 440 mg, 445 mg, 450 mg, 455 mg, 460 mg, 465 mg, 470 mg, 475 mg per dose during the second treatment period. In amounts of 480 mg, 485 mg, 490 mg, 495 mg, 500 mg, 505 mg, 510 mg, 515 mg, 520 mg, 525 mg, 530 mg, 535 mg, 540 mg, 545 mg, 550 mg, 555 mg, 560 mg, 565 mg, 570 mg, 575 mg, 580 mg, 585 mg, 590 mg, 595 mg, or 600 mg (i.e., per day during the second treatment period) The total amount is approximately 800mg to 1,200mg. For example, during the second treatment period, the daily doses would be approximately 800mg, 800mg, 810mg, 820mg, 830mg, 840mg, 850mg, 860mg, 870mg, 880mg, 890mg, 900mg, 910mg, 920mg, 930mg, 940mg, 950mg, 960mg, 970mg, 980mg, 990mg, and 1,000mg. It is administered to the target group in doses of 1,010 mg, 1,020 mg, 1,030 mg, 1,040 mg, 1,050 mg, 1,060 mg, 1,070 mg, 1,080 mg, 1,090 mg, 1,100 mg, 1,110 mg, 1,120 mg, 1,130 mg, 1,140 mg, 1,150 mg, 1,160 mg, 1,170 mg, 1,180 mg, 1,190 mg, or 1,200 mg.
[0238] In some embodiments, the PGF2α receptor antagonist is administered in amounts of approximately 450 mg to approximately 550 mg per dose during the second treatment period, for example, approximately 450 mg, 455 mg, 460 mg, 465 mg, 470 mg, 475 mg, 480 mg, 485 mg, 490 mg, 495 mg, 500 mg, 505 mg, 510 mg, 515 mg, 520 mg, 525 mg, 530 mg, 535 mg, 540 mg, 545 mg, or 550 mg per dose during the second treatment period (i.e., the second During the second treatment period, the subject is administered a total dose of approximately 900 mg to 1,100 mg per day, for example, approximately 900 mg, 910 mg, 920 mg, 930 mg, 940 mg, 950 mg, 960 mg, 970 mg, 980 mg, 990 mg, 1,000 mg, 1,010 mg, 1,020 mg, 1,030 mg, 1,040 mg, 1,050 mg, 1,060 mg, 1,070 mg, 1,080 mg, 1,090 mg, or 1,100 mg per day. In some embodiments, the PGF2α receptor antagonist is administered to the subject at a dose of approximately 500 mg per dose during the second treatment period.
[0239] In some embodiments, the PGF2α receptor antagonist is administered to the subject once every 10 to 14 hours during the second treatment period. In some embodiments, the PGF2α receptor antagonist is administered to the subject once every 11 to 13 hours during the second treatment period. In some embodiments, the PGF2α receptor antagonist is administered to the subject once every 12 hours during the second treatment period.
[0240] In some embodiments, the first treatment period is a period of 1 to 10 days (for example, a period of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days). In some embodiments, the first treatment period is a period of 1 to 5 days (for example, a period of 1, 2, 3, 4, or 5 days). In some embodiments, the first treatment period is a period of 1 day.
[0241] In some embodiments, the second treatment period is a period of 1 to 28 days (for example, a period of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28 days). In some embodiments, the second treatment period is a period of 4 to 14 days (for example, a period of 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days). In some embodiments, the second treatment period is a period of 5 to 10 days (for example, a period of 5, 6, 7, 8, 9, or 10 days). In some embodiments, the second treatment period is a period of 3 days. In some embodiments, the second treatment period is 4 days. In some embodiments, the second treatment period is 5 days. In some embodiments, the second treatment period is 6 days. In some embodiments, the second treatment period is 7 days. In some embodiments, the second treatment period is 8 days. In some embodiments, the second treatment period is 9 days. In some embodiments, the second treatment period is 10 days.
[0242] In some embodiments, the PGF2α receptor antagonist is administered to the subject until she reaches at least about 34 weeks of gestation (e.g., about 34 to about 40 weeks of gestation, e.g., 34, 35, 36, 37, 38, 39, or 40 weeks of gestation) or until she experiences childbirth. In some embodiments, the PGF2α receptor antagonist is administered to the subject until she reaches about 37 weeks of gestation.
[0243] In some embodiments, the PGF2α receptor antagonist is administered orally to the subject. The PGF2α receptor antagonist may be formulated, for example, as a tablet, gel capsule, powder, liquid solution, or liquid suspension.
[0244] Pharmaceutical composition Uterine contraction inhibitors suitable for use with the compositions and methods described herein (e.g., atosiban and PGF2α receptor antagonists) can be formulated into pharmaceutical compositions for administration to patients, such as pregnant human patients, in a biocompatible form suitable for in vivo administration. For example, PGF2α receptor antagonists such as atosiban or the PGF2α receptor antagonists described herein (e.g., pharmaceutical compositions comprising (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidined-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valinate or pharmaceutically acceptable salts thereof, e.g., chloride salts thereof) may further contain appropriate diluents, carriers or excipients. PGF2α receptor antagonists can be administered to patients, for example, or by oral or intravenous injection. Under normal storage and use conditions, the pharmaceutical compositions may contain, for example, preservatives to prevent microbial growth. Procedures and components for selecting and preparing suitable formulations are, for example, found in Remington: The Science and Practice of Pharmacy (2012, 22 nd It is described in (ed.) and The United States Pharmacopeia: The National Formulary (2015, USP38NF33).
[0245] The pharmaceutical composition may include a sterile aqueous solution, a sterile dispersion, or a powder for the immediate preparation of a sterile solution or sterile dispersion. In all cases, the form can be sterilized using techniques known in the art and can be fluidized to a degree that allows for easy administration to a patient in need of treatment.
[0246] The pharmaceutical composition may be administered to a patient, for example, a human patient, alone or in combination with one or more pharmaceutically acceptable carriers, as described herein, for example, in proportion to the solubility of the compound, the chemical properties of the compound and / or the selected route of administration. [Examples]
[0247] The following examples are provided to those skilled in the art to illustrate how the compositions and methods described herein may be used, manufactured, and evaluated, and are intended purely to illustrate the present invention and not to limit the scope of what the inventors consider to be their invention.
[0248] Example 1. Administration of a PGF2α receptor antagonist in combination with atosiban prolongs the pregnancy period in human patients. Introduction Compound (2) is an orally active prostaglandin F2α (PGF2α) receptor antagonist designed to control preterm birth by suppressing inflammation and uterine contractions without causing potentially serious vasoconstriction in the fetus (e.g., premature closure of the ductus arteriosus and / or renal impairment), as seen with nonspecific prostaglandin inhibitors such as indomethacin and other nonsteroidal anti-inflammatory drugs (NSAIDs).
[0249] This example reports the results of a Phase II clinical trial of compound (2) in pregnant women with threatened spontaneous preterm labor. In Part A of the experiment, compound (2) was administered openly to n=9 patients between 28 and 34 weeks of gestation to evaluate pharmacokinetics and safety. In Part B of the experiment, compound (2) was administered to a broader set of subjects, n=58, to evaluate efficacy and further evaluate safety.
[0250] Part A method The subjects participating in Part A of the experiment were diagnosed with premature birth and had already received a 48-hour infusion of atosiban. Compound (2) was administered orally to each subject twice daily for 7 days, with a loading dose of 1,000 mg on day 1, followed by a dose of 500 mg.
[0251] In Part A of the experiment, fetal cardiac safety was monitored using Doppler ultrasound, and the pharmacokinetics of compound (2) were evaluated on days 1, 2, 3, and 7 of the experiment. Amniotic fluid index was monitored from day 1 to day 14. Time to delivery was also evaluated.
[0252] result A total of nine patients with mononuclear pregnancies were enrolled in Part A of the experiment. The baseline characteristics of the participants in Part A are shown in Table 2 below. [Table 2]
[0253] Eight patients were observed not to give birth within 7 days of administration of compound (2). One patient gave birth on the second day after starting compound (2). The mean ± SD time to delivery was 41 ± 23 days.
[0254] The plasma concentration-time profile of compound (2) (Figure 1) indicates that compound (2) was well absorbed from day 1 to day 7. Steady-state concentrations were achieved on day 1. Pharmacokinetic parameters were similar to those previously observed in non-pregnant women.
[0255] No adverse events to the fetus have been reported. Furthermore, Doppler ultrasound revealed no clinically significant abnormalities, including no constrictive effect on the ductus arteriosus. The ductus arteriosus pulsation index (Figure 2) did not decrease over the duration of administration. There were also no clinically significant changes in the amniotic fluid index (Figure 3).
[0256] conclusion Compound (2) was well-tolerated after 7 days of oral administration to women with threatened spontaneous PTL receiving atosiban. Compound (2) was also well-absorbed, as its plasma concentrations and pharmacokinetics were comparable to those observed in non-pregnant women.
[0257] Part B method Having demonstrated the safety of compound (2) in Part A of the experiment, Part B was designed to evaluate the ability of compound (2) in combination with atosiban to more potently delay the onset of labor compared to a treatment regimen containing placebo and atosiban. A total of n=58 patients were treated with compound (2) and atosiban, and n=55 patients were treated with placebo and atosiban. As in Part A, patients received a 48-hour infusion of atosiban. On the first day of atosiban treatment, patients received a loading dose of either placebo or compound (2) at 1,000 mg. Thereafter, patients received either placebo or compound (2) twice daily at a dose of 500 mg each until labor.
[0258] participants Pregnant women aged 18 years or older with a single or twin pregnancy were eligible for this experiment if they experienced threatened spontaneous preterm labor between weeks 24 and 33 6 / 7 of gestation and their membranes had not ruptured. Gestational age was confirmed by first-term ultrasound scan or date of fertilization. Subjects were diagnosed with threatened spontaneous preterm labor if they presented with any of the following symptoms: (i) more than four uterine contractions per 30 minutes as measured by electromyography, contraction measurement, or abdominal palpation; (ii) cervical dilation of 1–4 cm (including both ends); and (iii) one or more of the following signs of preterm labor: positive IGFBP-1 or fetal fibronectin test, cervical length of 25 mm or less (by transvaginal ultrasound), or progressive cervical changes. Subjects were required to begin treatment with atosiban within 24 hours prior to the start of experimental treatment.
[0259] Exclusion criteria included: (i) stillbirth in the current pregnancy or a previous pregnancy beyond 24 weeks of gestation; (ii) high risk of stillbirth in the coming days; (iii) estimated fetal weight by ultrasound outside 2 standard deviations; (iv) oligohydramnios; (v) pathological Doppler ultrasound of the umbilical artery; and (vi) suspected placental abruption, but not limited to these; signs of chorioamnionitis, pre-eclampsia, eclampsia or HELLP syndrome; or iatrogenic delivery expected within the next 7 days, including contraindications for cessation of labor or extension of pregnancy for the mother or fetus. Other exclusion criteria included clinically significant abnormalities in screening safety laboratory test results (including AST, ALT, or total bilirubin greater than twice the upper limit of normal); known positive results from HBsAg (not due to vaccination), HCV or HIV1 or HIV2 virus tests; and a BMI of 35 kg / m² prior to the start of the current pregnancy. 2 Having undergone bariatric surgery; a condition that may interfere with drug absorption; use of a cervical closure or in situ pessary in a current pregnancy; current use of antihypertensive medication; treatment with a non-atosiban uterine contraction inhibitor within a specified period prior to baseline assessment of uterine contractions; a known history of alcohol or drug abuse; and being currently participating in or having participated in another clinical trial within 30 days prior to screening.
[0260] Table 3 below shows the demographics and baseline characteristics of the patients who participated in Part B of the experiment. [Table 3]
[0261] Randomization Eligible women received counseling from a physician about the experiment. Following informed consent, participants were randomly assigned to receive compound (2) or placebo in a 1:1 ratio using a web-based randomization system (IBM Clinical Development Randomization and Dispensing Modules, Durham, NC, USA). Randomization was stratified by gestational age (24-29 6 / 7 weeks and 30-33 6 / 7 weeks) and fetal size (singular or twins). The time of initiation of the experimental drug (IMP) was considered the formal time of randomization.
[0262] Both compound (2) and placebo granules were manufactured by Aptuit® (Via Fleming, Verona, Italy). The granules were identical in terms of size, thickness, physical properties, and appearance. The treatment kit, provided by Almac Clinical Services® (Craigavon, UK), consisted of one box containing a 15 mL bottle with 1666 mg of granules (i.e., 500 mg of compound (2)) for oral administration after suspension in water.
[0263] The treatment kit list and randomization schedule (in 4-block units) were generated using Cytel FlexRandomizer® (Cytel, USA) and uploaded to a web-based system by Cytel's open-label statisticians. Trial participants, physicians, healthcare providers and researchers, as well as the trial administration team, did not have access to the randomization list, and assignment concealment was maintained throughout the trial.
[0264] intervention All participants received intravenous administration of atosiban as standard treatment for 48 hours, according to the approved product label. Treatment with the experimental drug should ideally be initiated simultaneously with, or at most within 24 hours of, the start of atosiban treatment. The loading dose of compound (2) was 1000 mg, and the maintenance dose was 500 mg twice daily (12 hours apart for 7 days). Women assigned to the control group received the same dosing regimen as placebo. Participants were instructed to record IMP administrations in a patient diary and were required to bring both opened and unopened IMP packages with each visit so that compliance with the experimental treatment could be assessed.
[0265] Evaluation items The effectiveness of delaying preterm birth was evaluated using the following results: • Delivery within 48 hours of starting medication; • Delivery within 7 days of starting treatment; • Delivery before 37 weeks of gestation; and • Time from the start of treatment to the measured time until delivery.
[0266] As this was a proof-of-concept experiment, the primary efficacy endpoint was not defined in advance. Other results included: • Uterine contractions assessed hourly during the first six hours after the start of the trial treatment by electromyography, contraction measurement, or abdominal palpation; and • Maternal plasma concentration and pharmacokinetics (active metabolite of compound (2)) of compound (1) at the time of delivery, as well as fetal umbilical cord blood concentration.
[0267] Infant development is assessed by the incidence of infants whose one or more Ages and Stages Questionnaire® domain scores fall below the cutoff score at 6, 12, and 24 months of age. Data collection for this assessment is ongoing.
[0268] Safety was evaluated based on the following results: • Maternal incidence of adverse events (AEs), therapeutic adverse events (TEAEs), clinically significant changes in laboratory safety studies, and vital signs from 1 to 28 days postpartum; • Incidence of AEs indicating fetal distress, such as growth retardation and / or changes in fetal heart rate monitoring and / or amniotic fluid index (AFI) or amniotic fluid volume (in the case of twins); and • Measurement of the incidence of neonatal adverse events, clinically significant changes in vital signs, Apgar score, birth weight and head circumference, and neonatal morbidity from birth to 28 days postpartum.
[0269] statistical analysis The number of cases was estimated using the following assumptions: the delivery rates within 2 days (48 hours), 7 days (168 hours), and before 37 weeks of gestation after the start of compound (2) administration were assumed to be 11.2%, 25.4%, and 28.8%, respectively, after compound (2) treatment, compared to 33%, 40.4%, and 58.5%, respectively, after placebo. When analyzed using logistic regression, with a two-sided type I error probability of 0.1 and no multiplicity correction, 60 participants per group provide 93%, 55%, and 95% power for each endpoint. Power calculations were performed using the LOGISTIC statement within the POWER procedure in SAS version 9.4.
[0270] The incidence of deliveries within 2 days (48 hours), 7 days (168 hours), and before 37 weeks of gestation after the start of administration of compound (2) was analyzed using logistic regression with treatment group as the independent variable. Stratification effects (gestational age and number of fetuses) were included in the model. The treatment effect was expressed as odds ratios adjusted for 90% confidence intervals. Treatment for stratification interaction terms was investigated. Other covariates investigated included pre-administration uterine contraction rate and potential site-to-site effects. Time to delivery measured from the start of IMP administration was analyzed using Cox proportional hazards model. Furthermore, a log-rank test was performed. The analysis was performed using SAS® statistical software version 9.4. A p-value < 0.10 was considered statistically significant.
[0271] result A total of 122 women consented to the study, of whom 6 did not meet the eligibility criteria and 1 gave birth before randomization. After completion of screening, 115 women were randomly assigned to either compound (2) (n=58) or placebo (n=57). After randomization, but before the start of treatment, 2 women in the placebo group dropped out of the study. The remaining 113 women were included in the complete analysis set and the safety analysis set.
[0272] Baseline maternal characteristics were similar between the two groups (Table 3). The mean (SD) age was 29.6 (5.4) years, and the mean weight was 66.6 (11.6) kg. The median gestation period was 31.0 weeks, with 83 out of 113 women (73.5%) having single pregnancies, compared to 30 out of 113 women (26.5%) having twin pregnancies.
[0273] As shown in Figure 4, patients treated with compound (2) and atosiban experienced labor at a substantially lower rate within 48 hours of treatment initiation compared to patients treated with placebo and atosiban. This effect was observed in patients at 24–30 weeks of gestation and 30–34 weeks of gestation (Figure 4, categories (ii) and (iii) along the horizontal axis). The ability of compound (2) and atosiban to delay the onset of labor was particularly strong in patients with mononuclear pregnancies compared to the placebo and atosiban treatment regimen (Figure 4, category (iv) along the horizontal axis). Figures 5 and 6 further illustrate the labor-delaying effect of compound (2) and atosiban in patients with mononuclear pregnancies.
[0274] Surprisingly, as shown in Figure 5, only 9.5% of patients with mononuclear pregnancies at 24-30 weeks of gestation experienced delivery within 48 hours of starting treatment with compound (2) and atosiban, while 23.8% of patients with mononuclear pregnancies at 24-30 weeks of gestation experienced delivery within 48 hours of starting treatment with placebo and atosiban. The pregnancy-prolonging effect of compound (2) is summarized in Figure 8, which shows the percentage of trial participants who did not experience delivery in both the compound (2) + atosiban group and the placebo + atosiban group.
[0275] The ability of compound (2) and atosiban to extend gestation by 48 hours provides a significant therapeutic benefit, as it gives patients time to be treated with important prenatal medications that improve their chances of perinatal survival. These drugs include magnesium sulfate, which provides neuroprotective effects to the fetus, as well as corticosteroids such as betamethasone, dexamethasone, and hydrocortisone, which promote prenatal fetal lung maturation. This extension of gestation is particularly effective for patients in the early stages of pregnancy, such as 24 to 30 weeks, because the fetus at this stage particularly needs neuroprotection and lung maturation to increase its chances of survival. By delaying labor in a particularly reliable manner among patients in the early stages of pregnancy, compound (2), when administered in combination with atosiban, provides patients prone to preterm birth with the benefit of additional time to receive treatment with interventions that could potentially save the fetus.
[0276] While not limited to the mechanism, one way in which compound (2) may cause this delay in the onset of labor is by reducing uterine contractions. As shown in Figure 7, compound (2), when administered in combination with atosiban, may reduce uterine contractions more sustainably compared to baseline.
[0277] A more detailed summary of the efficacy results obtained from this experiment is shown in Table 4 below. [Table 4-1] [Table 4-2]
[0278] As shown in Table 4, data were obtained from 56 subjects in the compound (2) + atosiban group who delivered, and from all 55 subjects in the placebo + atosiban group who delivered. The delivery rate observed within 48 hours of the start of administration was 7 / 56 (12.5%) in the compound (2) group compared to 12 / 55 (21.8%) in the placebo group (aOR=0.52; 90%CI:0.22, 1.23). Among women with mononuclear pregnancies, the delivery rate observed within 48 hours of the start of IMP was 5 / 40 (12.5%) in the compound (2) group compared to 11 / 41 (26.8%) in the placebo group (aOR0.39; 90%CI:0.15, 1.04). In the case of twin pregnancies, these proportions were 2 / 16 (12.5%) for women treated with compound (2) compared to 1 / 14 (7.1%) for women treated with placebo (adjusted OR 2.05; 90% CI: 0.23, 18.1).
[0279] The rate of delivery within 7 days (168 hours) of IMP initiation did not differ between the compound (2) group (15 / 58; 26.8%) and the placebo group (15 / 55; 27.3%) (OR=1.00; 90%CI:0.49,2.1). In women with mononuclear pregnancies between 24 and 30 weeks of gestation, the 7-day delivery rate was 14.3% in women treated with compound (2), compared to 23.8% after placebo (aOR=0.53; 90%CI:0.14,2.0).
[0280] Importantly, compound (2) not only proved more effective than placebo as an add-on to atosiban therapy, but compound (2) also demonstrated superior safety. Patients treated with compound (2) who received atosiban infusions experienced fewer adverse events than those treated with placebo. The specific adverse events recorded in Part B of this experiment are summarized in Table 5 below. [Table 5]
[0281] conclusion Part B of this experiment demonstrates that compound (2), when administered as an add-on to atosiban treatment in patients at risk of experiencing preterm labor, results in a definite delay in the onset of labor. As shown in Figures 4–6, the pregnancy-prolonging effect of compound (2) and atosiban is particularly pronounced in patients with mononuclear pregnancies. The ability of compound (2) and atosiban to delay the onset of labor provides a significant therapeutic benefit: additional time for patients to receive medication that may increase the chances of fetal survival. Importantly, not only was compound (2) observed to achieve a significant reduction in the rate of impending labor, but compound (2) was also particularly safe. In summary, the results of Parts A and B of this experiment demonstrate that compound (2), when administered safely and effectively in combination with atosiban, can delay the onset of labor in patients at risk of experiencing labor before the full term of pregnancy.
[0282] Example 2. Use of atosiban and PGF2α receptor antagonists for the treatment or prevention of premature birth in human patients. Using the compositions and methods described herein, atosiban may be administered to patients who have experienced or are at risk of experiencing premature birth in combination with a PGF2α receptor antagonist, such as one of the compounds of formulas (I) to (VIII) described herein (for example, compounds (1), (2), or (3) described herein). A physician skilled in the art can assess a patient for the risk of premature delivery and may determine that a patient is at risk of experiencing premature delivery if the patient's gestational age prior to administration of the uterine contraction inhibitor is approximately 24 to approximately 36 weeks, exhibits four or more uterine contractions per 30 minutes, shows cervical dilation of approximately 1 cm to approximately 4 cm, tests positive for the presence of fetal fibronectin and / or insulin-like growth factor-binding protein-1 (IGFBP-1) in a sample of cervical secretions obtained from the patient, and / or has a cervical length of approximately 25 mm or less.
[0283] If a patient is determined to have experienced or be at risk of experiencing premature birth, the patient may be administered in vivo at doses once or twice daily with a PGF2α receptor antagonist such as compound (2) or its chloride salt, or another compound that produces compound (1). For example, a PGF2α receptor antagonist may be administered to the subject at doses of, for example, 1,000 mg to 2,000 mg once or twice daily. The subject may be administered atosiban according to the dosing regimen described herein.
[0284] After administration of atosiban and PGF2α receptor antagonists, patients can be evaluated for the success of treating or preventing preterm birth. The success of treatment of pregnant subjects with atosiban and the PGF2α receptor antagonists described herein may be indicated, for example, by observing a delay in the onset of labor in the patien...
Claims
[Claim 1] The invention described in this specification.
